>>WELCOME
EVERYONE TO THE 216TH COUNCIL
MEETING FOR NINDS. MOST OF OUR
COUNCIL MEMBERS ARE PRESENT, I
THINK CLAUDIA HAS A CONFLICT,
MIGHT POP IN LATER. CLAUDIA
LUCHINETTI, BOB BROWN WILL JOIN
US IN A COUPLE OF HOURS TODAY
LATER. AND EVERYONE ELSE SHOULD
BE HERE. HOPE EVERYONE IS DOING
WELL. BOB BROWN IS AN AD HOC
LAST TIME BUT NOW OFFICIALLY
APPOINTED AND PROBABLY PEOPLE
KNOW HE'S THE DIRECTOR OF THE
PROGRAM NEUROTHERAPEUTICS AT
UMASS. WE ARE LOOKING FORWARD TO
THIS NOW COMPLETELY COMPOSED
COUNCIL GROUP. IT IS COUPLE OF
HIGHLIGHTS IN TERMS OF PEOPLE
WHO HAVE BEEN MOVED INTO EVEN
HIGHER UP LEADERSHIP POSITIONS
AT NINDS, CHRISTINE LAMB WAS
PROMOTED TO OFFICE CHIEF BUDGET
OFFICER, AND JEW DI CHIEF
INFORMATION OFFICER. THOSE TWO
PEOPLE ARE INC ABLY IMPORTANT TO
THE INSTITUTE AND CERTAINLY JUDY
EVEN MORE SO SINCE COVID. SO
THANKS TO JUDY AND CHRISTINE FOR
TAKING THESE OVER. WE HAVE A
GREAT MEETING LINED UP AND I
WILL HAND IT TO BOB NOW.
>> THANKS A LOT, WALTER.
WELCOME, EVERYBODY. I SEE ANNA
-- AARON AND -- HAVE NOW JOINED
US. SO WE HAVE EVERYONE BESIDES
THE TWO WALTER MENTIONEDED.
WELCOME TO OPEN SESSION. GREAT
TO SEE YOU. MAYBE SOME DAY SOON
IN PERSON, WHO KNOWS. I WILL
START WITH MY USUAL REMINDER
THAT THESE EXCITING MEETINGS ARE
VIDEOCAST LIVE AND ARCHIVED.
THERE IS ALLAN. GREAT. SO BE ON
YOUR BEST BEHAVIOR AND TRY TO
LOOK YOUR BEST, SPRUCE UP U YOU
CAN DO THAT. /WON'T GO INTO THE
USUALS EXPLANATION OF ZOOM
RULES, I THINK EVERYBODY KNOWS
BY NOW. THE ONLY REMINDER IS
THAT IF YOU WANT TO SAY
SOMETHING OR MAKE A MOTION OR
WHATEVER, EITHER JUST SPEAK UP
OR RAISE YOUR HAND, YOU CAN
RAISE YOUR ACTUAL HAND AND WAVE
IT IN FRONT OF ME FACE, I WILL
SEE IT. AND THE VOTING AS USUAL
WILL BE DONE BY THE CHAT, TIM
WHO IS TAKING OVER AS OUR NEW
COUNCIL POINT PERSON WILL PUT
THE MOTION IN THE CHAT. AND
THEN YOU CAN ALL VOTE. SPEAKING
OF KELLY, KELLY HAS COVID AND
SHE -- WHICH IS REALLY
UNFORTUNATE. THIS WAS LIKE MY
NIGHTMARE THAT BEFORE COUNCIL
SOMETHING WOULD HAPPEN TO KELLY.
THE NIGHTMARE OCCURRED THOUGH
SHE IS FEELING BETTER BUT YOU
WON'T SEE HER ON THE VIDEO OR
HEAR HER. SHE IS WORKING IN THE
BACKGROUND TO MAKE THINGS
BETTER. SHE REFUSES TO GO TO BED
WHICH IS PROBABLY WHERE SHE
BELONGS. TIM AND BROOK ARE DOING
GREAT JOB SUBSTITUTING FOR KELLY
AND DOING THEIR PART. SO UNLESS
THERE IS ANY QUESTIONS I'M GOING
TO GO INTO MY USUAL BOILERPLATE
INTRODUCTION WHICH IS THAT WE
NEED YOUR APPROVAL OF THE
MINUTES FROM OUR LAST MEETING
WHICH WERE IN THE ELECTRONIC
COUNCIL BOOK FIRST POSTING
SECTION NINDS GENERAL
INFORMATION TAB. UNLESS YOU WANT
TO DISCUSS THE MINUTES I NEED A
MOTION. SO I SEE A MOTION FROM
LOUISE AND SECOND FROM TIM.
EVERYBODY, TIM HAS JUST ENTERED
THE MOTION INTO THE CHAT SO
EVERYBODY VOTE. THIS IS A TEST
OF OUR ABILITY TO MAKE A MOMENT
AND VOTE ON IT. LOOKS LIKE WE
PASSED. ALSO UNDER THIS NINDS
GENERAL INFORMATION TAB ECB
THERE IS A LISTING OF ALL
COUNCIL MEETINGS, THROUGH 2024.
THESE MEETINGS WILL CONTINUE TO
TAKE PLACE ON WEDNESDAY AND
THURSDAY THOUGH IF WE GO TO IN
PERSON AND WALTER WILL TALK
ABOUT THAT, OBVIOUSLY TIMES
MIGHT CHANGE, ONE THROUGH FIVE
OR ONE THROUGH SIX SO HOLD THESE
DATES IN YOUR CALENDAR AND LET
TIM OR KELLY OR RICK KNOW IF YOU
HAVE A PROBLEM WITH ANY OF THEM
MOVING RIGHT ALONG, WE HAVE I'M
REQUIRED TO TELL YOU ABOUT
EXPEDITED REVIEW PROCESS. THIS
IS JUST THE PROCESS IN WHICH
THREE DESIGNATED COUNCIL
MEMBERS, CLAUDIA TOM AND I
BELIEVE SAMEER, DESIGNATED THIS
YEAR. THESE THREE COUNCIL
MEMBERS APPROVE SUBSET OF
APPLICATIONS FOR FUNDING BEFORE
COUNCIL MEETS. THIS ALLOWS
GRANTS MANAGEMENT BRANCH TO GET
AWARDS OUT THE DOORS EVEN BEFORE
COUNCIL OCCURS OR JUST AFTER.
TYPICALLY FOCUSES ON RO1 AND
GRANTS WITH SCORES WITHIN PAY
LINE WITH NO ISSUES THAT REQUIRE
ANY COUNCIL DISCUSSION. SO
THANKS TO CLAUDIA, TOM AND
SAMEER. THERE WERE 150
APPLICATIONS EXPEDITED AND A LOT
WERE ALREADY OUT THE DOOR, I SAY
THIS EVERY SINGLE ROUND BECAUSE
IT IS IMPORTANT WHICH IS THAT
THIS IS A TESTAMENT TO HOW GOOD
OUR GRANTS MANAGEMENT STAFF ARE.
THESE ARE PEOPLE BEHIND THE
SCENES WHO ISSUE THE AWARDS. AND
THE GRANTS MANAGEMENT BRANCH IS
LED BY SHELLEY WILLBORN WHO
JOINED RECENTLY AND A TESTAMENT
TO OUR PROGRAM SATISFY WHO ARE
ABLE TO ENTER ALL THE
INFORMATION T AT GRANTS
MANAGEMENT NEEDS TO ENTER THE
AWARDS. SO EVERYBODY CONTINUE
DOING THIS DURING COVID AND IF
ANYTHING WE GOT MORE EFFICIENT
IN THIS PROCESS. SO THAT IS
GREAT. WE USED TO -- I'M TALKING
QUICKLY BECAUSE WE HAVE A LOT ON
THE AGENDA. WE USED TO
INDIVIDUALLY INTRODUCE ALL THE
NEW STAFF WHO ARE JOINING NINDS.
CAN SOMEBODY PUT THE LIST OF NEW
STAFF UP? JOHN IF JASMINE DOES
THAT OR BROOK. WHILE THEY ARE
DOING THAT, IN THE INTEREST OF
STREAMLINING THESE VIRTUAL
MEETINGS, WE DON'T INTRODUCE
EVERYBODY BUT ENCOURAGE YOU TO
LOOK AT THE BIOs OF ALL THESE
EXTREMELY INTERESTING PEOPLE IN
THE E C,B. VERY INTERESTING AND
IMPRESS SHIV BACKGROUNDS. THE
ONLY TWO THAT -- WALTER WHEN HE
SPEAKS IS GOING TO I THINK
INTRODUCE OUR NEW BUDGET OFFICER
AND AS WELL AS SOMEONE WHO I SEE
IS NOT -- THERE SHE IS, JUDY OUR
NEW CIO CHIEF INFORMATION
OFFICER, HE WILL BE TALKING
ABOUT THAT. THE ONLY PERSON THAT
I WILL TALK ABOUT IN DETAIL IS
ANNA TAYLOR, YOU CAN SEE HER ON
THE DIVISION OF EXTRAMURAL
ACTIVITIES. SHE IN A HIGH
LEADERSHIP POSITION NOW AND
INTERACTING SIGNIFICANTLY WITH
YOU IN THESE COUNCIL MEETINGS.
SO THE NEW POSITION ANNA TAYLOR
SPOKEN A NUMBER OF TIMES COUNCIL
PROMOTED TO IS CALLED DIRECTOR
OF RESEARCH OPERATIONS AND
ANALYSIS. SO ANNA FOR MANY YEARS
HAS LED VERY IMPORTANT
INITIATIVES AND ANALYSES FOR
EXAMPLE SHE SPEARHEADED THAT NIH
NEUROBIOBANK WHICH IS A VERY
IMPORTANT INITIATIVE AND SHE LED
OUR ANALYSIS THAT WAS PREVENTED
AT COUNCIL MULTIPLE TIMES TRENDS
AND FUNDING OF BASIC AND APPLIED
RESEARCH. THIS IS A BIG DEAL AT
THE TIME AND SOME OF YOU MIGHT
HAVE HEARD OF IT. IN ANY CASE,
SHE HAS ALWAYS PLAYED AD REALLY
IMPORTANT ROLE IN GETTING THE
DIFFERENT PARTS OF EXTRAMURAL TO
WORK TOGETHER AS EFFECTIVELY AS
POSSIBLE. GRANTS MANAGEMENT
PROGRAM, BUDGET OFFICE, ET
CETERA. O IN HER NEW POSITION
SHE WILL OVERSEE ADMINISTRATIVE
BRANCH LED BY KELLY BAKER OUR
GRANTS MANAGEMENT GROUP AND NEW
BRAND -- OFFICES OR RATHER
BRANCHES OF ANALYSIS AND
RESEARCH OPERATIONS WHICH WILL
BE -- YOU WILL BE HEARING MORE
ABOUT LATER SO THIS IS A
CRITICAL POSITION AND BY THE WAY
ONE OF ITS GOALS IS TO GET
GRANTS OUT THE DOOR MORE
EFFICIENTLY AND MORE QUICKLY,
WHICH IS DEFINITELY IN THE
INTEREST OF EXTRAMURAL
SCIENTIFIC COMMUNITY AND ALSO IN
THE INTEREST OF OUR STAFF MAKING
THINGS EASIER. SO WELCOME, ANNA,
TO OUR NEW POSITION. WALTER
ANNOUNCED CHRISTINE AND JUDY'S
NEW POSITION, SORRY YOU HAVE I
WAS READING MY NOTES SO LOOKS
LIKE WE ARE DONE WITH
INTRODUCTIONS. BUT AT THIS POINT
I WILL JUST TURN THINGS OVER TO
WALTER FOR HIS DIRECTOR'S TAL T.
>> OKAY. JASMINE, IF YOU COULD
-- IF YOU CAN HIT THE BUTTON, WE
PRE-RECORDED THE MESSAGE. TRY TO
BE MORE TIME EFFICIENT.
>> IT IS MY PLEASURE TO GIVE THE
NINDS DIRECTORS REPORT FOR THIS
216TH MEETING OF THE NINDS
COUNCIL. I WANT TO START BY
TALKING IN GENERAL
>> WAS ACTING DIRECTOR OF THE
FDA FOR A WHILE WHILE HE WAS
ALSO HERE AT NIH. THE PRINCIPLE
DEPUTY DIRECTOR DR. DOUG LOWY,
NCI ACTING DIRECTOR, POSITION HE
HAD MULTIPLE TIMES IN THE PAST
AND GREAT AT IT. AS PEOPLE MAY
KNOW THERE IS A SEARCH FOR NEW
DIRECTOR ONGOING AND I THINK
THEY HAVE CANDIDATES BUT WE
DON'T REALLY KNOW, WE MAY BE THE
LAST TO KNOW WHO THE FINAL
CHOICE IS. LOOKING FORWARD TO
WORKING WITH A NEW DIRECTOR
GOING FORWARD AS WE HAVE WITH
DR. COLLINS AND NOW DR. TABAK,
ACTING DIRECTOR. WE WERE ABLE TO
GET A BUDGET THIS YEAR THANK
GOODNESS AND WE TALKED IN THE
PAST THAT GOING WITH CONTINUOUS
CR THROUGHOUT THE YEAR CREATED
PROBLEMS FOR BUDGET BUT DID GET
BUDGET INCREASE, IN MARCH, YOU
CAN SEE HERE THE BASE BUDGET OF
THE INSTITUTE WHEN UP SLIGHTLY,
TO $2,082,000,000, 3.3% CHANGE,
PRETTY MUCH IN LINE WITH THE
OTHER INSTITUTES. HOWEVER WE DID
GET FUNDS FROM THE BRAIN
INITIATIVE. SOME WHICH COMES
FROM THE CURES ACT AND ALSO
MONEY FOR THE HEAL INITIATIVE
WHERE OUR FUNDS ARE USED BY
MULTIPLE INSTITUTES PAIN
RESEARCH AND SO ALL TOTAL THAT
GAVE US INCREASE OF 2.6 BILLION
OVERALL INCREASE TO 3.9 PERSES.
WE ALSO MANAGE 10% OF THE
DEMENTIA BUDGET TO THE AGING
INSTITUTE WHICH IS NOW UPWARDS
OF $274 MILLION A YEAR. SO
REALLY HAPPY ABOUT THESE NEW
RESOURCES, ABLE TO CONTINUE OUR
PAY LINE AT THE 14 PERCENTILE,
AND LOOKING FORWARD IN THE
ENSUING YEARS TO INCREASE THAT.
SO AGAIN HERE THE SAME BUDGET
ITEMS, HERE IS BRAIN, THE CURES
ACT MONEY WHICH IS ALSO FOR
BRAIN, THIS IS THE BASE OF THE
NINDS BUDGETS FOR BRAIN,
ADDITIONAL FUNDS FOR CURES ACT
THAT INSPIRES 2026, THIS IS THE
HEAL MONEY FOR RESEARCH TO
DEVELOP BETTER NON-ADDICTIVE
THERAPIES FOR PAIN AND THAT IS
TOTAL BUDGET. I WILL GO THROUGH
A NUMBER OF EYE TESTIMONIES, THE
COUNCIL COULD BE MADE AWARE OF
-- ITEMS, THE FIRST IS THE
CONGRESS STRENGTH NIH ABILITY TO
ADDRESS HARASSMENT AND NIH
FUNDED ACTIVITIES, WITHIN NIH
AND IN OUR GRANTEE INSTITUTIONS.
THE NEW AUTHORITY ENABLES
MANDATORY REPORTING TO NIH
REMOVALS OF DISCIPLINARY ACTIONS
WHEN 30 DAYS OF OCCURRENCE AT
INSTITUTIONS WE FUND. ENSURES
NIH IS MADE AWARE OF THE REASON
FOR DISCIPLINARY ACTION WHEN
THERE ARE CONCERNS OF
HARASSMENT, RETALIATION,
BULLYING OR HOSTILE WORKING
CONDITIONS SO THIS WILL HELP
ADVANCE OUR GOAL TO MAKE OUR
RESEARCH THE RESEARCH WE FUND
IMPORTANTED ENVIRONMENTS THAT
ARE WELCOMING TO ALL AND
CONDUCIVE TO EVERYBODY MAKING
THE BEST CONTRIBUTION THEY CAN
TO OUR SCIENCE. IN ADDITION,
THERE IS IN THE NEWS AND HAS
BEEN IN THE BUDGET FUNDING FOR A
NEW AGENCY, WHICH IS INSIDE NIH
BUT REPORTS DIRECTLY TO THE
SECRETARY OF HEALTH AS OPPOSED
TO THE NIH DIRECTOR. THIS IS THE
ADVANCE RESEARCH AGENCY PROJECT
FOR HEALTH AND IT IS KIND OF
MODELS OR SUPPOSED TO BE MODELED
ON THE DEFENSE AGENCY. DARPA.
THERE IS IHARP FOR THE
INTELLIGENCE AGENCIES. THE IDEA
IS THESE PROGRAMS SUPPORT
TRANSFORMATIVE HIGH RISK HIGH
REWARD RESEARCH TO SPEED
APPLICATION AND IMPLEMENTATION
OF HEALTH BREAK THROUGHS TO
SERVE ALL PATIENTS TO FOSTER
BREAK THROUGHS ACROSS VARIOUS
LEVELS FOR SOCIETAL AND BROAD
SCOPE AND TO BE ABLE TO BUILD
PLATFORMS THAT WILL BENEFIT A
RANGE OF DISEASES SO I THINK THE
IDEA IS TO BUILD THINGS THAT CAN
FLOAT ALL BOATS IN TERMS OF
MOVING THINGS PARTICULARLY
TOWARDS A TRANSLATIONAL END OF
THINGS. AS YOU MAY RECALL WE
WORK WITH DARPA WHERE THEY
PRODUCE A FANTASTIC PROSTHETIC
ARM FOR PEOPLE WHO HAD
AMPUTATIONS OF THE UPPER LIMB
AND WE WORK HAD GRANTS FOR
PEOPLE TO WORK THOSE PROSTHETIC
ARMS INTO INTERFACE SYSTEMS WITH
THE NERVOUS SYSTEM, REALLY
WONDERFUL PROJECT. AND THE IDEA
IS TO MOVE IDEAS INTO TANGIBLE
SOLUTIONS FOR PATIENTS SO IT IS
ON THIS BORDER ZONE OF MOVING
THINGS OUT TOWARDS
COMMERCIALIZATION AND TO
OVERCOME MARKET FAILURES THROUGH
CRITICAL SOLUTIONS AND
INCENTIVES. CERTAINLY IN THE
NEUROSCIENCE SPACE THERE IS A
LARGE NUMBER OF MARKET FAILURES
ACTUALLY LOT OF COMPANIES LEFT
THE NEUROSCIENCE SPACE BECAUSE
IT WAS HIGH RISK. SO WE HOPE
NEUROSCIENCE BENEFITS FROM THE
NEW AGENCY. WE DON'T HAVE A GOOD
IDEA WHERE IT WILL BE. THERE'S
TALK OF HAVING IT IN ANOTHER
PART OF THE COUNTRY TO TRY AND
MAKE IT DIFFERENT FROM WHAT NIH
DOES IN ITS USUAL MECHANISMS.
NOT SUPPOSED TO BE DUPLICATIVE
OF NIH PROGRAMS AND EFFORTS SO
LOOKING FORWARD TO DIRECTOR
BEING NAME AND HOPEFULLY THINGS
MOVE FORWARD QUICKLY FROM THERE.
TIME IS SHORT SO THIS WAS PUT
OUT IN OSTP IN 2021 IN A PAPER.
CONGRESS PASS AD BILL IN MARCH
OF 2022. THE AGENCY WAS
TRANSFERRED TO NIH AS I
MENTIONED, THE OFFICE OF
DIRECTOR STILL HAS TO BE
APPOINTED. I THINK THAT DR.
COLLINS IS NOW OSTP AND WORKING
ON BOTH TRYING TO FIND THIS
CANDIDATE AND ALSO CANDIDATE FOR
THE NIH DIRECTOR. WE WILL JUMP
NOW TO A SITUATION WITH REGARD
TO THE SYNDROMES THAT ARE
OCCURRING AT PEOPLE AFTER THE
COVID INFECTION. WE CALL THE
POST ACUTE SEQUELAE OF COVID.
SOME OF THESE ARE CONDITIONS WE
KNOW, DIABETES, SOME OF THESE
ARE CONDITIONS THAT REALLY
RESEMBLE MYALGIC ENCEPHMYELITIS
SYNDROME WITH DIFFERENT SYMPTOM
CLUSTERS WITH FATIGUE, AND
NEUROLOGIC PROBLEMS
CONCENTRATION MEMORY, PAIN
CONDITIONS, AUTONOMIC
DYSFUNCTION, SLEEP DISORDERS, IN
THE NEUROSPACE. SO WE HAVE BEEN
INSTRUCTED BY CONGRESS TO REALLY
PUT TOGETHER RESEARCH THAT CAN
UNDERSTAND WHAT IS THE BIOLOGY
UNDERLYING THE POOR RECOVERY IN
PATIENTS OVER TIME TO FIND THE
RISK FACTORS, THE DIFFERENT SUB
PHENOTYPES, TRYING TO UNDERSTAND
THE PATHOGENESIS OF THESE
PHENOTYPES AND WHAT ORGAN
SYSTEMS ARE DYSFUNCTIONAL AND
THEN TO USE THAT KNOWLEDGE TO
IDENTIFY INTERVENTIONS TO REDUCE
SUFFERING WHICH IS AFFECTING
LARGE NUMBERS OF PEOPLE WHO ARE
NO LONGER ACUTELY AFFECT BUT
STILL SUFFERING FROM MANY
SYMPTOMS. SO H IS MAJOR PROJECT
NINDS HAS BEEN WORKING WITH
NHLBI AND NIAID ON. WE HAVE
COHORT STUDY BRINGING IN PEOPLE
TO BE STUDIED, WE ARE LOOKING
FOR TENS OF THOUSANDS OF PEOPLE,
SOME ACUTELY INFECTED, STUDY HOW
YOU RECOVER SOME PEOPLE WHO ARE
AFFECTED IN THE PAST STILL
HAVING TROUBLES, COMPARED TO
PEOPLE WHO WERE INFECTED IN THE
PAST AND NOT HAVING TROUBLE, IT
WAS AN OPPORTUNITY TO TEASE
APART WHAT IS THE BIOLOGY
DIFFERENTIATES THOSE GROUPS OF
PEOPLE. WE ARE NOW UP TO 3,000
PARTICIPANTS MANY THE COHORT
SYSTEM, WE HAVE ELECTRONIC
HEALTH RECORD SYSTEMS THAT SCAN
AND DO RESEARCH ON RECORDS OF
ABOUT 60 MILLION PEOPLE, OF
COURSE THE U.S. AND WE HAVE A
CALL OUT AND ACTUALLY GRANT --
PROPOSAL TO COME IN, FOR STUDIES
TO TRY TO UNDERSTAND THE
PATHOGENESIS WHETHER IT IS
IMMUNE SYSTEM, NEUROLOGICAL
SYSTEM, MENTAL HEALTH DISORDERS,
GI TROUBLE, YOU NAME IT. IN
TERMS OF WHAT IS UNDERLYING
THESE SYMPTOMS OF PEOPLE STILL
SUFFERING FROM MONTHS AFTER
THEIR INFECTION. THERE IS A
REPOSITORY FOR TISSUE, WE HAVE
AN AUTOPSY COMPONENT TO THIS AS
WELL TO LOOK INSIDE AND WITH THE
MICROSCOPE TO TRY TO UNDERSTAND
WHAT IS GOING ON IN PEOPLE WHO
DIED WHO HAVE SYMPTOMS OF POST
ACUTE SEQUELAE OF COVID. COMPARE
THEM TO PEOPLE WHO HAD COVID AND
MADE A GOOD RECOVERY BECAUSE IT
IS AFFECTED SO MANY PEOPLE WE
THINK THIS IS GOING TO BE
FRUITFUL BECAUSE PEOPLE DIE OF
OTHER CAUSES AND WILL BE ABLE TO
TRY TO TEASE APART IF THEY HAD
THESE PERSISTENT SYMPTOMS VERSUS
THOSE WHO DIDN'T WHO HAD
PREVIOUSLY BEEN AFFECTED WITH
COVID. NOW WE ALSO PUT OUT A
CALL FOR CLINICAL TRIALS, I
SUSPECT IN THE BEGINNING THESE
MAY BE TARGETED SYMPTOMS,
IMPROVE THE PAIN CONDITION,
IMPROVE THE AUTONOMIC
DYSFUNCTION, WITH POTENTIAL --
WITH THERAPIES THAT DOCS WITHIN
USING FOR DECADES TREATING
PATIENTS WITH THOSE SIMILAR TYPE
DISORDERS. AND NOW SEE WHICH ONE
WORKS BEST IN THIS POST ACUTE
SEQUELAE COVID SITUATION. OVER
TIME WE HOPE TO BRING IN
MECHANISTICALLY RATIONAL TRIALS
TO TRY TO GET AT THE UNDERLYING
BIOLOGY THAT CAN TURN THIS
PROBLEM AROUND. AND ALL ITS
MANIFESTATIONS. SO EXCITING
PROJECT AND LOTS OF PEOPLE
WORKING ON, I WANT TO SHOUT OUT
TO THE NINDS TEAM THAT IS
WORKING WITH THE NHLBI GROUP.
NLLBI GROUP AMY PATTERSON IS THE
MAJOR LEFT, IT IS A GREAT
COLLABORATION. I WANT TO TALK
ABOUT NOW THE ACT FOR ALS SIGNED
BY THE PRESIDENT IN DECEMBER.
AND THEN IN THE APPROPRIATIONS
NIH RECEIVED 25 MILLION TO THE
OFFICE OF DIRECTOR TO LAUNCH
IMPLEMENTATION FOR ALS, IT HAS A
COUPLE OF COMPONENTS, THE ONE
MENTIONED HERE IS THE BILL CALLS
FOR THE HHS TO SET UP A PROGRAM
THAT WOULD ENABLE PEOPLE WHO
HAVE ALS WHO ARE NOT ELIGIBLE
FOR RECURRENT TRIALS TO GAIN
ACCESS TO INVESTIGATIONAL DRUGS
THAT ARE IN PHASE 3 TRIALS. THAT
OCCURS UNDER WHAT IS CALLED AND
EXPANDED ACCESS APPLICATION TO
THE FDA. SO WE SUSPECT THAT WELL
WE KNOW FOR THE ALS CLINICAL
TRIALS THE FOCUS IS ON PEOPLE
WHO HAVE EARLY STAGE DISEASE. SO
THE LARGEST PERCENTAGE OF PEOPLE
WITH ALS ARE NOT ELIGIBLE
BECAUSE THEY PASS THAT WINDOW SO
THE THOUGHT IS THAT THIS GROUP
WOULD BENEFIT BECAUSE THEY
REALLY FEEL THEY NEED THE RIGHT
TO TRY THESE INVESTIGATIONAL
DRUGS. THAT IN COMBINATION WITH
POTENTIAL TO LEARN SCIENTIFIC
THINGS OF SCIENTIFIC VALUE BY
STUDYING THOSE PATIENTS, IS WHAT
WE HOPE TO ACHIEVE BY EXECUTING
OUR PART OF THIS BILL WHICH IS
TO FUND CLINICAL -- IMPORTANT
CLINICAL RESEARCH UNDER EXPANDED
ACCESS IN PEOPLE WHO HAVE ALS
NOT ELIGIBLE FOR CLINICAL
TRIALS. THE ONE CAVEAT IS THE
BILL LIMITS THE DRUGS THAT WOULD
BE TESTED AND PAID FOR TO DRUGS
THAT ARE IN PHASE 3 CLINICAL
TRIALS THAT ARE FDA APPROVED
TRIALS AND THEY HAVE TO BE
SPONSORED BY A SMALL BUSINESS SO
WE ARE LOOKING FOR APPLICATIONS
NOW AND HOPE TO GET SOME
PROJECTS GOING WITH FY 22 FUNDS.
NEXT I WILL JUMP TO THE NIH DATA
SHARING POLICY, I THIS THINK WE
MENTIONED THIS BEFORE BUT THINGS
ARE MOVING. AS WE HAVE SAID IN
THE PAST THE POLICY GOES INTO
EFFECT IN JANUARY 2023. SO FOR
GRANTS TO DOCUMENT IN AFTER THAT
POINT THEY HAVE TO SUBMIT A DATA
MANAGEMENT SHARING PLAN THAT
OUTLINES HOW SCIENTIFIC DATA ANY
ACCOMPANYING METADATA WILL BE
MANAGED AND SHARED TAKING INTO
ACCOUNT POTENTIAL RESTRICTIONS
OF LIMITATIONS WHETHER THEY ARE
LEGAL OR PRIVACY AND THIS --
THIS IS COVERING NOT JUST DATA
THAT IS PART OF A PUBLICATION
BUT RIGOROUS DATA THAT NIH FUNDS
AND IS NOT PUBLISHED. SO WE WILL
TALK ABOUT THAT IN A SECOND BUT
WHAT IS GOING TO HAPPEN WHEN
THESE COME IN THEY WILL BE
JUDGED WHETHER THEY COMPLY WITH
YOUR PLAN AND YOUR GRANT,
COMPLIES WITH A OPEN SHARING
POLICY AND YOUR PLAN WOULD HAVE
TO BE APPROVED BY OUR PROGRAM
DIRECTORS FOR US TO FUND THE
GRANT. THINGS ARE CHANGING AND
WE WILL HAVE TO SEE HOW THIS
WORKS OUT BUT THE IDEA IS THAT
THERE IS SO MUCH GOOD RIGOROUS
DATA THAT IS JUST NOT AVAILABLE
FOR OTHER PEOPLE TO LOOK AT, TO
INVESTIGATE, POTENTIALLY ANALYZE
IN A WAY THAT WAS DIFFERENT THAN
IN THE PAPER. AND IT IS THIS
DATA IS FUNDED BY THE GOVERNMENT
AND SO THE FACT THAT IT IS NOT
AVAILABLE IS A REAL PROBLEM. HOW
TO MAKE IT USEFUL IS I THINK WE
ARE GOING TO BE WORKING ON IT SO
THE DATA WILL HAVE TO BE
AVAILABLE, NOW THE QUESTION IS
HOW DO WE MAKE IT USEFUL. SO WE
THINK THAT RESEARCHERS NEED TO
COME TOGETHER AS A COMMUNITY,
OPTIMIZE COMMON DATA ELEMENTS,
METADATA, STANDARDS, THAT WOULD
APPLY TO THE TYPE OF DATA THAT
THEY HAVE AS A COMMUNITY THAT
THEY WOULD NECESSARILY BE
SHARING BUT NOW SHARING IN A WAY
WHERE IT IS GOING TO BE USEFUL
TO EACH OTHER SO WE NEED TO
STRENGTHEN THE DATA STANDARDS
AND WE HAVE TO IDENTIFY TO SHARE
HIGH QUALITY UNPUBLISHED DATA.
SO SHY SILVERBURG WORKING
HEAVILY ON PUSHING THE VALUE OF
SHARING RIGOROUS DATA OR NO DATA
SO IT IS DATA THAT YOU DID THE
EXPERIMENTS, GREAT EXPERIMENTS
YOU HAD ACCESS TO DATA, DIDN'T
SUPPORT THE HYPOTHESIS. YOU ARE
NOT GOING TO PUBLISH IT. THAT IS
REAL SHAME BECAUSE IT IS GOOD
DATA AND OTHERS WILL GO DOWN THE
SAME RABBIT HOLE YOU DID UNLESS
-- OUT THERE PEOPLE KNOW ABOUT
IT SO WORKING HARD TO TRY AND
FIGURE OUT A SYSTEM THAT WOULD
ALLOW THAT TO BE FINDABLE AND
USEFUL DATA AS WELL. SO FAR NIH
HAS BEEN DEVELOPING A REPOSTORY
THERE ARE REPOSITORIES THAT ARE
FUNDED THAT ARE MEETING THE
STANDARDS NIH THINKS ARE
IMPORTANT FOR DATA SHARING. FAIR
PRINCIPLES. THIS IS THE LIST OF
-- THAT ARE FUNDED BY NIH AT
THIS POINT. THERE IS ALSO A LIST
OF DOMAIN SPECIFIC REPOSITORIES
THAT THE INSTITUTES HAVE. WE
HAVE A NUMBER OF OUR OWN SET
UNUSUALLY WITH SOME SPECIAL
FUNDING OR OTHER PURPOSE IN
MIND. SO AMPD, PARTNERSHIP FOR
PARKINSONS IS A A PUBLIC PRIVATE
PARTNERSHIP, DEPARTMENT OF
DEFENSE TRAUMATIC BRAIN INJURY.
BRAIN INITIATIVE OF COURSE
MASSIVE DATA COLLECTION, THAT
SPACE, THESE ARE REALLY NOT
SCALABLE ACROSS THE INSTITUTE
SCIENCE. SO WE NEED OTHER WAYS
IN WHICH NOW THAT THE DATA HAVE
TO BE POSTED THAT GROUPS COME
TOGETHER TO MAKE THAT DATA
USEFUL FOR THEIR COMMUNITY.
THERE ARE RFAs OUT WHERE
PEOPLE COME IN TO GET GRANTS TO
BUILD THOSE -- THAT KIND OF
FRAMEWORK FOR THEIR SCIENCE. ARE
YOU HAPPY TO -- HAPPY TO WORK
WITH ANYBODY INTERESTED IN DOING
THAT. LYNN JAKEMAN AND PAT
BELLGOWAN DIVISION OF
NEUROSCIENCE ON TOP OF THOSE
DEVELOPMENTS. THE NEXT THING TO
JUMP TO WAS A NEW RO1 MECHANISM
THAT WE ARE GOING TO GET OUT, IT
IS AN RO1 FOR NEW AND AT RISK
INVESTIGATORS TO PROMOTE WORK
FORCE DIVERSITY. THESE ARE
PEOPLE WHO FROM
UNDER-REPRESENTED GROUPS IN OUR
SCIENCE WHICH IS FOR US A REAL
PROBLEM. ONLY 6% OF OUR
APPLICANTS ARE UNDER-REPRESENTED
GROUPS AND ONLY 5% OF THE
AWARDEES ARE FROM
UNDER-REPRESENTED GROUPS. SO
THIS PROGRAM WHICH NIDA DRUG
ABUSE INSTITUTE AND MENTAL
HEALTH HAVE ALSO SIGNED ON WILL
BE A SPECIAL RO1, ENCOURAGE MORE
DIVERSE POOL OF PIs TO
CONTRIBUTE. IT WILL BE FOR THOSE
VULNERABLE PIs, FOR THOSE
EARLY STAGE, ALSO NEW
INVESTIGATORS, WHO MAY BE PAST
THE EARLY STAGE TIME WINDOW. SO
LOOKING FORWARD TO SEE HOW THIS
CAN HELP US KIND OF ACHIEVE THIS
GOAL OF GETTING MORE -- BETTER
DIVERSITY INTO OUR WORK FORCE
BECAUSE WE THINK THAT IS WHAT IS
GOING TO HELP ADVANCE SCIENCE IN
A MORE STRONG DIRECTION.
SIMILARLY, WE HAD A SIMILAR
PROGRAM FOR BASIC SCIENCE WHEN
WE REALIZED APPLICATIONS FOR
BASIC SCIENCE RESEARCH WERE
FALLING AND SO THIS IS WHAT I
MENTIONED ABOUT THE DIVERSITY
RO1 IS SOMEWHAT RELATED. WE WERE
ABLE TO STEM THAT TIDE
DECREASING BASIC SCIENCE
APPLICATIONS, BUT WE FEEL WE
SPEND A GREAT DEAL OF EFFORT IN
MANY DISEASE SPACES AND THOUGHT
IT WAS REALLY IMPORTANT TO TAKE
A LOOK AT HOW WE SUPPORT BASIC
NEUROSCIENCE RESEARCH. THIS IS
RESEARCH THAT IS FUNDAMENTAL, IT
IS NOT DISEASE AGNOSTIC BUT WHAT
WE KNOW IS THAT THIS IS A
FOUNDATION FOR WHAT EVERYTHING
COMES NEXT, WHICH IS DISEASE
FOCUS RESEARCH. SO INCREDIBLY
IMPORTANT FOR OUR INSTITUTE THAT
THIS IS STRONG. WHAT WE ARE
DOING IS WE ARE PUTTING OUT A
REQUEST FOR INFORMATION TO GET
IDEAS ON WHAT IS IT THAT COULD
REALLY HELP OUR BASIC
NEUROSCIENCE RESEARCH. IS IT
RESOURCE, IS IT DATA SYSTEMS? IS
IT NEW TOOLS? WE LEARNED FROM
THE BRAIN INITIATIVE HOW
IMPORTANT TOOLS ARE. THOSE ARE
FOCUSED ON BASICALLY
NEUROCIRCUIT BASIC VERGE. SO
THIS IS MORE -- RESEARCH. THIS
IS MORE WIDE SCOPE THAN THAT.
WHAT WE ALSO ESTABLISHED WORKING
GROUP OF COUNCIL SO WE WILL BE
LOOKING FOR COUNCIL MEMBERS TO
TAKE A ROLE AS IN THIS WORKING
GROUP TO THINK THROUGH THE
FEEDBACK WE GET, WORK WITH US
AND THE COUNCIL DEVELOP --
WORKING GROUP DEVELOPS
RECOMMENDATIONS HOW WE CAN BEST
ADVANCE OUR FUNDAMENTAL
NEUROSCIENCE RESEARCH. AGAIN
LIKE ALL THE WORKING GROUPS WE
BRING BACK THEIR RECOMMENDATIONS
TO THE GREATER COUNCIL FOR
DISCUSSION AND FINALLY
EVENTUALLY APPROVAL BY THIS
BODY. SO REALLY WANT PEOPLE TO
THINK HARD ABOUT THIS ISSUE, IT
IS SO IMPORTANT TO THE
INSTITUTE. NOW I WILL JUMP TO
THE CLINICAL TRIAL NETWORKS. WE
HAVE TWO THAT WERE -- WILL BE
RECOMPETING, STROKE NET OR
STROKE RESEARCH BOTH PHASE 1,
PHASE 2, PHASE 3, ACUTE STROKE
PREVENTION AND REHAB, THAT IS
WHERE MOST CLINICAL TRIALS IS
AND THE NEURONETWORK WHICH IS
PHASE 2 TRIALS OF NEW THERAPIES,
THAT REALLY COVERS THE WATER
FRONT OF ALL OUR DISORDERS, WITH
EXCEPTION TO STROKE TO GO INTO
STROKE NET. BOTH ARE RUNNING,
BOTH EVALUATED, BY THE WORKING
GROUP OF OUR COUNCIL. AND THE
RECOMMENDATIONS ARE GOING TO BE
INFLUENCING HOW WE SET UP NEW
NETWORKS, PRIORITIES ISSUE CAME
UP LOUD AND CLEAR. THAT THE
COUNCIL IS ASKING US MAKE IT
MORE CLEAR TO THE COMMUNITY OF
GRANTEES, WHAT THE PRIORITIES
FOR RESEARCH ARE. I WILL TURN
THAT AROUND ON THE COMMUNITY AND
SAY WHAT YOU DON'T WANT IS THE
GOVERNMENT TELLING YOU WHAT TO
DO. WHAT WE DO WANT IS PEOPLE
WORKING TOGETHER TO GO TO THE
COMMUNITY, THE SCIENCE
COMMUNITY, GET GOOD IDEAS, AND
AS A GROUP COME UP WITH
PRIORITIES AND NOT REALLY TOP
DOWN BUT THEY ARE COMMUNITY
BASED PRIORITIES AND THAT IS
WHAT WE HAVE DONE IN THE PAST.
THAT IS ALSO WHAT WE NEED TO
KIND OF UP OUR GAME PLAN FOR
THESE NETWORKS AND DO IN THE
FUTURE. NETWORKS WERE SET UP TO
IMPROVE EFFICIENCY, WE THINK
THEY HAVE IMPROVED EFFICIENCY
BUT THERE IS STILL A LONG WAY TO
GO TRYING TO GET THINGS MOVING
MORE QUICKLY. THE PREPARATION
AND THE PROCESSES TO GET THROUGH
THESE APPROVAL FOR CLINICAL
TRIALS IS REALLY QUITE LONG AND
LABORED. THEY ARE VERY EXPENSIVE
SO WE HAVE TO BE JUDICIOUS, ALSO
NETWORKS HAVE BANDWIDTH SO WE
HAVE TO BE CAREFUL ON HOW MUCH
WE GIVE THEM AT A TIME BUT
CLEARLY WE TAKE THE MESSAGE LOUD
AND CLEAR. A LOT WE CAN DO TO
STREAMLINE THIS PROCESS AND WE
WILL BE WORKING ON THAT. WE ALSO
HAVE -- WE GOT -- WE LEARNED A
LOT FROM THE WORKING GROUP
INPUT, THIS WAS TEN YEAR AFTER
TEN YEARS AN ACTUALLY GO DOWN A
LITTLE BIT OF TIME TRYING TO
DEVELOP A FIVE YEAR EVALUATION
PLAN INSTEAD OF WAITING TO TEN,
THAT MAKES A LOT OF SENSE. SO
THANK YOU VERY MUCH TO THE
WORKING GROUP FOR ALL THE WORK
YOU DID ON THIS. YOU WILL SEE
THE VALUE AS A NETWORK
TRANSITIONS INTO NEW PHASE.
AGAIN, THANKS TO SO MANY PEOPLE
WHO WORKED ON THIS WORKING GROUP
FROM COUNCIL, PAST COUNCIL,
PARTICULARLY BARB VICRY AND
RICK, CO-CHAIRS AND ALL THE
FOLKS WHO WORKED FROM NIH AND
NETWORKS REALLY PROUD OF THE
WORK THEY DID. I WANT TO TALK
ABOUT COUPLE OF MEETINGS COMING
UP, THE RECENT MEETINGS WAS A
REALLY INTERESTING BRAIN ATTACK
COALITION SYMPOSIUM EQUITIES AND
ACCESS TO DELIVERY TO SHOW CARE.
-- STROKE CARE. THE BRAIN INTACT
COALITION IS A GROUP MEETING FOR
25 YEARS TRYING TO DEVELOP BEST
PRACTICES FOR PRIMARILY ACUTE
STROKE CARE AND BEGAN WITH THE
ADVENT OF GEARED UP WITH ADVENT
OF TPA COMING ON THE SCENE. THEY
HAVE DONE A LOT OF WORK, MOST
RECENTLY FOCUSED ON THIS ISSUE,
THAT WE HAVE TO FIGURE OUT HOW
TO CHANGE THE SYSTEM WHERE WHAT
HAPPENS TO YOU WHEN YOU HAVE A
STROKE DEPENDS ON WHERE YOU
LIVE. THAT IS REALLY THIS ISSUE
OF TRYING TO ADDRESS INEQUITIES
IN ACCESS. THE ISSUE AS YOU KNOW
IS THAT IN AN ACUTE ISCHEMIC
STROKE, CHANCE OF HELPING
SOMEONE IS REALLY QUITE LARGE,
YOU CAN MAKE DRAMATIC HIGH
EFFECT SIZE DIMENSIONS BUT THEY
HAVE TO BE EXECUTED WITHIN HOURS
AND MINUTES IS EVEN BETTER, BUT
THEY HAVE -- THEY HAVE THIS
REALLY QUICK TIME LINE, IF YOU
ARE NOT IN A PLACE THATTING SOD
YOU MISS OUT ON THE OPPORTUNITY
AND UNFORTUNATELY CAN SUFFER
MASSIVE BRAIN DAMAGE AND NEVER
REALLY RECOVER TO ABLE TO TAKE
CARE OF YOURSELF AGAIN. SO IT IS
REALLY A TERRIBLE INEQUITY, HOW
TO FIX I THINK WORKING WITH
HEALTHCARE SYSTEMS, THERE ARE A
LOT OF THINGS YOU CAN DO, THERE
IS A LOT OF MODELS OUT THERE. WE
HAVE THE ALZHEIMER'S RELATED
DEMENTIA SUMMIT, YOU WILL HEAR
ABOUT THEM IN SEPTEMBER ABOUT
THE RECOMMENDATIONS THAT CAME
OUT OF THAT. FOR THE ALZHEIMER'S
DISEASE RELATED RESEARCH THAT WE
CAN NOW DO AT A LEVEL WE CAN
NEVER HAVE IMAGINED BEFORE WITH
THE FUNDING THAT COMES FROM THE
AGING INSTITUTE MANAGED FOR
THESE PROGRAMS THAT ARE MANAGED
BY NINDS. AND THEN OUR GROUP
INSIDE IS PUT TOGETHER A REALLY
GREAT WEBINAR SERIES FOR PEOPLE
WHO ARE INTERESTED IN
UNDERSTANDING HOW TO NEGOTIATE
THE NIH SYSTEM PARTICULARLY FOR
THOSE PEOPLE FROM DISADVANTAGED
COMMUNITIES. THEN COMING UP ARE
REALLY IMPORTANT CONFERENCE NEXT
WEEK CALLED CATALYZING
COMMUNITIES OF RESEARCH RIGOR
CHAMPIONS, THIS IS ONE BY SHI
AND DEVIN CRAWFORD, THEY ARE
WORKING HARD TO PROMULGATE
RIGOROUS SCIENCE IN THE DESIGN
AND ANALYSIS OF HOW PEOPLE DO
EXPERIMENTS AS YOU WILL SEE IN
CLOSED SESSION WE WILL BE
LOOKING AT GRANTS TO FUND
CENTERS THAT WOULD DEVELOP
EDUCATION MATERIALS AND IMPROVE
RIGOR CENTERED TO EVALUATE AND
VALIDATE THESE AND WE REALLY
WANT TO CREATE A NEW CULTURE
WHICH PUTS THE QUALITY AND RIGOR
OF THE SCIENCE AT THE TOP OF
GOAL IN TRAINING AND ACTUALLY
THE EXECUTION OF SCIENCE IN THE
LABORATORY. SO LOOKING FORWARD
TO THIS CONFERENCE NEXT WEEK. WE
HAVE OUR NON-PROFIT FORUM COMING
UP IN THE SUMMER WHICH BRINGS IN
GROUPS FROM 70 DIFFERENT
DISEASES ADVOCACY ORGANIZATIONS
THAT REPRESENT PATIENTS OF MANY
DIFFERENT DISORDERS WHERE WE GET
REAL INPUT VALUABLE INPUT FROM
THE GROUND UP FROM THE PATIENTS
THEMSELVES AND THEIR CAREGIVERS
THE BRAIN INITIATIVE
INVESTIGATION MEETING ALSO
FANTASTIC MEETING WHERE THE NEW
TOOLS AND SCIENCE COMING OUT OF
THE BRAIN INITIATIVE IS
PRESENTED AND DISCUSSED, THAT IS
COMING UP IN JUNE, THAT WILL BE
A HYBRID MEETINGING. THE PAIN
MANAGEMENT THROUGH THE LENS OF
WHOLE PERSON HELP SYMPOSIUM FOR
THE PAIN CONSORTIUM WHICH IS THE
TRANS-NIH GROUP OF INSTITUTES
WORKING IN PAIN. THAT IS OUR
ANNUAL MEETING THERE. SO GOOD
STUFF COMING UP QUESTION SPITE
COVID. SPEAKING OF COVID WE
CERTAINLY WANT TO GIVE A REAL
CHEER TO OUR STAFF WHO WORKED
THROUGH COVID, DIFFICULT TIMES
BUT HAVE DONE A REALLY
RETREMENDOUS JOB. THINKING ABOUT
THE FUTURE WORK A LOT WE HAVE
BEEN THINKING HOW TO WORK AS AN
INSTITUTE BUT WE WANT TO ASK YOU
ABOUT HOW SHOULD WE WORK AS A
COUNCIL. SO WE KNOW SOME THINGS
ABOUT VIRTUAL MEETINGS NOW THE
PROS AND THE CONS AND WE LIKE TO
DO NOW IS TO HEAR FROM PEOPLE
ABOUT WHAT YOU EACH SHOULD DO IN
THE FUTURE TO DO FOR COUNCIL.
WHAT DO YOU LIKE ABOUT THE
VIRTUAL MEETING, WHAT DO YOU
MISS ABOUT THE IN PERSON
MEETING. WHAT DO YOU THINK THE
VALUE IS OF IN PERSON VERSUS
HYBRID MEETINGS? AND WHAT WOULD
YOU LIKE TO SEE IN THE FUTURE?
JUST JUMPING THE GUN A LITTLE
BIT, I THINK THAT GUESSING BUT
WE WILL SEE BUT WE WANT TO
UNDERSTAND WHAT YOU THINK ABOUT
WHAT IS THE OPTIMAL BALANCE
BETWEEN VIRTUAL HYBRID AND IN
PERSON MEETINGS NOT JUST
INDIVIDUAL MEETING IS IMPORTANT
BUT WHAT ABOUT BALANCE OVER THE
YEARS, SOME MEETINGS IN PERSON
AND SOME ARE VIRTUAL, SOME
HYBRID. SO REALLY OPEN THIS UP
FOR DISCUSSION. AND WITH THAT I
WANT TO THANK YOU AND LET'S TALK
ABOUT WHAT PEOPLE THINK ABOUT
COUNCIL IN THE FUTURE. THANK YOU
VERY MUCH.
>> WE TAKE DOWN THE SLIDE AND WE
HAVE --
>> HAPPY TO ANSWER ANY
QUESTIONS. AND THEN I THINK WHAT
WE WOULD LIKE TO DO IS CALL ON
PEOPLE GETTING THEIR ADVICE
ABOUT FUTURE COUNCIL MEETINGS
AND HOW THEY WOULD LIKE TO SEE
THEM.
>> SAMEER WAS FIRST.
>> BEAT YOU BY A FRACTION OF A
SECOND.
>> I THINK REGARDING COUNCIL, I
HAVE NOT BEEN IN AND IN PERSON
COUNCIL MEETING. BEEN IN OTHER
MEETINGS THAT HAPPEN IN PERSON
SO I SUPPOSE MY VOTE FOR WHAT
IT'S WORTH IS WHEN WE ARE ABLE
TO DO SO I WOULD LOVE TO DO
THAT. IT IS OBVIOUSLY A LOT MORE
-- LESS COMMUTING IN TERMS OF
TRAVEL TIME AND EXPENSE AND
CARBON FOOTPRINT AND THAT STUFF
BUT THERE IS A REAL VALUE TO
THESE DISCUSSIONS. IT IS ONE
THING TO LECTURE A ONE WAY
TRANSMISSION OF INFORMATION,
THAT IS EASY ENOUGH TO DO WITH
THIS FORMAT AND IT IS FANTASTIC
BUT A LOT OF WHAT WE DO HERE
REQUIRES BENEFITS FROM
DISCUSSION, THAT'S VERY HARD TO
DO WITH ONE PERSON IN A BOX WITH
A GREEN THING AROUND THEM AT A
TIME.
>> THANKS, SAME,R. TIM.
>> I HAD A QUESTION RELATED TO
THE WALTER'S TALK, IN ADDITION
TO JUST SIMPLY AGREEING WITH
SAMEER WITH RESPECT TO COUNCIL
MEETINGS AND VALUE OF IN PERSON
INTERACTION FOSTERING
DISCUSSION. MY QUESTION WAS MORE
I DON'T KNOW IF THIS IS THE
APPROPRIATE TIME SINCE IT WAS
WHAT WALTER SPENT HALF HOUR
TALKING ABOUT, THE DATA SHARING
INITIATIVE THAT STARTS IN 2023,
ONE THING THAT IS VALUABLE I CAN
TELL YOU NOW THE UNCLEAR FROM
USERS POINT OF VIEW, IS EXACTLY
WHAT LEVEL APPLIES -- IT IS ONE
THING I COULD PAY GOOD MONEY FOR
A CORE FACILITY TO GENERATE A
PROTEOME SEQUENCING THAT IS
READY TO SHIFT TO OPEN SOURCE
DATABASE BUT THAT IS THAT
CATEGORY. THERE IS A A LOT OF
OTHER THINGS THAT SUPPORT THE
WORK WE DO IN MY LAB THAT WILL
TAKE A HUGE AMOUNT OF ANNOTATION
TO MAKE IT USEFUL TO PUT INTO A
DATABASE SO IT WILL BE GREAT IF
THE PROGRAM OFFICERS COULD
SOMEHOW BEFORE DEADLINE HITS
MAKE IT CLEAR THE CATEGORIES AND
EXPECTATION OF WHAT THEY THINK
IS -- WHAT SHOULD BE SHARED,
WHAT THEY THINK IS THE RIGHT WAY
TO SHARE, WE ARE KIND OF GOING A
BIT LIKELY FOR STUFF, WHEN RIGOR
SHOWED UP AS CRITERIA FOR STUDY
SECTIONS, WE DIDN'T KNOW WHAT
THE STANDARDS WERE. SO IT
CHANGED EVERY STUDY SECTION. WE
HAD LIKE ON THE SITTING ON IT
JUST YEAH SOUNDS RIGOROUS TO ME.
BUT WE DIDN'T REALLY KNOW -- SO
I THINK SINCE THIS IS NEW AND IT
HAS SORT OF COSTS IMPLIED AS
NINA POINTED OUT FOR INTRAMURAL,
YOU DON'T KNOW HOW TO DO IT. BE
NICE IF THEY COULD WORK UP SOME
TEMPLATE FOR WHAT HOW WE SHOULD
THINK ABOUT IT. THANK YOU.
>> THANKS, TIM. ALLAN.
>> MIGHT BE INTERESTED IN HAVING
AT LEAST ONE MEETING IN PERSON A
YEAR, NOT SO MUCH -- DON'T TAKE
IT PERSONALLY TO SEE PEOPLE IN
HOLLYWOOD SQUARES BUT TO SEE THE
PEOPLE SITTING AROUND THE TABLE.
WE DON'T GET TO INTERACT WITH
THEM AND A LOT OF INFORMATION
CAN BE GATHERED NOT ONLY JUST TO
GET TO KNOW THEM BECAUSE
SOMETIMES WE DEAL WITH THEM BY
EMAIL BUT TO ACTUALLY WHEN THERE
IS A FREE TIME TO TALK ABOUT
SOME OF THE QUESTIONS THAT ARE
RELEVANT TO COUNCIL DECISIONS,
WE JUST DON'T HAVE ANY
INTERACTION WITH THEM AT ALL
WHEN IT IS ONLY A VIRTUAL
MEETING WHERE I SEE PEOPLE ARE
SITTING AROUND THE TABLE.
>> BY THE WAY TIM IN TERMS OF
YOUR POINT, WE HAVE AN INTERNAL
WORKING GROUP RUNNING FOR SOME
TIME LED BY LYNN JAKEMAN
ADDRESSING ISSUES OF DATA
SHARING AMONG OTHERS. YOUR POINT
IS THAT WE HEARD LOUD AND CLEAR.
LOUISE.
>> I AGREE WITH BOTH, THERE'S
SOMETHING MISSING WITHOUT FACE
TO FACE INTERACTIONS BUT I ALSO
RECOGNIZE DUE TO PEOPLE'S
SCHEDULES AND THE COST
ASSOCIATED WITH ALWAYS DOING IT
IN PERSON, THERE IS PROBABLY
MAYBE WIGGLE ROOM TO ALTERNATE
WHERE -- AGAIN, IF THERE IS AN
IMPORTANT HEME IN COUNCIL YOU
MISS THIS IN PERSON INTERACTION
MEETING WITH COLLEAGUES,
THINKING OF THINGS. I THINK A
LOT OF THE OFF HOURS DISCUSSIONS
ARE VERY HELPFUL TOO. BUT IT IS
COSTLY AND PERHAPS THOSE COSTS
COULD BE FUNNELED INTO SOMETHING
MORE USEFUL AS I THINK SOMEONE
ELSE MENTIONED. BECAUSE IT WOULD
BE A MAJOR COST SAVINGS IF WE
DID WANT IT ONE LIVE, ONE
REMOTE, ONE LIVE ONE REMOTE.
>> THERE IS A NUMBER OF
INSTITUTESES THAT ARE THINKING
ABOUT HAVING ONE IN PERSON
MEETING A YEAR. ALTERNATING IS
ANOTHER POSSIBILITY. COUNCIL
MEMBERS HAVE TOLD ME THEY MISSED
COUNCIL DINNER WHICH WAS A FORUM
WHERE EVERYBODY SHARED
INFORMATION AND SHARED OTHER
THINGS AS WELL.
>> I REALLY MAKE THE CASE THAT
THE IN PERSON MEETINGS ARE WORTH
THE EXPENSE. I THINK IT IS
BUILDS COMMUNITY AMONG THE
COUNCIL, HELPS US WORK TOGETHER
BETTER AS A TEAM WHEN WE CAN BE
TOGETHER. I THINK ALSO BEING
ABLE TO SEE THE NINDS STAFF,
DINNER BOB MENTIONED I THINK IS
REALLY IMPORTANT. SO HAVING DONE
BOTH IN PERSON AND REMOTE, I
REALLY WOULD URGE US TO GO BACK
TO THE IN PERSON. WE CERTAINLY
HAD THE TECHNOLOGY TO DO REMOTE
BEFORE THE PANDEMIC AND IT IS
OBVIOUSLY DECISION WAS MADE TO
NOT DO THAT. I WOULD URGE AT
LEAST TO GO BACK IN PERSON AND
GIVE IT A TRY.
>> THANKS A LOT, ED. KEN.
>> THANKS. SO NOT SURPRISINGLY
I'M ECHOING WHAT YOU HEARD
BEFORE, I THINK THE ADDITIONAL
PERSPECTIVE THAT I WOULD SHARE
IS IF THERE IS A SENSE THAT WE
CAN SAVE ON TRAVEL AND SAVE ON
EXPENSES AND THINGS LIKE THAT,
BY HAVING ONE VIRTUAL MEETING, I
WOULD SUGGEST THAT THINKING
AROUND WHAT TOPICS GET DISCUSSED
IN THE FACE TO FACE MEETING IS
REALLY IMPORTANT. SO IF YOU --
IF NINDS IS UNDERGOING SOME
STRATEGIC CHANGES, THERE'S SOME
IMPORTANT STRATEGIC INITIATIVES
COMING OUT FROM CONGRESS THAT
NEED TO BE DISCUSSED OR PUT ON
THE TABLE, INSTITUTE REVIEWS,
REALLY WEIGHTY TOPICS WHERE YOU
WANT TO HEAR FROM EVERY MEMBER
OF YOUR COUNCIL, THAT IS A FACE
TO FACE MEETING. BECAUSE WE ARE
ALL ENGAGED BUT WHEN YOU ARE IN
A VIRTUAL MEETING FOR THREE
HOURS, FOUR HOURS, YOUR
CONCENTRATION IS NOT GOING TO BE
THERE. IT IS MUCH MORE THERE,
MUCH MORE ANIMATED YOU ARE MORE
LIKELY TO GET MORE PEOPLE REALLY
THINK WHEN YOU ARE FACE TO FACE,
I THINK WHEN YOU ARE DEALING
WITH THOSE KINDS OF WEIGHTY
ISSUES THAT'S WHEN YOU WANT TO
HAVE FACE TO FACE.
>> THAT IS REALLY INTERESTING
POINT THAT I HADN'T THOUGHT
ABOUT. TAILORING THE TOPICS TO
THE TYPE OF MEETING. THERE IS A
BUNCH OF COMMENTS IN THE CHAT,
GINA WAS TALKING ABOUT MONEY
COST SAVING AND ENVIRONMENTAL
HELPFUL NOT TO HAVE IN PERSON
MEETINGS. AND CHRIS WAS ALSO
AGREEING WITH THAT, SAYING I
WOULD LOVE TO KNOW HOW MUCH
MONEY SAVED BY VIRTUAL MEETINGS
AND HOW THAT MONEY WAS USED. THE
OTHER THING I WANT TO CLARIFY,
WHEN WE ARE TALKING HYBRID WE
ARE NOT TALKING ABOUT SOME
MEETINGS VIRTUAL AND SOME IN
PERSON. A HYBRID MEETING IS ONE
WHERE SOME PEOPLE ARE THERE IN
PERSON AND OTHERS ARE THERE ON
ZOOM. I ACTUALLY HAVE -- IN YOUR
COMMENTS, I HAVE A QUESTION FOR
YOU BECAUSE I'M NOT SURE HOW
WELL THAT MODEL WORKS. IS YOUR
HAND OUT -- YOU ARE MUTE MUTED.
>> COUPLE OF COMMENTS. ONE I
TAUGHT A HYBRID CLASS, THIS PAST
SEMESTER, IT IS REALLY HARD TO
DO WELL AND I THINK PEOPLE WHO
ARE ONLINE JUST ARE NOT AS WELL
INTEGRATED. IT WAS WORSE THAN
ALL IN PERSON OR ALL ONLINE. I
THINK ALL ONLINE THE STUDENTS
FELT LIKE THEY WERE ALL ENGAGED,
ALL IN PERSON IS NOT ONLY
DIFFICULT FOR PERSON MODERATING
IT BUT IT HAS -- FIGURE OUT
GREAT SUCCESSFUL MODEL FOR THAT.
THE SECOND IS I THINK THAT'S
SPECIALLY FOR PARENTS WITH
CHILDREN LIKE ME FOR YOUNG
CHILDREN THAT THE VALUE OF
VIRTUAL AND BURDENS OF VIRTUAL
ENABLE GREATER PARTICIPATION IN
WAYS THAT PEOPLE WITH SMALLER OR
YOUNGER CHILDREN OR OLDER
CHILDREN, I DON'T KNOW WHAT THAT
IS LIKE YET, EXPERIENCE IN
TRAVELING AND I KNOW THAT THAT
TENDS TO SOMETIMES BE GENDER
DISTRIBUTION OF ROLES AND
BURDENS, SO I THINK A LOT OF
PEOPLE L ARE LOOKING AT THE
IMPACT OF DIFFERENT CAREGIVER
ROLES AND HOW VIRTUAL ENABLES
BETTER PARTICIPATION AND MY
PLAYING FIELD A BIT IN THAT WAY.
I THINK THAT WE ALL ARE GOING TO
FIGURE OUT WHAT ONLINE MEETINGS
LOOK LIKE, WHAT WE TRIED THE
PAST TWO YEARS WAS SHORTEN THEM
BUT LARGELY HAD TO BE SAME
EXPERIENCE WHAT IT WAS IN PERSON
AND THAT DOESN'T WORK. I THINK
IT IS THE WEIGHT OF THE FUTURE
IS TO EXPECT MORE ONLINE
MEETINGS BUT FIGURING OUT HOW TO
DO SO, THAT IT ISN'T PASSIVE
ENGAGEMENT IN WAYS THAT BREAKS
MEETINGS IN PERSON ENABLED THAT
MODEL TO WORK. THAT MODEL
DOESN'T WORK ONLINE. AS WE ALL
KNOW. THERE ARE MANY
DISTRACTIONSES AND DIFFICULTIES
HAVING WATER COOLER
CONVERSATIONS AND EVERYTHING
ELSE BUT I THINK IT MEANS THE
MORE WE START TO INNOVATE WITH
SHORTER MEETINGS, SPREAD OVER
MORE DAYS MORE INTERACTIVE
MEETINGS MORE BREAK OUT SESSIONS
MORE DIFFERENT MODELS WE WILL
GET BETTER AT IT BUT WE HAVE TO
GET BETTER AT IT FOR IT TO COME
CLOSE TO APPROXIMATE MATEING
WHAT THE IN PERSON EXPERIENCE OF
MEETINGS IS LIKE.
>> SOMEONE ASKED MISDEMEANOR THE
CHAT, SURELY THIS HAS BEEN
STUDIED. THE ANSWER IS ALREADY
STUDIED TREMENDOUS EXTENT, WE
LOOK AT ALL KINDS OF PAPERS ONE
THAT WALTER SENT RECENTLY SEEMED
TO SUGGEST, THAT BRAINSTORMING
IS BETTER IN PERSON. THE OTHER
HAND THERE'S ALL KINDS OF
STUDIES THAT SHOW SITTING ALONE
COMING UP WITH IDEAS SO WHO
KNOWS HOW TO INTERPRET BUT ANY
CASE, IN PERSON MEETINGS
DEFINITELY ARE DIFFERENT AND A
LOT OF THINGS ARE BETTER. BUT
THERE IS ADVANTAGES TO -- I
GUESS THE CONSENSUS THAT SEEMS
TO BE EMERGING IN THE CHAT IS
THAT HYBRID MEETINGS ARE LOUSY.
THAT THEY DON'T WORK. I SEE
HEADS NODDING UP AND DOWN.
>> WALTER, DO YOU WANT ANY MORE
FEEDBACK, DO YOU WANT TO SAY
ANYTHING ABOUT THIS? ON THAT
PARTICULAR TOPIC?
>> I THINK THE POSITION WE HEARD
IS LET'S SEE IF WE GET SOME MORE
IDEAS OUT THERE PEOPLE PUT THEIR
OWN THOUGHT MS. THE CHAT. SO
SOUNDS LIKE WE DEFINITELY WANT
TO HAVE ONE IN PERSON MEETING.
QUESTION IS DO WE WANT TWO OR WE
GOOD WITH ONE? IT ALSO SOUNDS
LIKE WE DON'T WANT HYBRID BUT WE
SOME PEOPLE WOULD LIKE TO
ACTUALLY HAVE A VIRTUAL MEETING
SO ONE OPTION MIGHT BE TWO IN
PERSONS AND ONE VIRTUAL OR ONE
IN PERSON TWO VIRTUALS. SO IF
YOU CAN PUT IN THE CHAT -- WE
ARE TALKING ABOUT YOU GUYS WE
ARE HAPPY TO DO WHATEVER YOU
THINK IS BEST, TRY SOMETHING
SOMETHING DIFFERENT LATER BUT
PUT IN THE CHAT WHAT YOU WOULD
THINK. SAVE THE CHAT.
>> VIRTUAL AT WINTERTIME AND
NUMBER OF PEOPLE SAID THAT. I
THINK GINA'S HAND, ACTUAL HAND?
THAT IS WHAT I SAID. SHOJI IN
AND NINA, THEN WE NEED TO MOVE
ON.
>> HI, EVERYBODY. THANK YOU,
ROBERT FOR TELLING US ABOUT THE
STUDIES THAT HAVE BEEN DONE. I
WANT TO THANK EVERYBODY FOR
THEIR GOOD THOUGHTS. NINA, I
HAVE ALSO TRIED TO TEACH A
HYBRID CLASS AND IT IS REALLY,
REALLY DIFFICULT. BUT WHEN YOU
DO IT WITH OTHER CO-TEACHERS IN
THE ROOM WHO CAN MONITOR THE
CHATS AND CALL ON PEOPLE ASKING
QUESTIONS, IT WORKS ACTUALLY
PRETTY WELL, ESPECIALLY IF
SOMEONE IS SICK AND HAS TO STAY
HOME, IT ALLOWS THEM TO BE PART
OF THE CLASS STILL AND HEAR IT
LIVE. I REALLY THINK ACTUALLY
HYBRID CAN WORK IF DONE
PROPERLY, IF DONE WITH LOTS OF
SUPPORT PEOPLE MONITORING THE
CHATS AND MAYBE WITH PROPER
KINDS OF MICROPHONES SPREAD
AROUND THE ROOM FOR THOSE WHO
WERE THERE IN PERSON SO THAT
THOSE LISTENING ONLINE CAN TUNE
IN TO VARIOUS MICROPHONES
PERHAPS IF THAT WORKS. THERE
MIGHT BE A THOUGHTFUL WAY TO
MAKE IT WORK WELL. I ALSO LIKE
THE IDEA OF MAYBE ONE IN PERSON
MEETING OR TWO IN PERSON
MEETINGS, AND THE REST VIRTUAL.
SO ANYWAY, IT IS A GOOD QUESTION
AND THERE ARE DEFINITELY PLUSES
AND MINUSES TO EVERYTHING. FOR
EXAMPLE, ONE OF THE MINUSES FOR
VIRTUAL MEETINGS IS THAT SOME
PEOPLE DON'T HAVE GOOD ACCESS TO
THE INTERNET AND/OR HAVE A NOISY
ENVIRONMENT WHICH TO ACCESS THE
INTERNET. ANYWAY, PLUSES AND
MINUS ON BOTH SIDES.
>> TIM AND BROOK, CAN SOMEONE
SAVE THE CHAT FROM THIS MEETING
I WANT TOE STAY ON SCHEDULE, I
HAVE OPEN ACCESS. NEXT, ONCE A
YEAR WE ARE REQUIRED TO HAVE A
DISCUSSION OF WHAT IS GOING ON
IN OUR INTRAMURAL PROGRAM AND
NINA WHO IS THE -- NINA SCHOR
THE PRINCIPAL DEPUTY TREK TO OF
NINDS BUT HEAD OF INTRAMURAL
NOW, OBVIOUSLY VERY NOW, SHE'S
GOING TO DO THAT. NOT A GREAT
INTRODUCTION NINA, BUTLY TURN IT
TO YOU.
>> PRETTY FAMILIAR TO THIS GROUP
AND AS ALWAYS GRATEFUL TO ALL OF
YOU NOR TUNING IN AND -- FOR
TUNING IN, WONDERFUL TO SEE YOU
EVEN IN ZOOM PLATFORM. I AM
GOING TO SHARE MY SCREEN AND DO
A LITTLE BIT OF REALLY VERY
BRIEF PRESENTATION ON THE
INTRAMURAL PROGRAM. I'M GOING TO
FOCUS ON WHAT IS OUR REALLY
CURRENTLY OUR MAJOR ACTIVITY
WHICH IS TO PUT IN PLACE NEW
LEADERSHIP FOR THE INTRAMURAL
PROGRAM. I'M GOING TO TALK ABOUT
WHAT I HAVE TERMED THE FOUR STEP
PROCESS FOR PREPARATION. WE
BEGAN BY TAKING STOCK OF WHAT IT
IS THAT WE HAVE AND THEN
THINKING OF WHAT IT IS THAT WE
WOULD LIKE TO DO GOING FORWARD
IN ORDER TO IDENTIFY THE RIGHT
LEADER FOR THAT. WE THEN
EMBARKED ON A SURGE, SOME OF YOU
WERE PART OF THAT. WE SET
EXPECTATIONS FOR OURSELVES OF
THE PEOPLE THAT WE INTERVIEWED
BUT WE ALSO TRIED VERY HARD, I
TRIED AS I TALKED TO FACULTY AND
TO TRAINEES, TO SET THEIR
EXPECTATIONS FOR A NEW PERSON
COMING ON BOARD AS A LEADER. AND
FOR THEIR ABILITY TO HAVE INPUT
INTO THAT PROCESS. REALLY, I SAW
PART OF MY JOB COMING AFTER
LORENA HAVING STEPPED DOWN
RELATIVELY SOON AFTER ASSUMING
THE POSITION. I SAW MY JOB AS
NOT JUST LOWERING THE
TEMPERATURE IN THE ROOM BUT ALSO
AS ENABLING OPTIMISM TO
REEMERGE. ONCE WE HAVE A NEW
DIRECTOR ON SITE, OUR JOB AS A
FACULTY IS GOING TO BE TO
FACILITATE THE SUCCESS OF THAT
INDIVIDUAL. FINALLY AS WE
INAUGURATE A NEW SCIENTIFIC
DIRECTOR, I THINK WE HAVE TO
BEGIN THE PROCESS OF DEVELOPING
LEADERSHIP ABILITIES IN OUR MORE
JUNIOR MEMBERS AND PLANNING FOR
WHAT SUCCESSION LOOKS LIKE.
TAKING STOCK IN DREAMING DREAMS
WE BEGAN WITH THIS GROUP LARGELY
KNOWS ALREADY WITH THE STRATEGIC
PLANNING PROCESS AND CAME UP
WITH THREE CORNERSTONES OF WHAT
WE HAD TO BUILD UPON IN THE
INTRAMURAL PROGRAM AS
COLLABORATION, COMMUNICATION,
AND EQUITY. WE DID A SPACE AUDIT
TO ACTUALLY BE ABLE TO SAY TO
PEOPLE TAKING A LOOK AT THE
POSITION THIS IS THE SPACE THAT
YOU HAVE AVAILABLE NOT ONLY FOR
YOUR OWN RESEARCH PROGRAM BUT
ESPECIALLY FOR GROWING THE
PROGRAM, ESPECIALLY FOR
RECRUITMENT AND REPLACEMENT OF
PEOPLE IN THE PROGRAM. WE MADE A
MAJOR EFFORT AND I HAVE TO
CREDIT LORENA ROLE WITH
INITIATING THIS AND GETTING TO
SALARY EQUITY AND ENSURING THAT
THAT IS MAINTAINED AS WE BRING
PEOPLE IN. WE AND EVERYBODY AT
NIH HAVE BEEN FOCUSED ON WORK
FORCE DIVERSIFICATION. THEN MY
JOB AGAIN AS THE OPTIMIST OF THE
ENTERPRISE WAS TO ENABLE PEOPLE
TO DREAM BEYOND WHAT WE ARE
RIGHT NOW. WHAT DO WE WANT TO BE
THAT WE AREN'T RIGHT NOW. AND
WHAT DO WE NEED OPERATIONALLY TO
BEGIN THE PROCESS OF ACQUIRING
THAT AND ACHIEVING THA THAT. WEE
FORMED IN THE INTEREST OF
COLLABORATION AND COMMUNICATION
MANY GROUPS THAT DID NOT EXIST
BEFORE AND MANY VENUES INFORMED
AND ENABLED I THINK IN PART BY
ZOOM THAT DIDN'T EXIST BEFORE,
MY FAVORITE IS THE PORTER
NEUROSCIENCE BOOK CLUB THAT
PICKS EVERY QUARTER A DIFFERENT,
PORTER IS THE NAME OF THE
BUILDING WHICH OUR NEUROSCIENCE
COMMUNITY IS HOUSED. AND WE
CHOOSE A BOOK EVERY QUARTER AND
IT IS OFTEN A SCIENCE FICTION
BOOK OR A BOOK ABOUT CLIMATE
CHANGE OR BOOK ABOUT THE PEOPLE
OF THE HISTORY OF NEUROSCIENCE
AND EVERYBODY READS THE SAME
BOOK AND HAS A VERY ROBUST
DISCUSSION. BUT WE ALSO HAVE
AFFINITY GROUPS AND SPECIAL
INTEREST GROUPS THAT DIDN'T
EXIST BEFORE. A PROGRAM FOR
CAREER ADVANCEMENT THAT YOU HAVE
HEARD ABOUT IN THE PAST CALLED
BEACON FOR OUR NURSES. AND A
CORE IDEALS PROGRAM THAT REALLY
FOCUSES ON HOW DO WE ENSURE
INCREASING CIVILITY COLLEGIALITY
AMONG THE PEOPLE THAT ARE NEU
NEUROSCIENCE AT NINDS. WE HAVE
MUCH TO BE PROUD OF AND TO
SHOWCASE IN FRONT OF CANDIDATES
THAT WE RECRUIT FOR THE NEXT
SCIENTIFIC DIRECTOR. I WANT TO
LET YOU KNOW OUR OWN ANTONINA
ROLL MECAK WON THE AWARD OF
BIOCHEMICAL SOCIETY. SHE WORKS
ON TUBULIN CODE, THE WAY IN
WHICH TUBULIN POST SYNTHETIC
MODIFICATION ACTUALLY SHAPES
WHAT GOES ON IN THE CELL. WE
HAVE HAD MANY ON HAIR ELECTIONS
TO MEMBERSHIPS THIS YEAR BOTH
AAAS AND AMERICAN SOCIETY FOR
CLINICAL INVESTIGATION. AMONG
THE CLINICS FOR THE ASSOCIATION
OF AMERICAN PHYSICIANS. AND
DANNY WRIGHTS ELECTION TO HENRY
CONKEL SOCIETY FOR IMMUNONOLOGY.
AGAIN, A GREAT DEAL OF PRIDE IN
WHAT WE BUILT TO DATE. THE
EXAMPLE OF THAT AND SOMETHING WE
HOLD UP TO SOME OF OUR YOUNGEST
MEMBERS IS THE FACT THAT THIS
YEAR WE HAVE A NEW SCIENTIST
EMERITUS AND TWO INDIVIDUALS WHO
GAVE VALEDICTORY PRESENTATIONS,
JEFF SMITH AND MARK HALLETT.
THIS WAS THE BSC PRESENTATION
THAT REQUIRED NO CRITIQUE BUT
GAVE PEOPLE RETIRING A CHANCE
FOR A VICTORY LAP AROUND THE
STADIUM AND JUST REALLY
SPECTACULAR TALKS ABOUT NOT JUST
STUDIES IN SCIENCE BUT CAREERS
IN SCIENCE AND LIVES DEVOTED TO
SCIENCE, THAT REALLY STOOD AS AN
EMBLEM TO THOSE IN OUR GROUP
THAT ARE JUST STARTING OUT THEIR
CAREERS. SO THEN WE EMBARKED
UPON A SEARCH, AS I SAY, SOME OF
YOU WERE INVOLVED IN THAT
PROCESS. WE HAD AN INCREDIBLE
COMMITTEE. I AT EVERY STEP OF
THE PROCESS SAW IT AS MY
BUSINESS TO KEEP THE MEMBERS OF
THE NINDS INTRAMURAL RESEARCH
PROGRAM ENGAGED AND INFORMED TO
THE DEGREE THAT IT WAS
APPROPRIATE TO DO SO WITHOUT
DIVULGING ANYTHING THAT SHOULD
HAVE BEEN KEPT QUIET AND
CONFIDENTIAL FROM THE
CANDIDATES. IT IS A LITTLE BIT
OF A TIGHT ROPE WALK BUT THOUGHT
IT CRITICALLY IMPORTANT THAT THE
MEMBERS OF OUR COMMUNITY FEEL
ENGAGED AND INVOLVED AND
INFORMED FROM MINUTE ONE. WE
REACHED OUT BY EMAIL, BY PHONE,
BY SKYPE BY C WEEKEND, TO A
VERY, VERY LARGE POOL OF
POTENTIAL APPLICANTS AND
INDIVIDUALS THAT MIGHT INFORM US
OF POTENTIAL APPLICANTS. YOU CAN
SEE FROM THE TABLE ON YOUR LEFT,
IT WAS A RELATIVELY DIVERSE
GROUP THAT WE REACHED OUT TO.
AND ALMOST AS DIVERSE A GROUP
THAT APPLIED FOR THE POSITION. I
THINK LAST COUNT WE HAD 27
APPROXIMATE MR. I CAN'T FOR THIS
ONE POSITION. THEY WERE
Ph.D.s, M.D.s, MD
Ph.D.s AND VETERINARIANS. WE
FELT VERY, VERY GOOD ABOUT THE
DIVERSITY OF THIS GROUP IN EVERY
SENSE OF THE WORD. WE REALLY
CAST A VERY HIGH BAR FOR THE
QUALITY OF THESE APPLICANTS BUT
SAID THAT WE SHOULD CAST THE NET
VERY, VERY WIDELY FOR THE
SPECIFICS OF THEIR INTEREST IN
NEUROSCIENCE AND WHERE THEY CAME
FROM, WHO THEY REPRESENTED AS
CONSTITUENCIES. WE FELT VERY
IMPORTANT THAT AMONG NOT ONLY
THE APPLICANTS BUT AMONG THOSE
WHO BECAME FINALISTS AFTER A
FIRST ROUND OF INTERVIEWS, WE
INCLUDED MEN AND WOMEN. WE
INCLUDED M.D.s, Ph.D.s AND
M.D. Ph.D.s. THEIR INTEREST
RAN THE GAMUT OF NEUROSCIENCE
AND WHAT HELD THEM TOGETHER AS A
GROUP OF FINALISTS IS THAT EVERY
SINGLE ONE OF THEM HAS
LEADERSHIP EXPERIENCE, HAS HIGH,
HIGH QUALITY AND HIGH VISIBILITY
SCIENCE. THEY ARE ALL INTERESTED
IN TRAINING AND MENTORING AND
THEY ARE ALL DEDICATED TO
DIVERSITY EQUITY INCLUSION AND
ACCESS IN THE WORK FORCE. WE ARE
NOW IN THE MIDDLE OF HAVING THE
FINALISTS COME THROUGH IN ACTUAL
IN PERSON PHYSICAL VISITS. AND
MEET WITH JUNIOR FACULTY
TRAINEES, SEEN YOUR FACULTY AND
LAB AND OFFICE STAFF. REALLY
GIVING THEM A 360-DEGREE VIEW OF
WHO WE ARE AND GIVING OUR PEOPLE
A VIEW FROM EACH OF THEIR
VANTAGE POINTS OF THESE
CANDIDATES. AS I SAID, WE ARE IN
THE MIDDLE OF THE VISITS OF OUR
FINALISTS. ONCE WALTER WHO IS
THE DECIDING OFFICIAL DECIDES
WITH A VERY, VERY BROAD CROSS
SECTION OF INPUT, WHO IT IS THAT
IS THE DECISIONEE AND ONCE THAT
INDIVIDUAL SENSE THE POSITION, I
THINK THAT IS WHERE WE ALL AS A
COMMUNITY START FACILITATING
THAT INDIVIDUAL'S SUCCESS. I
WANT TO POINT OUT SEVERAL THINGS
THAT I THIS I EVOLVED LARGELY
THROUGH LORENA'S ADMINISTRATION
TO HELP ENSURE THAT PERSON'S
SUCCESS. THAT INCLUDES THE
INCREDIBLE OFFICE OF THE
SCIENTIFIC DIRECTOR STAFF THAT
WILL PROVIDE CONTINUITY,
COMPETENCY AND AUTHORITY THAT
TAKES SOME OF THE BOILERPLATE
THINGS OFF OF THE PLATE DIRECTLY
OF THE SCIENTIFIC DIRECTOR. WE
NOW HAVE A STANDARD OPERATING
PROCEDURES MANUAL FOR THESE
BOILERPLATE THINGS THAT WILL
ORIENT EVERYBODY VERY QUICKLY
AND STANDARDIZE THINGS. I THINK
ALL OF US WHO ARE INTRAMURAL
LEADERS OR WHO HAVE BEEN
SCIENTIFIC DIRECTORS IN THE PAST
HAVE A DUTY TO COACH AND ADVISE
BUT TO STAND BACK ENOUGH THAT
THE NEW INDIVIDUAL WILL HAVE
THEIR OWN PERIMETER ON THE
PROGRAM. I THINK WE ALL HAVE TO
BE MINDFUL OF THE UNIQUENESS OF
THE RELATIONSHIP AND POTENTIAL
FOR INTERACTION BETWEEN BASIC
AND CLINICAL NEUROSCIENCE ON THE
NIH CAMPUS. I THINK THAT WILL BE
BOTH A POINT OF PRIDE AND
OPPORTUNITY AND SOMETIMES A
CHALLENGE FOR THE NEW SCIENTIFIC
DIRECTOR. THESE ARE JUST
EXAMPLES OF THE PEOPLE IN THE
OFFICE OF SCIENTIFIC DIRECTORS
STAFF, RACHEL SCHACHERER REALLY
LEADS THE GROUP. MANY OF YOU
HAVE BEEN INTERACTIVE, IF YOU
HAVE ON THE GROUP WITH LIZA
LITVINA, SIMON HALEGOUA DEPUTY
SUPERB PARTNER, I VET PITMAN IS
INVOLVED IN TRAINING AND CAREER
DEVELOPMENT, ANGEL DE LA CRUZ
LANDRAU IS IN OUR SUMMER
PROGRAMS AND PROGRAMS FOR
MINORITY INDIVIDUALS AND RITA
DEVINE, SHE SAYS SHE'S INVOLVED
IN SPACE AND FA IT ISES AND
TRAINING, SHE IS THE UTILITY
OUTFIELDER WHO REALLY HANDLES
BROAD SWATH OF WHAT GOES IN THE
INTRAMURAL PROGRAM. WE HAVE
NAVIGATED, I THINK QUITE
SUCCESSFULLY HOW WE DO SCIENCE
AND STAY IN TOUCH WITH ONE
ANOTHER AND DO EDUCATION AND
TRAINING IN THE ERA OF COVID. I
THINK WE WILL BOTH HELP AND I
THINK MORE THAN ANYTHING ELSE
INFORM THE -- AND MAKE THINGS
EASIER FOR THE NEXT SCIENTIFIC
DIRECTOR. I THINK YOU BEGIN
SUCCESSION PLANNING THE DAY THE
NEW PERSON ON THE BLOCK ARRIVES.
WE HAVE BEGUN SEVERAL PROGRAMS
INVOLVED IN MENTORING FOR MANY
OF OUR SCIENTISTS FOR LEADER
LEADERSHIP, DESPITE THE FACT
THAT WE HAVE WHAT HAS BEEN
CALLED A FLAT ORGANIZATIONAL
STRUCTURE, WE MUST BEGIN
CREATING NEW OPPORTUNITIES FOR
GRADED LEADERSHIP, WE MUST
ENABLE TRANSITIONS FOR
INDIVIDUALS THAT ARE INTERESTED
IN TAKING ON LEADERSHIP
POSITIONS. I THINK WE HAVE TO
RECOGNIZE AND ADVANCE THE TALENT
AND INTEREST OF THOSE PEOPLE,
AND WE HAVE TO BEGIN DOING THIS
AS I SAID BEFORE THE END OF THE
TERM OF THE NEXT SCIENTIFIC
DIRECTOR. AND I THINK WE AT NIH
AND CERTAINLY I SAW THIS DURING
MY MORE THAN 30 YEARS IN THE
ACADEMIC SECTOR, IT IS A
HALLMARK OF SCIENTISTS IN SOME
MEASURE THAT WE TREAT LEADERS AS
IF THEY ARE -- I'M GOING TO USE
A TERM I HAVE HEARD USED JUST
ADMINISTRATORS, I THINK WE HAVE
TO BUILD RESPECT AND REALLY
RECOGNIZE THE FACT THAT AN
ADMINISTRATOR WHO IS NOT JUST
ADMINISTRATOR BUT IS A LEADER IS
A RARE COMMODITY AND IT IS NOT
SOMETHING THAT ANYBODY IS BORN
KNOWING HOW TO DO. WE HAVE TO
BREED THESE PEOPLE, WE HAVE TO
NURTURE THESE PEOPLE AND WE HAVE
TO TRAIN AND RESPECT THESE
PEOPLE FOR WHAT THEY BRING TO
THE SCIENTIFIC ENTERPRISE. SO I
WANT TO SHOW YOU SOME OF OUR --
I THINK FUTURE LEADERS, DERRICK
NURENDA WAS NAME AD LASKER
SCHOLAR, PHYSICIAN SCHOLAR,
DECEMBER MONDAY BROWN IS LATEST
IN SUCCESSION OF DISTINGUISHED
SCHOLARS NAMED BY NIH AS A WHOLE
AND QWON WAS AWARDED TENURE THIS
YEAR DESPITE I WAS A NEONIGHT
PRESENTING PEOPLE BEFORE TENURE
AT NIH. I DON'T KNOW WHO WAS
MORE NERVOUS ABOUT THIS QWON OR
ME BUT SHE EARNED IT AND AWARDED
THIS YEAR. VERY EXCITING
SUCCESSION PLANNING, SIMON IS
THE CLOSEST WE CURRENTLY HAVE TO
A DEPUTY SCIENTIFIC DIRECTOR.
WILL BE RETIRING FROM THAT
POSITION AND GOING BACK TO HIS
FACULTY POSITION AT STONY BROOK
ONE OF OUR STAFF SCIENTISTS WHO
HAD BEEN DOING PROJECT
MANAGEMENT FOR OUR PRESENCE BILL
INVESTIGATOR DAVID SIBLEY. FOR
MANY, MANY YEARS BEN WORKS AS
DOES DAVID ON ALLOSTERIC
REGULATION OF BINDING OF LIGANDS
TO DOPAMINERGIC FAMILY OF
RECEPTORS. BEN EXPRESSED AN
INTEREST IN REALLY SHOWED
APTITUDE DURING COVID OF MOVING
FROM PROJECT MANAGEMENT TO
PROGRAM MANAGEMENT AND SO WE
HAVE RECRUITED HIM WITH DAVE'S
BLESSING AND HELP TO THE OFFICE
OF THE SCIENTIFIC DIRECTOR. HE
WILL LARGELY TAKE SIMON'S PLACE
AS SIMON MOVES ON BACK TO STONY
BROOK. REALLY EXCITED ABOUT
THAT, REALLY THRILLED TO BE
WORKING NOW WITH BEN AS HE
TRANSITIONS. WE HEARD IN THIS
GROUP ABOUT THE BEACON PROGRAM
THAT OUR CLINICAL DIRECTOR AVI
AND OUR FORMER ADMINISTRATIVE
DEPUTY DIRECTOR MAUREEN GORMLEY
SPEARHEADED PROGRAM CALLED
BEACON. THAT PROVIDES CAREER
DEVELOPMENT AND LEADERSHIP
OPPORTUNITIES FOR OUR
NEUROSCIENCE NURSES IN THE
INTRAMURAL PROGRAM. POTENTIAL
FOR SUCCESSION PLANNING BUT
REALLY AN OPPORTUNITY FOR CAREER
DEVELOPMENT AND ADVANCEMENT FOR
PEOPLE IN THE CLINICAL PART OF
OUR INTRAMURAL PROGRAM AND
FINALLY WE CONDUCTED FOR THE
LAST COUPLE OF YEARS AN ENTIRELY
REMOTE SUMMER INTERNSHIP PROGRAM
AT NINDS. EVEN I WAS AMAZED AT
HOW EFFECTIVE THIS PROGRAM WAS.
WE HAD VIRTUAL PRESENTATIONS AND
POSTERS, WE HAVE CLASSES, WE HAD
PROJECTS THAT EVOLVED IN WAYS
THAT I NEVER WOULD HAVE EXPECTED
COULD BE DONE ON ZOOM. JUST
INCREDIBLY DIVERSE ENGAGED
INVOLVED AND SCARY SMART
COLLECTION OF UNDERGRADUATES AND
MEDICAL STUDENTS WHO JOINED US
FOR THE SUMMER AND REALLY
DEVELOPED AMAZING PROJECTS. SO I
HOPE THAT WITH THE RECRUITMENT
ONGOING OF OUR NEXT SCIENTIFIC
DIRECTOR WE WILL GO AS THEY SAY,
FROM STRENGTH TO NEW STRENGTH. I
THANK YOU FOR YOUR ATTENTION AND
I'M HAPPY TO ANSWER ANY
QUESTIONS.
>> I SEE PEOPLE APPLAUDING AND
THERE'S COMPLIMENTARY COMMENTS
IN THE CHAT. A HAND WENT UP
THEN KI DISAPPEARED. ARE THEREY
QUESTIONS? ALLAN, YOU ARE MUTED
>> I HAVE JUST A GENERAL
QUESTION. I'M CURIOUS ABOUT TO
WHAT EXTENT ARE YOU ABLE GET
INTERACTION FROM A SCIENTIFIC
AND EVEN OTHERWISE BETWEEN BASIC
SCIENTIST AND CLINICAL
SCIENTIST? IT IS A HUGE ISSUE ON
THE UNIVERSITY SIDE NOW WHERE
MONEY COMING INTO THE HOSPITAL
IS SO KEY TO SURVIVAL ALMOST
MAKING IT MORE COMPLICATED, I
WONDER IS THERE A SPECIFIC
EFFORT TO ENCOURAGE THAT OR THIS
JUST HAPPEN HOPEFULLY?
>> THERE IS -- THERE IS A
SPECIFIC EFFORT, I HAVE MADE IT
MY JOB, IT IS WHAT I DID IN THE
ACADEMIC SECTOR FOR 30 YEARS. SO
IT WAS VERY -- TO ME IT FELT
LIKE AN IMPERATIVE AND PELT LIKE
A DISAPPOINTMENT TO NOT HAVE
SEEN THAT AS I ASSUME THIS
POSITION. IT DOES -- I THINK IT
TAKES AN EFFORT AND IT IS FUNNY
THAT WE ARE, ON MANY ACADEMIC
CAMPUSES THE HOSPITALS ARE
PHYSICALLY QUITE DISTANT FROM
THE GRADUATE SCHOOL CAMPUS. SO
YOU ARE TALKING ABOUT PEOPLE
GETTING THEIR CARS. FOR US IT IS
FIVE, TEN MINUTE WALK ON THE
SAME CAMPUS BUILDING 10 AND
BUILDING 35 DEPENDING HOW
QUICKLY YOU WALK, I'M NOT A
SPRING CHICKEN ANY MORE BUT
MAYBE IT TAKES ME EIGHT MINUTES
TO GO FROM BUILDING 35 TO
BUILDING 10. YET THE DISTANCE
PHILOSOPHICALLY AND THE DISTANCE
INTELLECTUALLY IS MUCH BIGGER
THAN THAT. I DON'T THINK THERE
IS ANY ANIMOSITY AT AL ALL. I DT
THINK ANYBODY FEELS NEGATIVELY
ABOUT THAT. I THINK PEOPLE ARE
IN THEIR CACOON AND DON'T THINK
TO DO IT. SO IT TAKES CONVENERS,
PART OF WHAT IT IS TO BE A
LEADER IS TO SIT AT 30,000 FEET
SO YOU SEE THE WHOLE LANDSCAPE
AND MAKE THE PERSON ON THE LEFT
KNOW THAT THE PERSON ON THE
RIGHT IS DOING SOMETHING THAT
MIGHT BE OF INTEREST TO THEM. IN
THE YEARS THAT I HAVE BEEN THE
SCIENTIFIC DIRECTOR ONE OF THE
-- SOME OF THE SIMPLEST THINGS
HAVE FOSTERED BIG
COLLABORATIONS. SIMPLE CHEAP
COST FREE THINGS LIKE SAYING
THAT IF WE ARE GOING TO HAVE
CLINICAL GRAND ROUNDS AND IT IS
GOING TO BE A RESEARCH INTENSIVE
OFTEN BASIC SCIENCE ORIENTED
GRAND ROUNDS IN THE HOSPITAL, WE
ARE GOING TO NOW DO IT ON ZOOM,
WHY DON'T WE JUST TELL EVERYBODY
IN THE INTRAMURAL PROGRAM THAT
THIS IS GOING TO HAPPEN SO SOME
OF THE BASIC SCIENTISTS CAN
LISTEN IN. IT REALLY HAS MADE IT
EASY TO DO THAT. SO THERE IS NO
PHYSICAL DISTANCE YOU CAN
TRAVEL.
>> ONE SUGGESTION, YEARS AGO I
RAN A PROGRAM AT THE AMERICAN --
SOCIETY CALLED THE PAIN PATIENT
FOR THE BASIC SCIENTIST. WHERE
THE CLINICIAN ACTUALLY PRESENTED
PATIENTS, THIS WAS -- THEY HAD
FROM A BASIC SCIENTIST, A
NEUROLOGIST AND A PSYCHIATRIST,
DISCUSSING AND IT WAS A REAL
PATIENT THERE. IT WAS INCREDIBLY
INFORMATIVE. MY BIG PUSH IS TO
TRY TO EXPLAIN TO PEOPLE IN MY
LAB THAT A MOUSE IS A NOT A
HUMAN. THAT WHAT WE LEARNED
DOES TRANSLATE, BUT THERE IS A
DIFFERENT BRAIN ATTACHED. EVEN
TO GET THE BASIC SCIENTISTS
INVITED TO SHADOW PERIODICALLY
PEOPLE IN MY LAB DO THAT, THEY
GO TO PAIN CLINIC. AND IT IS AN
EXPERIENCE THAT INFLUENCES THE
WAY THEY THINK ABOUT THEIR
SCIENCE. I WOULD HOPE YOU CAN DO
THAT AT THE NIH LEVEL ESPECIALLY
WHEN THE HOSPITAL IS SO CLOSE.
>> I COULDN'T AGREE WITH YOU
MORE. NOW IT IS A LITTLE BIT
CHALLENGING BECAUSE OF THE
REQUIREMENTS WITH COVID IN THE
PATIENT ENVIRONMENT. WE HAVE
STARTED SOMETHING THAT I HAD
DONE WHEN I WAS IN ROCHESTER
WHERE THE FIRST 10 OR 15 MINUTES
OF EVERY FACULTY MEETING IS A
DATA GLITS BY SOMEBODY IN EITHER
CLINICAL OR BASIC RESEARCH WHERE
THEY GET UP AND THEY HAVE TO
PRESENT SOME DATA THAT HASN'T
YET BEEN PUBLISHED BECAUSE
EVERYBODY CAN READ THE
PUBLICATIONS. THEY GET UP THERE
AND SHOW THREE, FOUR SLIDES
MAXIMUM, SOME OF THEM JUST ONE
SLIDE. AND EVERYBODY HAS A VERY
ENGAGED DISCUSSION. WE HAD
COLLABORATIONS ALREADY DEVELOPED
OUT OF THAT. I JUST THINK PART
OF IT IS JUXTAPOSING PEOPLE WHO
DON'T ORDINARILY THINK OF COMING
TOGETHER. THERE IS NOBODY MEAN
OR PRIVATE OR WHATEVER, IT IS
JUST PEOPLE THAT NEVER MET.
>> ECHOING ALLAN, IT SEEMS YOU
HAVE THIS GREAT OPPORTUNITY
BECAUSE I KNOW EXAMPLES THAT ARE
INCREDIBLY GREAT TEMPLATES
GETTING BASIC SCIENCE IMPACTFUL
ON CLINICAL SCIENCE AND VICE
VERSA WITHIN YOUR INSTITUTE. I
WAS THINKING OF THE WORK ON CASO
WITHOUT NAMING NAMES THAT TURNED
OUT REALLY IMPORTANT. BECAUSE IT
SHOWED UP IN HUMANS WITH
MUTATIONS. COMPLETELY
UNEXPECTED ROLE FOR THIS,
CHANNEL IN THAT ASPECT OF THE
DISEASE, WHAT I WOULD LIKE TO
MAKE SURE EVERYONE IS AWARE THAT
THESE CONNECTIONS HAPPEN. THIS
IS -- SO ACQUAINT ALWAYS PLAN
FOR IT BUT SOMETIMES BASIC
SCIENTISTS, THEY THINK OF IT AS
PEOPLE WHO DO CLINICAL DISEASE
HUNTING, FOCUS ON DISEASE, THEY
HAVE A FEW CLUES DOWN THAT PATH
BUT SOMETIMES IT DOESN'T HAPPEN
THAT WAY. IT REALLY HAPPENS
BECAUSE YOU HAD TRUE BASIC
INTEREST AND MADE AWARE OF THE
CONNECTIONS THAT ARE POSSIBLE.
SO I THINK THE GOOD THING TO DO
IS TO MAKE AS MANY PEOPLE AWARE
OF IT AS POSSIBLE.
>> SO YOU REMIND ME TO MENTION
THAT LORENA INITIATED SOMETHING
THAT IS NOW EXTREMELY ROBUST.
AND THAT IS A SMALL GRANT
MECHANISM INTERNAL THAT WE
PROVIDE FROM THE INTRAMURAL
BUDGET FOR CARES OR TEAMS OF
PEOPLE WHO WORK ON SOMETHING AT
THE INTERFACE BETWEEN A CLINICAL
PROBLEM AND A SCIENTIFIC
OBSERVATION, THESE COLLABORATIVE
GROUPS. AN EXAMPLE VERY MUCH
LIKE PIASO STORY IS THE ATP 1A 3
STORY WITH ALTERNATING
HEMIPLAGIA. THERE WAS AN
INDIVIDUAL PARTICULARLY
INTERESTED CLINICALLY IN
ALTERNATING HEMIPLEGIA AND
RELATED DISORDERS. THERE IS A
WHOLE SPECTRUM, SOME OF THEM NOT
EVEN CLEAR AT THIS POINT WHY
THEY CO-SEGREGATE WITH
ALTERNATING HEMIPLEGIA. IT TURNS
OUT THESE PATIENTS HAVE
MUTATIONS OF THE ATP 1A 3
CHANNEL. WE HAD A BASIC
SCIENTIST IN OUR PROGRAM THAT
WAS ACTUALLY WORKING ON SODIUM
PUMPS AND ATP 1A 3 CHANNELS AND
SO FORTH THAT HAD NO IDEA THIS
DISEASE EXISTED. TWO OF THEM
NOW ARE FUELED BY THIS GRANT TO
WORK TOGETHER. I THINK AS I SAY,
90% OF IT IS JUST MAKING PEOPLE
AWARE OF ONE ANOTHER.
>> YES, WHICH IS AS DAVID POINTS
OUT IN THE CHAT IT IS MUTUALITY
SO DAN IS TALKING ON THE FLIP
SIDE BRINGING HOT TOPICS AND
BASIC RESEARCH TO THE ATTENTION
OF CLINICIANS. EDUCATING
CLINICIANS ABOUT WHAT IS GOING
ON AT A MECHANISTIC LEVEL FOR
EXAMPLE EQUALLY IMPORTANT.
>> I THINK AVI DOES A GREAT JOB
WITH -- DOES A FANTASTIC JOB OF
THAT WITH CLINICAL GRAND ROUNDS
BECAUSE CLINICAL GRAND ROUNDS
ARE A CASE PRESENTATION FOLLOWED
BY A MECHANISTIC TALK RELATED TO
THAT PARTICULAR PATIENT.
>> ARNOLD.
>> I WANT TO BRING ATTENTION TO
THE FACT THAT THERE HAS BEEN A
NEUROBIOLOGY DISEASE WORKSHOP AT
THE SOCIETY FOURNEAU SCIENCE, I
HAVE BEEN INVOLVED IN FOR A
DOZEN YEARS SPONSORED BY THE
NIH. THIS IS OF COURSE WHEN WE
HAD IN PERSON MEETINGS. AND IT
WAS TERRIFIC, IT WAS BASICALLY
BASIC SCIENCE PRESENTATION BUT
IT REQUIRED A PATIENT TO BE
BROUGHT IN AT THE BEGINNING. AND
CONSIST CUSSED IN FRONT OF
EVERYBODY. AT TIME DISEASE
ORIENTED, WE ARE AN OPEN EYE
EXPERIENCE FOR PEOPLE WHO DIDN'T
HAVE EXPOSURE TO PATIENTS
BEFORE. IT WAS EXTREMELY POPULAR
AND I THINK IT WAS VERY
EFFECTIVE, IT WAS STOPPED A
NUMBER OF YEARS AGO. IING HOW IT
WAS GREAT WHEN LAST WHILE IT WAS
BEING DONE. NOT SURE WHY IT WAS
STOPPED BUT I WOULD URGE THE NIH
TO CONSIDER RESTARTING. I HEARD
SOME RUMORS THAT IT WAS STOPPED
BECAUSE THEY FELT THE PURPOSE
HAD BEEN ACCOMPLISHED AND
SOCIETY FOR NEUROSCIENCE MEETING
HAD ENOUGH CLINICAL
PRESENTATIONS THAT THEY DIDN'T
NEED EXTRA BOOST. IF SO, THEN
THAT IS EVEN MORE SUCCESS FOR
THAT PROGRAM.
>> THAT IS NOT --
>> SORRY ABOUT THAT, THAT IS NOT
EXACTLY TRUE. WE CAN TALK ABOUT
IT OFFLINE BUT YOU HAVE TO WRITE
A GRANT AND SOME PEOPLE JUST DID
NOT PUT ENOUGH EFFORT INTO
WRITING THE GRANT. NO WE WOULD
BE HAPPY TO DO THAT AGAIN. I RAN
A COURSE FOR 20 YEARS WITH BOB
BROWN WE DID THIS. FOR THE
GARAGE BAIT STUDENTS SO I THINK
IT IS VERY POWERFUL.
>> NINDS WAS COMPLETELY
INSTRUMENTAL IN THAT
NEUROBIOLOGY DISEASE AND MANY
STAFF WOULD GO DAY EARLY TO SFN
TO LISTEN, IT WAS GREAT. ANY
LAST QUESTIONS, TIME MAYBE FOR
ONE MORE QUESTION TO ANYNA IF
THERE IS ONE?
>> THANKS A LOT.
>> CAN'T HEAR YOU, BOB.
>> I SAID I THINK I'M NEXT ON
THE AGENDA, SEE IF I CAN
ACCOMPLISH THE FEAT OF SHARING
MY SCREEN I INTEND TO SCREW UP.
LET'S SEE. CAN YOU SEE THAT?
>> YES, BOB.
>> OKAY. PUTTING IT IN THE SLIDE
MODE H. IN SLIDE MODE NOW,
RIGHT?
>> HOLD ON A SECOND. I'M GOING
TO TALK FOR MAYBE TEN MINUTES
ABOUT PROPOSED UPDATE TO OUR
NINDS SPECIAL COUNCIL REVIEW,
AKA SCR PROCESS. THE UPDATE IS
ACTUALLY AS YOU WILL SEE PRETTY
MINOR BUT SINCE WE HAVE A WHOLE
BUNCH OF NEW PEOPLE I WANT TO
TALK A LITTLE BIT ABOUT SCR AND
HOW IT CAME ABOUT. SO
ORIGINALLY I'M SEEING STRANGE
THINGS ON MY SCREEN, SOW YOU ARE
SEEING JUST MY SLIDE.
>> YES.
>> GREAT. NIH IMPLEMENTED SCR
ABOUT TEN YEARS AGO AND JUST TO
OVERSIMPLIFY WHAT SCR IS THAT
EVERY COUNCIL MUST APPROVE NEW
RESEARCH APPLICATIONS WHEN PIs
ARE CURRENTLY HAVE NO MORE THAN
ONE MILLION IN DIRECT COSTS IN
ANNUAL NIH SUPPORT. THAT WAS
THE ORIGINAL POLICY AND NOTE
THAT WE ARE JUST LOOKING AT NIH
SUPPORT. NOT HHMI, NOT OTHER
FOUNDATION SUPPORT AND IT WAS
ALSO MADE CLEAR THAT INDIVIDUAL
INSTITUTES CAN MODIFY THE SCR
PROCESS BUT THAT THEIR RULES
HAVE TO BE AT LEAST STRINGENT OF
THOSE AT NIH. SO WHY DID THIS
COME AGENT? I WILL JUST SHOW YOU
ONE PIECE OF DATA THAT WE SHOWED
MANY TIMES BY NIH. THERE IS A --
WHAT WE CALL PHENOMENON
HYPERCOMPETITION, HOPEFULLY YOU
CAN SEE MY CURSOR. THE NUMBER OF
AWARDS DURING THIS PARTICULAR
PERIOD, 2003, WAS THE END OF THE
BUDGET FIVE YEAR BUDGET DOUBLING
FOR MINI. AFTER THAT THE NUMBER
OF AWARDS ISSUED BY NIH STAYED
ALMOST COMPLETELY CONSTANT
AMAZINGLY ENOUGH BUT NUMBER OF
APPLICANTS FOR THOSE AWARDS KEPT
RIDING AND IS CONTINUING TO
RISE. SO H IS PHENOMENON WE
LABOR HYPERCOMPETITION. THERE'S
NUMBER OF REACTIONS TO THE NIH
POLICY.LY SHOW A COUPLE OF THEM
THIS IS HIGH LEVEL PAPER BY
BRUCE ALBERTS AND MARK SHOWING
TELEGRAM AND HAROLD VARMUS AND
THE VOTE IS AGENCIES SHOULD BE
SENSITIVE TO TOTAL NUMBER OF
DOLLARS GRANTED TO INDIVIDUAL
LABS THOUGH DIFFERENT RESEARCH
ACTIVITIES HAVE DIFFERENT COSTS.
I WILL TALK ABOUT THAT POINT IN
A MINUTE. AT SOME POINT RETURNS
FOR DOLLAR DIMINISHED. WE
APPLAUD THE DECISION FROM NIH TO
EXAMINE GRANT PORTFOLIOS DIRECT
RESEARCH SUPPORT FOR A LAB
BEYOND 1 MILLION IN DIRECT COSTS
PER YEAR, ONE OTHER COMMENT THAT
I'M SHOWING CAME FROM FASEB.
THEY SAID THAT LIMITING THE
AMOUNT FUNDING AWARDED TO ANY
SCIENTIST OR LAB WOULD ENABLE
MORE PEOPLE, THIS IS THE
IMPORTANT POINT, ACTIVELY
ENGAGED IN RESEARCH. NIH
ANALYSES SHOWED LIMITING PI
TOTAL RPG, RESEARCH PROJECT
GRANT, SUPPORT TO 1 MILLION IN
DIRECT COSTS, WOULD ENABLE THE
FUNDING OF 2000 ADDITIONAL RPG
AWARDS AT AN AVERAGE COST OF
$400,000. NUMBERS TURN OUT ARE A
LITTLE BIT OFF YEAR BUT NOT --
APPROXIMATELY CORRECT. ANOTHER
CONSIDERATION THAT IS VERY
IMPORTANT TO WALTER AND REST OF
US AT NINDS IS THAT INDIVIDUAL
DEVOTES MINIMAL EFFORT TO
OVERSEEING A GRANT, I WILL PAUSE
FOR A SECOND AND TELL YOU THAT
WE HAVE HAD MANY, MANY
INVESTIGATORS WHO DEVOTE .8
CALENDAR MONTHS TO RO1, .6
CALENDAR MONTHS TO RO1. .8
CALIBER MONTHS MEANS YOU CAN
HAVE MORE HAHN 12 RO1s YOU
OVERSEE. ANY CASE WE BELIEVE
THAT IF INVESTIGATORS DEVOTING
MINIMAL AMOUNT TO THE GRANT,
THAT THE TRAINING AND THE
MENTORING ENVIRONMENT IN THE LAB
SUFFERS AND THE THE QUALITY OF
THE RIGOR DONE IN THE RESEARCH
LAB ALREADY ALSO SUFFERS SO THIS
IS ANOTHER ISSUE THAT WE HAVE
BEEN THINKING ABOUT. SO THE
NINDS, THE OLD NINDS POLICY
WHICH WAS APPROVED BY COUNCIL IN
MANY 2017, AND I WILL SAY THIS
WAS AFTER MANY LOT OF DISCUSSION
TWO PREVIOUS COUNCIL MEETINGS.
APPLIES TO PIs WHOSE NIH
SUPPORT EXCEEDS 1 MILLION DIRECT
COSTS, WE INCLUDE THE NEW, THE
PENDING APPLICATION WHEN
CALCULATING THAT 1 MILLION IN
DIRECT COSTS. WHEN COUNCIL
DECIDED WAS THAT WE SHOULD
ESTABLISH A MORE STRINGENT SCR
PAY LINE WHICH THEY AGREED
SHOULD BE HALF GENERAL NINDS PAY
LINE. SO FOR EXAMPLE, NOW
REGULAR PAY LINE WAS 14
PERCENTILE, HALF OF THAT IS 7.
THIS WAS THE FORMER NINDS SCR
POLICY THAT WE ARE ABOUT TO
MODIFY. THE QUESTION, I SHOULD
MENTION THERE ARE MANY
EXCEPTIONS TO SCR POLICY, MANY
OF APPLICATIONS THAT GENERATE
SCR SCRUTINY DO NOT END UP BEING
EXEMPTED FROM SCR. I WILL TELL
YOU WHY. SO FIRST OF ALL WE EXAM
TRAINING AND CAREER DEVELOPMENT
APPLICATIONS, F T K, R 13 AND
RESEARCH RESOURCE APPLICATION.
THOSE ARE AUTOMATICALLY EXEMPT
FROM SCR. THE NEXT TWO
EXEMPTIONS ARE IMPORTANT ONES.
WE EXEMPT ANY APPLICATION TO
INITIATIVE THAT SUPPORTED BY A
CONGRESSIONALLY DIRECTED FUNDING
STREAM. I HAVE LISTED SEVERAL OF
THOSE HERE. BUT THE THINKING IS
FOR EXAMPLE HEAL IS A NATIONAL
EMERGENCY AND THAT WE WANT ANY
INVESTIGATOR TO BE FREE TO APPLY
TO HEAL. WE DON'T WANT THERE TO
BE CONSTRAINTS ON THAT. THE
OTHER THING THAT WE LACK AT
INDIVIDUALLY, AS POTENTIAL
EXEMPTION ARE APPLICATIONS OR
EXISTING GRANTS THAT INVOLVE
WHAT WE CALL INHERENTLY COSTLY
RESEARCH. I LISTED DIFFERENT
TYPES OF SUCH RESEARCH HERE,
THERE ARE OTHERS FOR EXAMPLE,
IMAGING STUDIES. INHERENTLY
COSTLY. SO JUST FOR EXAMPLE, IF
A PERSON IS THE PI ON CLINICAL
TRIAL THAT COSTS $3 MILLION A
YEAR WE DON'T WANT THAT PERSON
TO BE PROHIBITED FROM GETTING
ONE RO1 FOR EXAMPLE. Z WE WILL
SEE AN EXAMPLE OF THIS, IN A
CLOSED SESSION. SO SECOND TWO
BULLETS ARE THE MAIN EXCEPTIONS
WE TALK ABOUT. WHEN WE ARE
DECIDING WHO IS NOT SUBJECT TO
SCR. WHY DO WE -- ARE WE
CHANGING THIS POLICY, THERE'S
TWO REASONS. FIRST, THIS CAME AT
HHS FROM OSTP WHICH IS OFFICE OF
PRESIDENT SCIENCE ADVISOR.
TRICKLING DOWN AND IT IS ALSO
NOW AN INITIATIVE AT NIH, IS
THAT WE ARE NOW REPLACING NOW
USING INCREASINGLY TOTAL COSTS
RATHER THAN DIRECT COSTS, AS A
FUNDING METRIC. SO -- THE OTHER
REASON FOR CHANGING SCR AFTER
TEN YEARS IS THAT OBVIOUSLY
THERE'S BEEN INFLATION, IT COSTS
MORE TO DO RESEARCH. HERE IN A
NUTSHELL IS NEW NIH WIDE POLICY
AND THE ONLY THING THAT CHANGES
IS THE SCR THRESHOLD INSTEAD OF
BEING 1 MILLION IN DIRECT COSTS
IS NOW INCREASED TO 2 MILLION
TOTAL COST. LET ME EXPLAIN FOR A
MINUTE, 1 MILLION IN DIRECT
COSTS IS APPROXIMATELY
1.5 MILLION IN TOTAL COSTS. THE
AVERAGE NOW JACKHAMMER STARTED
OUTSIDE MY WINDOW. THE AVERAGE
INDIRECT COST IS ROUGHLY 50%,
ACTUALLY A LITTLE BIT LESS. SO 1
MILLION IN DIRECT COST IS ABOUT
1.5 MILLION TOTAL. OR
CONVERSELY, 2 MILLION IN TOTAL
COSTS IS APPROXIMATELY
1.3 MILLION DIRECT COST. SO THIS
IS A SIGNIFICANT INCREASE IN THE
SCR THRESHOLD. WHAT WE ARE
PROPOSING IS SIMPLY TO USE THAT
SAME NIH METRIC INCREASE OUR
THRESHOLD FROM 1 MILLION DIRECT
COST TO 2 MILLION TOTAL. AS
BEFORE CONTINUE TO INCLUDE THE
NEW OR PENDING APPLICATION. WHEN
MAKING THAT COMMUTATION. ALL
THE OTHER PARAMETERS INCLUDING
EXCEPTIONS I JUST TALK ABOUT ARE
REMAINING THE SAME. THIS IS THE
PROPOSAL. LET ME JUST SHOW YOU A
FEW FUNDING CONSIDERATIONS HERE
OUR PREVIOUS NINDS SCR POLICY
SAVED US, IN OTHER WORDS BY
APPLICATIONS THAT DIDN'T GET
FUNDED, ON THE AVERAGE ROUGHLY
6.3 MILLION A YEAR. THIS
COMPUTATION WAS DONE ACROSS THE
LAST SIX COUNCIL ROUNDS FOR
NINDS. THE PROPOSE NEW POLICY IF
YOU LOOK RETRO ACTIVELY WOULD
SAVE SIGNIFICANTLY LESS
OBVIOUSLY BECAUSE THE SCR
THRESHOLD IS NOW HIGHER. 2
MILLION TOTAL COSTS, WOULD HAVE
SAVED US ABOUT 3.8 MILLION. SO
IN A SENSE IT IS COSTING US
2.5 MILLION PER YEAR. BY THE
WAY, THESE ARE NOT GIGANTIC SUMS
OF MONEY, TIM, DO YOU HAVE A
QUESTION?
>> PEOPLE IN THE CHAT ARE SAYING
THE SAME THING BUT IT WAS
RELATED TO GOING TO DIRECT TOTAL
COST, COMMENT ABOUT HOW THE FACT
THAT WHAT MY INSTITUTION DECIDES
IS NEGOTIATED INDIRECT COST RATE
IS UNRELATED TO MY SCIENCE OR
QUALITY ANYTHING HOW MUCH MONEY
RAISED BUT WHAT MY INSTITUTION
CHARGES IS MORE THAN 50%, IT IS
LOT LESS THAN SOME OTHER PLACE
THAT CHARGES CLOSE TO 100 SO
WORRIED ABOUT IT BEING A TOTAL
COST IS PUNISHING THE INDIVIDUAL
BASED ON WHO THEY HAPPEN TO WORK
FOR.
>> THIS IS ABSOLUTELY TRUE.
PERSONALLY I RAISE THIS POINT
EXTREMELY LOUDLY AT MULTIPLE
JUNCTURE BEFORE THE POLICY WAS
ADOPTED. IF YOU INTRODUCE
INSTITUTION WITH INDIRECT COST
RATE IS 90%, THERE AREICALLY --
PLENTY OF HIGH VISIBILITY
INSTITUTIONS WITH THAT.
OBVIOUSLY GOING BY TOTAL COST
YOU ARE AT EXTREME DISADVANTAGE.
OVER INSTITUTION THAT HAS A 30%
IN DIRECT -- INDIRECT COST RATE
THIS IS TRUE, WE ARE MOVING WITH
THIS ANYWAY. THIS CAME DOWN FROM
ABOVE. THIS IS NOT AN NINDS
DECISION. HOPEFULLY THE FACT
THAT WE ARE INCREASING DOLLAR
AMOUNT WILL HELP, THAT IS ONE OF
THE REASONS THAT NIH CENTRAL
CHOSE INCREASE THE DOLLAR AMOUNT
BY 50% IN TERMS OF TOTAL COST,
BECAUSE EXACTLY THAT POTENTIAL
FOR BLOW BACK. YOUR POINT IS
ABSOLUTELY CORRECT. I'M NOT
GOING TO ARGUE WITH IT.
>> OKAY.
>> I CANNOT SEE THE CHAT SO ANY
QUESTIONS FOR ME WILL SAVE UNTIL
I'M DONE WHICH IS IN ABOUT THREE
MINUTES. TO CONTINUE HERE THERE
IS NOT A ONE ON ONE MAPPING HERE
BUT FUNDS GENERATED THROUGH SCR,
THESE EXTRA DOLLARS USED TO
MAINTAIN WHEN WE CAN INCREASE
THE PAY LINE, THEY ALSO CAN BE
USED TO PROMOTE A MORE DIVERSE
WORK FORCE IN THE PROD SENSE OF
THE WORD. FOR EXAMPLE MORE EARLY
STAGE INVESTIGATORS, WE SPENT
MONEY FUNDING THEM BEYOND THE
PAY LINE. AND INDIVIDUALS WITH
DIVERSE SCIENTIFIC PERSPECTIVES
AND VULNERABLE INVESTIGATORS.
VULNERABLE INVESTIGATORS IS A
PERSON IF THEY LOSE THEIR GRANT
WILL HAVE ESSENTIALLY NO MONEY,
LIGHTLY OVERSIMPLIFIED. SO THE
LAST THING I'M GOING TO SHOW YOU
THESE ARE JUST TWO SCENARIOS,
THIS WAS OUR OLD NINDS POLICY I
EXPLAINED TO YOU, 7% SCR PAY
LINE. THIS IS THE NEW POLICY
THAT I'M PROPOSING. WE DID, IT
IS A LITTLE EASIER TO CALCULATE
AN INVESTIGATORS EXISTING
SUPPORT THAN IT IS TO CALCULATE
PENDING GRANT. SOMETIMES STUDY
SECTION ASKED US TO MODIFY THE
BUDGET WE DO ADMINISTRATIVE
CUTS, WE ARE EXPLORING THE
POSSIBILITY OF DOING THIS NOT
INCLUDING THE PENNING
APPLICATION. WE HAD VARIOUS
SCENARIOS. THE FIRST WAS 2
MILLION TOTAL COSTS, WHICH IS
NOT INCLUDING THE PENDING, THIS
IS THE GENERAL NIH POLICY. THERE
ARE OTHER INSTITUTES THAT HAVE
MORE STRINGENT POLICIES. NIGMS
IS IN THE SAME BALLPARK THAT WE
ARE IN TERMS OF IN EFFECT CAMPUS
SAME AS OURS. DOING THIS NOT
ONLY PENDING DECREASE THE
SAVINGS THE 2.2 MILLION, IF WE
DECIDED TO NOT INCLUDE THE
PENDING BUT TO MAKE UP FOR IT TO
LOWER THE TOTAL COST, THIS WOULD
ESSENTIALLY BE ABOUT 1 MILLION
DIRECT COST. SO MORE LIKE OUR --
POLICY, DECIDED TO DO THIS, THE
SAVINGS WOULD OBVIOUSLY GO UP.
IN FACT ABOVE WHAT WE ARE
PROPOSING. AND THEN WE ALSO
DABBLE WITH THE IDEA OF HAVING A
MORE -- EVEN MORE STRINGENT PAY
LINE WITH OTHER INSTITUTES DO
FOR EXAMPLE, PROGRAM PROJECT
GRANTS AND OTHER BIG GRANTS. SO
IF WE FIX THE SCR PAY LINE AT
5TH PERCENTILE, AND THEN WENT
WITH THE GENERAL NIH POLICY,
THIS IS ABOUT -- THESE SAVINGS
ARE NOT HUGE BUT I WILL TELL YOU
WHEN WE ARE CALCULATING PAY LINE
WHICH IS GREAT INTEREST TO MANY
PEOPLE, EVERY BIT HELPS. OKAY.
BEFORE I STOP AND ASK THE
QUESTIONS I REALLY WANT TO THANK
BRIAN HAUGEN, THE HEAD OF OUR
ANALYSIS BRANCH AND ALSO ALISA
SHAVER IN MY OFFICE FOR DOING
THE CALCULATION US SHOWED YOU
THESE INVOLVE EVERY SINGLE GRANT
THAT WAS NOT FUNDED IN COMPUTING
THE SAVINGS. WHICH WASN'T
TRIVIAL. YOU CAN ASK ANY
QUESTIONS YOU WANT AT THIS
POINT. SOME QUESTIONS WE THINK
ABOUT HOW TO CREATE INCREASE
AWARENESS OF SCIENTIFIC
COMMUNITY. TO SCR BUT PEOPLE
DON'T KNOW THE NIH POLICY, DON'T
KNOW OUR POLICY PENDING
APPLICATION AND WE EVEN THOUGHT
OF REACHING TO PIs BEFORE THEY
WRITE GRANT APPLICATIONS THAT
MIGHT TRIGGER SCR, WHICH IS NOT
EASY TO DO BUT IT IS UNFORTUNATE
A PERSON WRITES A GRANT
APPLICATION TO NINDS AND
REALIZES THEY HAVE TO GET 7TH
PERCENTILE TO BE FUNDED. THEN
THERE IS A QUESTION IS THERE ANY
TARGETED USE THAT WE COULD HAVE
OF THE SCR SAVINGS. MORE
IMPORTANT HAHN THESE TWO BULLETS
AS ANYTHING ELSE YOU WANT TO ASK
ABOUT. SO WHY DON'T WE TAKE DOWN
THE SLIDES, THAT WILL GIVE ME A
CHANCE TO MORE EASILY LOOK AT
THE CHAT. SOMEBODY TAKE DOWN THE
SLIDES? I CAN STOP -- LET'S SEE
I CAN STOP SHARING MY SCREEN. I
WILL STOP THE SHARE. OKAY. I
WENT THROUGH THAT QUICKLY. GINA,
YOU HAVE A QUESTION?
>> TO ANSWER THE LAST BULLET
POINT WHICH IS HOW SHOULD THE
FUNDS -- THE SAVINGS BE USED. I
THINK SINCE THE IDEA IS TO
DIVERSIFY THE VOICES AND
INCREASE THE NUMBER OF VOICES IN
SCIENCE, THAT IS HOW THE FUNDS
SHOULD BE USED. THAT IS THROUGH
DECREASING OR INCREASING THE PAY
LINE OR PROBABLY BETTER WITH
EARLY STAGE INVESTIGATORS, ET
CETERA. THAT YOU SUGGESTED ARE
BEING DONE ALREADY. I THINK THAT
IS A GREAT USE FOR IT.
>> YES, SO ONE THING YOU SHOULD
UNDERSTAND, THAT IS A GREAT
POINT. IS THAT EVERY YEAR WE --
AS YOU HAVE SEEN IN CLOSED
SESSION WE SET ASIDE CERTAIN
DOLLARS TO FUND PEOPLE BEYOND
THE PAY LINE FOR THINGS LIKE
HIGH PROGRAM PRIORITY
APPLICATIONS. ONE OF THE
CRITERIA FOR THAT IS BRINGING
DIVERSE SCIENTIFIC PERSPECTIVES
INTO THE WORKPLACE. WE GIVE
BRIDGE AWARDS AND LIKE I SAID WE
PUT IN ESI. WE COULD MAKE AN
ATTEMPT TO TARGET ANY OF THE
SAVINGS TOWARD THOSE USES BUT
WALTER WILL NEVER ALLOW THOSE TO
GO BEYOND CERTAIN FLOOR BECAUSE
HE IS COMMITTED TO THE KINDS OF
USES I WAS TALKING ABOUT FOR
HTP.
>> YOU HAVE THE ECHO THERE
WALTER.
>> WE DON'T WANT TO BE BEHOLDEN
TO HOW MUCH EXTRA MONEY WE HAVE
TO DO WHAT WE NEED TO DO. WE ARE
GOING TO DO WHAT WE NEED TO DO
NO MATTER WHAT BUT AS BOB SAID
EVERY LITTLE BIT HELPS.
>> WE CAN DO WHAT WE NEED TO DO,
WE CAN DO MORE THAN WHAT WE NEED
TO DO WITH THE EXTRA MONEY AS
WELL. SO THERE ARE A NUMBER OF
PROGRAM DIRECTORS WHO WOULD LOVE
TO HAVE THE HTP DOLLARS
OUTFITTED TO THAT INCREASE SO
THEY CAN FUND FOR EXAMPLE
VULNERABLE INVESTIGATORS OR
INVESTIGATORS WHO ARE DOING
THINGS THEY THINK IS IMPORTANT.
DR. RYAN.
>> HOW MANY GRANTS DOES THIS
APPLY TO PER YEAR AT NINDS?
>> THE ANSWER IS THAT IT APPLIES
TO LARGE NUMBER OF APPLICATIONS,
HOWEVER THE LARGE MAJORITY OF
THEM ARE EXEMPT BECAUSE THEY ARE
EITHER APPLICATIONS TO HEAL,
BRAIN, ADRD, ET CETERA, ET
CETERA.
>> THE ONES THAT AREN'T EXEMPT
HOW MANY ARE THERE?
>> I WILL GIVE AN EXAMPLE, THIS
-- THIS WAS AN UNUSUAL ROUND,
THERE WERE FOUR APPLICATIONS,
YOU WILL SEE TOMORROW, SUBJECT
TO SCR AND WE ARE PLANNING ON
FUNDING ALL OF THEM. PENDING
COUNCIL APPROVAL. I THINK I'M
ALLOWED TO SAY THAT IN OPEN
SESSION. SO BASICALLY THE NUMBER
OF GRANTS THAT ARE ACTUALLY ON
THE TABLE THAT COUNCIL LOOKS AT,
YOU ARE USING YOUR DISCRETION
AND TALKING ABOUT IT, IS
SOMETHING LIKE ALISA CAN JUMP IN
IF I'M WRONG, 10 TO 15.
>> PER YEAR.
>> NO, PER COUNCIL ROUND. TEN
PER COUNCIL ROUND. MOST OF THEM,
MANY -- EVERYTHING PERCENTILE 7
OR BETTER GETS FUND SOD THAT
TAKES CARE OF SIGNIFICANT NUMBER
OF THOSE. APPROXIMATELY HALF OF
THEM, THE OTHER HALF POTENTIALLY
DON'T GET FUNDED UNLESS THEY ARE
DOING INHERENT RESEARCH, ET
CETERA, ET CETERA. WHAT IS
BEHIND YOUR QUESTION?
>> TWO OR THREE PER COUNC COUNC.
>> TWO OR THREE WHAT?
>> ON AVERAGE.
>> SO WE SAVE ON THE AVERAGE
ABOUT 2 AND A HALF IN THE OLD
POLICY, TWO AND A HALF MILLION
DOLLARS PER COUNCIL ROUND. SO
YOU CAN FIGURE OUT HOW MANY
GRANTS THAT IS.
>> I GUESS I WOULD JUST TRY TO
PUT ON THE SCALE THE SHEER
NUMBER OF GRANTS PER COUNCIL
ROUND BEING CONSIDERED FOR
FUNDING, THE SHEER NUMBER OF
DOLLARS WERE APPROVING FOR
COUNCIL ROUND, THIS IS SORT OF
-- I REALIZE EVERY PENNY COUNTS
AND CAN BE USED FOR BETTER. BUT
WE ARE TALKING ROUND OFF ERRORS
HERE. AREN'T WE?
>> ROUND OFF ERRORS BUT NOT TO
PEOPLE WHO END UP GETTING
FUNDING.
>> OF COURSE.
>> SO THE AMOUNT WE QUOTE
UNQUOTE SAVE BY SCR FLUCTUATES
WILDLY. THERE MIGHT BE A ROUND
WHERE WE SAVE $4 MILLION, THIS
IS ONE COUNCIL ROUND I'VE SEEN
SUCH A ROUND. $4 MILLION IS
ENOUGH TO FUND A LOT OF RO1s
OF PEOPLE WHO MIGHT NOT
OTHERWISE GET RO1. IF YOU ARE
ANOTHER ONE OF THOSE RO 1ES, IT
IS A BIG DEAL.
>> NOT ARGUING WITH THAT, JUST
PUTTING THE SCALE, A LOT OF
THINGS TO PAY ATTENTION TO.
>> THAT IS THE SCALE I THINK.
>> YOU KNOW YOU HAVE BEEN IN THE
GOVERNMENT TOO LONG WHEN TWO OR
THREE MILLION DOLLARS IS CHUMP
CHANGE.
>> THAT'S RIGHT. THE LAST TIME
WALTER SAID TO ME HE SAID ABOUT
$1 MILLION. $2 MILLION IS
NOTHING.
>> AARON.
>> TO YOUR QUESTION ABOUT HOW TO
ADVERTISE THIS ONE IDEA MIGHT BE
IF THERE'S SOME WAY TO USE THE
ERA COMMONS TO JUST SORT OF WHEN
SOMEONE IS APPLYING FOR A
PROJECT IF IT CALCULATES THEIR
OWN TOTAL COSTS AND REPORTS BACK
TO THEM JUST LIKE WHEN WE ARE
APPLYING FOR GRANTS WE HAVE TO
CHECK A BOX IF WE ARE USING
VERTEBRATE ANIMAL OR STEM CELLS,
IT CAN BE ANOTHER BOX TO SAY
THIS IS MY TOTAL COSTS. I
UNDERSTAND THAT THIS WILL BE
SUBJECT TO SPECIAL COUNCIL
REVIEW OR SOMETHING LIKE THAT.
>> SO SORT OF AUTOMATIC WITH
FEATURES THAT ALREADY KNOW.
>> I THINK THAT IS A REALLY GOOD
IDEAIDEA. WE TALKED ABOUT THATT
KEEP IN MIND THIS IS AFTER THE
PERSON IS ALREADY WRITTEN THE
APPLICATION.
>> OR WHEN THEY ARE APPLYING. SO
WHEN THEY -- THE PROPOSAL
CENTRAL OR WHATEVER PUTTING
TOGETHER THE APPLICATION.
>> THAT IS A GOOD IDEA. DAVID.
>> THANKS. MANY OF US I THINK
HAVE BEEN THINKING ABOUT HOW ARE
WE GOING TO FIND DIVERSITY
EQUITY AN INCLUSION ACTIVITY T
AND MANY OF US SPENT TIME
THINKING ABOUT THE TRAINING
PROGRAMS AND DOMAIN DIVERSITY
EQUITY INCLUSION. HOPEFULLY HAVE
PAPER PRETTY SOON BUT THIS WILL
BE A PERFECT OPPORTUNITY EXACTLY
WHERE THE MONEY COULD BE, YOU
COULD FUND IT SEVERAL MORE RO
1ES BUT YOU CAN FUND MORE
GRADUATE SCHOOL STIPENDS OR
POST-DOCTORAL STIPENDS OR JUNIOR
FACULTY TRANSITION AWARDS, YOU
CAN MAKE THE ASSISTAL MONEY GO
FURTHER IN THAT DOMAIN AND PUT
MONEY WHERE OUR VALUES ARE.
>> THAT IS A EXCELLENT IDEA AND
I WILL MENTION SOMETHING I TOLD
WALTER YESTERDAY, OUR STAFF OUR
PROGRAM DIRECTORS SOME OF THEM
TOLD ME THESE SCR CALCULATIONS
INVOLVE WORK BY OUR STAFF. THIS
IS QUITE COMPLICATED, IF IT IS A
MULTIPLE PI GRANT HOW MUCH IS
YOURS, HOW MUCH IS THE OTHER
PERSON, ET CETERA. BUT SOME
STAFF IF WE KNEW THE MONEY WAS
SPECIFICALLY GOING TO BE
TARGETED TO SOMETHING REALLY
GREAT WHY FOR EXAMPLE LIKE DAVID
SAID PERHAPS INCREASE THEIR
HAPPINESS LEVEL. TOM.
>> THESE ARE ALL GREAT IDEAS AND
I COULD SEE SUPPORTING DAVID AND
ESI IDEAS. I HAD TWO, ONE IS
GOING TO BE DELIBERATELY
CONTROVERSIAL. I DON'T
NECESSARILY SUPPORT IT A WHOLE
LOT BUT I THINK IT IS WORTH
CONSIDERING. I THINK WE ALL KNOW
WHEN WE LOOK AT STUDY SECTION
REVIEW THAT THERE IS A SMEAR
BETWEEN THIS IS QUANTIFIED IN A
WELL KNOWN 2016 ELI PAPER, IF
YOU LOOK AT IMPACT OF RESEARCH
PROJECT GRANT, STUDY SECTIONS
ARE REALLY GOOD AT UNDERSTANDING
BOTTOM 40%. THEY ARE OKAY
UNDERSTANDING THE TOP 3% IN
TERMS OF PUBLICATIONS AND THEN
THE CITATIONS OF THOSE
PUBLICATIONS. BUT BETWEEN 3 AND
20% THERE IS NO SIGNIFICANT
DIFFERENCE AT ALL. THE OUTPUT OF
THOSE RESEARCH PROGRAMS. SO THE
STUDY SECTION IS REALLY
IMPORTANT AT THAT. SEW ONE IDEA
IS TO FUND AN EXPERIMENT AND
THAT IS BETWEEN THE THREE AND
THE 20% SOMETHING ORTHOGONAL IS
PUT ON. LIKE A DOUBLE -- LIKE A
DOUBLE PROTEIN SEPARATION.
SEPARATE THEM IN ANOTHER
DIMENSION USING SOME OTHER
CRITERION TO UNDERSTAND WHO YOU
MIGHT PICK UP AS ADDITIONAL
GRANT TO FUND. THIS IS NOW USING
JUST THE LENS OF IMPACT. JUST
THINKING IMPACT. IF WE JUST ADD
A LONGER TAIL EVIDENCE SUGGEST
WE WON'T NECESSARILY PICK UP
GREATER IMPACT. SO THAT IS ONE
IDEA. A SECOND IDEA IS WHEN I
THINK IT WAS NIDA LOOKED AT
THIS, THEY LOOKED AT THE
ULTIMATE SUCCESS OF SOME THEIR
TRAINEES AND FOUND IT WASN'T ESI
IS IMPORTANT AND GETS PEOPLE
INTO THE RACE, IT WAS THE
RENEWAL THAT MATTERS. WONDERING
THERE IS SOME CREATIVE WAY TO
HELP WITH THAT. WITH THE
RENEWAL. I DON'T KNOW HOW TO DO
IT BUT IT IS JUST AN IDEA.
>> IT WAS A POINT WHICH -- WHAT
YOU ARE SAYING IS EXACTLY ON
TARGET TOM WITH A LOT OF
DISCUSSIONS GOING ON. AT ONE
POINT I'M OLD ENOUGH TO REMEMBER
THIS, THERE WAS AN NIH
INITIATIVE TARGETED ON FIRST
TIME RENEWALS. I HAVE MOST
DIFFICULT POINT IN MY CAREER IS
RENEWING MY FIRST RO1, AFTER
THAT THINGS WERE EASIER. IN
TERMS OF FIRST THING SAID, THAT
IS A GOOD SUGGESTION, THERE ARE
THREE OVERSIMPLIFY THREE
POSSIBLE FUNDING MODELS, PERHAPS
WE SHOULD TALK ABOUT THIS IN A
FUTURE OPEN SESSION. THE FIRST
IS WHAT NINDS DOES WHICH IS
USUALLY CALLED THE HARD PAY LINE
MODEL. WE FUND RIGHT NOW
EVERYTHING UP TO THE 14TH
PERCENTILE AND THEN WALTER SETS
ASIDE A CHUNK OF MONEY TO FUND
BEYOND THAT. THE OTHER EXTREME
IS WHAT NIGMS DOES WHERE THEY
LOOK AT EVERY GRANT
INDIVIDUALLY. I DON'T QUITE KNOW
HOW THEY DO THAT BUT THAT IS
WHAT THEY DO. THE INTERMEDIATE
MODEL WHAT NIMH DOES IS SIMILAR
TO WHAT YOU PROPOSED, TOM, WHICH
IS SAY THEY HAVE ENOUGH MONEY
FOR PAY LINE 15 PERCENTILE, THEY
SET A ZONE FROM 10% TO 20%,
DECIDE THEY ARE GOING TO FUND
HALF THE APPLICATIONS IN THAT
ZONZONE. AND THEN DO A DEEP DIVE
INTO THOSE APPLICATIONS. TRYING
TO PICK OUT ONES THAT WE MIGHT
SKIP BELOW 15 OR FUND BEYOND 15.
THAT IS NOT EXACTLY WHAT YOU
WERE SAYING. WE ALSO HAD
DISCUSSIONS JIM NOT ONE PROGRAM
DIRECTOR Z HAS DONE ANALYSES OF
STUDY SECTION IMPRECISION AND
IMPLICATIONS OF THAT. AND SOME
FUNDING MODELS THAT MIGHT COME
OUT OF THAT BUT YOU ARE RIGHT,
OUR MODEL ADDING A TAIL IS NOT
THE ONLY POSSIBLE MODEL. I SORT
OF THAT ADDRESSES WHAT YOU ASK.
ALLAN.
>> I WANT TO GO BACK TO THE
BRUCE ALBERT'S PAPER YOU
MENTIONED. ONE OF THE THINGS
THAT WAS WRITTEN THERE WAS
CONCERN IS A GIVEN LAB JUST
CAN'T GENERATE ALL THAT WORK
WHEN THEY HAVE SO MUCH MONEY.
THEY CAN APPOINT 6% EFFORT THAT
IS RIDICULOUS, I CAN AGREE WITH
THAT. DOESN'T THAT REALLY -- TWO
THINGS. I KNOW I'M GOING WHERE I
SHOULDN'T GO BUT THAT COUNTERS
THE WHOLE ARGUMENT. BASICALLY
YOU HAVE ALL THIS MONEY, DOESN'T
MATTER YOU CAN STILL GET UP TO
$1 MILLION IN NIH FUNDING NUMBER
ONE. THE OTHER RELATED THING
WHICH IS VERY RELEVANT NINDS ARE
THE R 35s. R 35s REQUIRES
THAT YOU HAVE 50% EFFORT IN
ORDER TO GET THAT R 35. YOU
DON'T HAVE TO HAVE 50% EFFORT TO
GET $500,000 GRANT ON AN RO1.
YOU CAN PUT 25% YOU CAN PUT 15%.
I DON'T KNOW WHO LOOKS AT THAT.
SO AS THE ULTIMATE QUESTION IS
WHAT IS THE PRODUCTIVITY COMING
OUT OF ALL THIS MONEY? I DON'T
KNOW IF EVER LOOK
RETROSPECTIVELY IN A BLIND WAY
AND SAY THAT PERSON HAD A
MILLION DOLLARS, THAT PERSON HAD
$500,000, WHAT WAS THE
PRODUCTIVITY THAT GENERATED FROM
THOSE GROUPS? WAS IT REALLY
TWICE AS MUCH WITH A MILLION
DOLLARS? OR WAS IT NOT?
>> WHAT IS THE BASIS FOR MAKING
THESE DECISIONS?
>> SO FIRST ONE THING IN TERMS
OF GOING WHERE YOU SHOULDN'T GO,
I DEFINITELY DON'T WANT TO START
RELITIGATE.
>> OKAY. I'M SORRY.
>> I HAVE PTSD. WE SPENT SO MUCH
TIME AND BY WE I'M TAUGHT
TALKING NIH DIRECTOR ON THEM.
DISCUSSING THAT. BUT IN TERMS OF
WHAT YOU JUST SAID THOSE STUDIES
HAVE ACTUALLY BEEN DONE IN GREAT
DETAIL THOUGH SOME PEOPLE
CHALLENGED THEM. SO I DON'T KNOW
IF YOU RECALL THAT WHEN OER,
OFFICE OF EXTRAMURAL RESEARCH,
NIH OD, IN ADDITION TO
GENERATING A HYPERCOMPETITION
THOSE CURVES THAT I SHOWED YOU,
THEY GENERATED A CURVE ABOUT
PRODUCTIVITY AGAIN THIS WAS
USING A VERY POOR MEASURE WHICH
IS -- IF USE NUMBERS OF PAPERS
OR IMPACT BACK TO SOMETHING LIKE
THAT, THOUGH IT WAS DONE BY
ANOTHER GROUP LOOKING CAREFULLY
BUT BASICALLY THEY SHOW THERE
WERE CONTINUALLY DIMINISHING
RETURNS AMONG -- ABOVE A CERTAIN
AMOUNT OF MONEY, I DON'T
REMEMBER THE DETAILS ANY MORE,
BUT THAT WAS ACTUALLY A FAMOUS
ANALYSIS MIKE SHOWED BACK THEN
AND THE ANSWER WAS THAT THEY ARE
ABOVE SOME THRESHOLD 750,000,
FORGET WHAT IT WAS T RETURN --
IN TERMS OF THAT IMPERFECT
METRIC SHARPLY DECREASE
COLLABORATORY. THAT IS OBVIOUSLY
NOT TRUE OF EVERY AND COUNTING
PAPERS IS OBVIOUSLY A POOR WAY
DOFFING THINGS BUT -- OF DOING
THINGS BUT THOSE STUDIES HAVE
BEEN DONE AND USED TO SUGGEST A
CASE INITIALLY FOR SCR PROCESS.
WHAT EVERYONE THINKS OF THOSE
STUDIES.
>> WHAT ABOUT THE R 35 ISSUE?
50%?
>> WHAT IS THE QUESTION?
>> THERE IS A MINIMUM. YOU HAVE
TO PUT 50% AND MAYBE YOU CAN --
YOU CAN GET POSSIBLY $300,000 A
YEAR, MAYBE $500,000 A YEAR AND
YET YOU CAN PUT AN RO1 IN AT
$500,000 BECAUSE NOBODY GOES IN
MODULAR AND PUT IT IN 10% OR
15%.
>> HERE IS THE CRITICAL FEATURE.
WHICH IS WHAT YOU ARE SAYING IS
ABSOLUTELY TRUE BUT CRITICAL
POINT IS INVESTIGATOR CHOOSES
WHETHER TO HAVE AN RO1 OR AN R
35. SO MOST PEOPLE WHEN THEY
SUBMIT AN R 35 APPLICATION
ALLOWED TO DO THIS SUBMIT FOR
EXAMPLE AN OVERLAPPING RO1 OR
MULTIPLE OVERLAPPING RO1s,
THERE ARE QUITE A FEW
INVESTIGATORS WHO ARE -- WHO
PUTTING 50% EFFORT ON FOR
EXAMPLE 350,000, THAT'S THE
MINIMUM R 35 AMOUNT, GRANT, THAT
I DON'T WANT TO DO THAT. THEY
DON'T WANT TO TIE UP 50% EFFORT
FOR THAT GRANT. THERE IS A LOT
OF OTHER INVESTIGATORS, ACTUALLY
MAJORITY WHO DO WANT TO BE
GUARANTEED EIGHT YEARS OF
CONTINUOUS FUNDING AT THE R 35
LEVEL. SO YES YOU ARE RIGHT, BUT
INVESTIGATOR GETS TO CHOOSE
WHETHER IT IS IN THEIR OWN
INTEREST. MAYBE LAST QUESTION
FROM GINA.
>> I -- WHEN WE CONSIDER ABOUT
WHETHER TO PUT THIS EXTRA MONEY
INTO TRAINING OR FUNDING LINES,
I THINK IT WOULD BE GOOD TO
ADDRESS ALL THE RESEARCH THAT IS
ALREADY BEEN DONE IN TERMS OF
WHAT IS REALLY PREVENTING
SCIENCE FROM BEING MORE DIVERSE
THAN IT IS RIGHT NOW. IT IS NOT
JUST WHAT WE GUESS WHICH IS OH
WE NEED TO TRAIN MORE PEOPLE IT
IS NOT THAT, THOUGH TRAINING IS
GREAT, IT IS BEYOND TRAINING
LEVEL GETTINGED WITH RO1 HAVING
AN INSTITUTION THAT ACCEPTS AND
WELCOMES YOU, THINK A LOT OF THE
EFFORTS THE NINDS IS ALREADY
DOING REALLY WELL ESPECIALLY
WELL EXEMPLARY FASHION, I THINK
THAT IS THE PLACE WHERE WE
SHOULD CONTINUE THOSE EFFORTS
BECAUSE IT IS WORKING. OR WE
HOPE IT IS WORKING.
>> I WOULD BE HAPPY TO HAND
THESE OVER TO MY SHE WOULD JONES
LONDON. SO OKAY, DO YOU WANT TO
SAY ANY LESS COMMENTS WALTER? WE
DONE NEED TO VOTE ON THIS BUT I
WANTED TO TELL YOU WHAT'S GOING
ON AND FIND OUT IF THERE ARE ANY
INJECTIONS. -- OBJECTIONS.
OKAY. I GUESS THE ANSWER IS NO
FOR WALTER. OKAY. WHY DON'T WE
TAKE A BREAK UNTIL 3:15 THEN YOU
WILL HEAR ABOUT THE HEAL
INITIATIVE. DISCUSSION AT THE
END OF THE DAY BY THE WAY WHICH
STARTS AT 4:45 IS GOING TO BE
ABOUT OPEN ACCESS PUBLISHING, WE
WILL GIVE YOU HEADS UP LATER.
WOULDN'T BE SURPRISED IF THAT
DISCUSSION GOES OVER SOMEWHAT.
WHEN I WAS A KID IN NEW YORK
CITY THE NEW SHOW WOULD SAY WE
ARE FORMING NETWORK AFFILIATES
THAT WE MAY GO OVER SO I'M
INFORMING AFFILIATES THAT
DISCUSSION COULD GO OVER AND I
THINK IT WILL BE AN INTERESTING
ONE. SEE YOU 3:15.
OKAY. SO THE NEXT ONCE A YEAR
WE GIVE AN UPDATE OF
APPROXIMATELY ONCE A YEAR ABOUT
HEAL BRAIN AND ALZHEIMER'S AND
THIS TIME WE ARE UP TO HEAL SO
WILL LET LINDA PORTER AND
MICHAEL OSHINSKY INTRODUCE
THEMSELVES. LINDA, ARE YOU
FIRST?
>> I AM. YES. THANK YOU. I'M
LINDA PORTER, DIRECTOR OF OFFICE
OF PLANNING AND POLICY, AND ONE
OF THE CO-CHAIRS FOR THE HEAL
INITIATIVE.LY START THIS
AFTERNOON. AND THEN MICHAEL WILL
PICK UP. SO I WILL COVER THE
CLINICAL PAIN RESEARCH
COMPONENTS OF HEAL AND THEN
MICHAEL WILL GIVE YOU AN UPDATE
ON THE TRANSLATIONAL AND
PRE-CLINICAL COMPONENTS.
THERE'S A LOT IN BOTH PACKAGES
SO WE WILL MOVE QUICKLY. SHARE
MY SCREEN NOW. AND ONE SECOND.
HOPEFULLY THAT LOOKS LIKE A
SLIDE SHOW.
>> YES, IT DOES.
>> READY TO GO. IT IS NOT
ADVANCING. SO JUST TO GIVE A
LITTLE BACKGROUND ABOUT THE
PUBLIC HEALTH CRISIS OF CHRONIC
PAIN IN THE U.S. WE KNOW THAT WE
HAVE 50 MILLION ADULTS WHO
REPORT HAVING CHRONIC PAIN OVER
THE PAST THREE MONTHS, 25
MILLION WHOM SEVERE PAIN AND 20
MILLION WITH HIGH IMPACT CHRONIC
PAIN DEFINED AS MAYBE WITH THREE
OR FOUR MONTHS THAT INTERFERES
WITH LIFESTYLE SO CAN KEEP
PEOPLE FROM GOING TO WORK OR
SCHOOL, AND ENJOYING THEIR
ACTIVITIES AND THEIR SOCIAL
LIVES. RECENTLY BECAUSE A LOT
OF PAIN QUESTIONS ARE NOW IN THE
NATIONAL HEALTH SURVEY, WE ARE
ACTUALLY GETTING MORE AND MORE
DATA ON THE PUBLIC IMPACT OF
PAIN, WE KNOW MORE WOMEN THAN
MEN HAVE PAIN CHRONIC AND HIGH
IMPACT CHRONIC PAIN. WE KNOW
RURAL DWELLERS ARE MORE AFFECTED
BY BOTH CHRONIC AND HIGH IMPACT
CHRONIC PAIN THAN ARE -- MOSTLY
DUE TO ACCESS TO GOOD CARE. THEN
WE ALSO KNOW THAT PREVALENCE OF
BOTH CHRONIC AND HIGH IMPACT
CHRONIC PAIN INCREASES
SIGNIFICANTLY OVER THE LIFE SPAN
MOST OF THE DATA IS FROM 18
YEARS OLD AND ON. WE KNOW THAT A
NUMBER OF DIFFERENT OTHER
CHRONIC CONDITIONS ARE
ASSOCIATED WITH BOTH PAIN AND
HIGH IMPACT CHRONIC PAIN. THIS
IS JUST ONE EXAMPLE OF MANY
WHERE THEY ARE CORRELATED.
DEMENTIA AND CHRONIC PAIN THE
ASSOCIATION RESULTS IN POOR
HEALTHCARE. AND INCREASING
SIGNIFICANTLY INCREASING MANNER
WHETHER YOU HAVE ONE, THE OTHER
ESPECIALLY IF YOU HAVE BOTH. SO
HEAL IS EXPANDING AND I THINK
ENHANCED PROGRAM IS EVOLVING
STILL OVER ITS ALREADY SHORT
LIFE SPAN, IT IS ALREADY CREATED
A NUMBER OF DIFFERENT IMPORTANT
PROGRAMS. INVOLVING SOME REALLY
CREATIVE WAYS THAT FILLS
RESEARCH GAP GAPS. TO DATE THEY
SPENT $2 BILLION ON RESEARCH FOR
PAIN AND OUD COMPONENTS OF HEAL
THAT MAKES UP 6 PROJECTS 26
LARGER PROGRAMS, SO WE WILL TALK
HANDFUL OF PROGRAMS TODAY. ALL
50 STATES ARE SOMEHOW INVOLVED.
THEY HAVE RELEASED 50, 30 WHICH
CAME OUT FISCAL YEAR 22, FUNDING
OPPORTUNITY ANNOUNCEMENTS FOR
HEAL INITIATIVE ACTIVITIES. IF
YOU LOOK AT THE SPENDING ON THE
PAIN SIDE TO DATE I MICHAEL WILL
TALK 335 MILL WORTH OF
PRE-CLINICAL AND TRANSLATIONAL
RESEARCH, WE WILL TALK ABOUT
$350 MILLION IN CLINICAL
RESEARCH WHICH IS SPENDING TO
DATE. MAIN THEMES ON THAT WE
WILL BE LOOKING AT TODAY ARE
THOSE THAT ARE RELATED TO THIS
IS A FAIRLY NEW ONE, INTEGRATED
THERAPIES FOR PEOPLE WHO HAVE
CO-OCCURRING PAIN AND ADDICTION
WHICH IS MANY OF THE PEOPLE WHO
HAVE OUD SUFFER FROM CHRONIC
PAIN, MICHAEL WILL TALK ABOUT
NEW THERAPEUTICS AND
UNDERSTANDING PAIN BETTER IN
CERTAIN PAIN CONDITIONS SO HELP
TARGET NEW THERAPIES AND I WILL
TALK ABOUT WHY THE PAIN
MANAGEMENT PROGRAMS. SO WE LOOK
AT THE PROGRAM OVERALL I THINK
YOU HAVE SEEN THIS CHEVRON CHART
IN A MUCH SMALLER OFFERING A
COUPLE OF YEARS AGO AND AGAIN
LAST YEAR, AS THE PROGRAM
EVOLVES WE ARE ADDING MORE
COMPONENTS TO IT. AND WE WILL
TALK ABOUT THESE PROGRAMS, NOT
GOING TO RUN THROUGH THE LIST
NOW BUT THE IDEA IS TO SHOW YOU
RESEARCH RUNS ALL THE WAY FROM
DISCOVERY THROUGH TO
IMPLEMENTATION/DISSEMINATION
RESEARCH. SO IT DOES COVER THE
CONTINUUM OF DIFFERENT TYPES OF
RESEARCH, WORKING TOWARDS
GETTING NEW THERAPIES INTO THE
CLINIC. HEAL IS ALSO BEGINNING
TO EMBED, GOT REALLY GOOD START
NUMBER OF CROSS CUTTING ISSUES
INTO THEIR PROGRAMS THROUGH
SUPPLEMENTS OR SEPARATE FOAs
AND THOSE INCLUDE THINGS LIKE
REALLY ENHANCING PATIENT
ENGAGEMENT IN ALL STAGES OF THE
RESEARCH ENDEAVOR IN AN
INDIVIDUAL FOA AND INDIVIDUAL
TRIALS. INDIVIDUAL PROJECTS.
WORKING REALLY HARD TO ENHANCE
THE WORK FORCE FOR THE CLINICAL
AND PRE-CLINICAL PAIN RESEARCH
THAT INCLUDES THE SIZE OF WORK
FORCE, THE QUALITY OF WORK FORCE
AN DIVERSITY OF THE WORK FORCE.
MICHAEL AND I WILL EACH TALK
ABOUT THE PROGRAMS THAT FALL
UNDER THAT CATEGORY. DATA
HARMONIZATION HAS BEEN A HUGE
PART OF THE EFFORT FOR THE
CLINICAL RESEARCH TEAM AND THERE
IS A DATA PROGRAM THAT IS BEING
LAUNCHED THROUGH HEAL WHICH YOU
HAVE HEARD ABOUT HERE AND THERE
EARLIER. WE HAVE SOME PROGRAMS
NOW OR A PROGRAM NOW TO LOOK AT
SECONDARY DATA ANALYSIS AS DATA
BEGINS TO FLOW FROM THE HEAL
STUDIES BUT IT WOULD ALSO BE
ABLE TO LOOK AT OTHER STUDIES
THAT HAVE BEEN PUBLISHED AND
PRODUCED SIGNIFICANT DATA OTHER
THAN HEAL STUDIES. I HAVE TO
HIT THE DOWN BUTTON THREE TIMES
BECAUSE IT IS STILL NOT WORKING
TIM DUE HAPPEN TO HAVE MY SLIDE
-- THERE WE GO. SO THE CLINICAL
RESEARCH AND PAIN MANAGEMENT
PROGRAM COVERS RESEARCH NETWORKS
THAT CAN BRING THERAPEUTICS
WHETHER THEY BE PHARMACOLOGICAL
OR NON-PHARMACOLOGICAL THROUGH
ALMOST ALL STAGES OF CLINICAL
TRIAL INVESTIGATION. WE HAVE A
PHASE 2 EPIC NET INVESTIGATION
NETWORK. WE HAVE THE BACK PAIN
CONSORTIUM, CALLED BACKPACK
WHICH INCLUDES NOT ONLY EARLY
PHASE TRIALS BUT BRINGS THEM ALL
UP THROUGH STAGE 3 CLINICAL
TRIALS LARGE EFFECTIVENESS
TRIALS, RUNNING A LARGE
HEMODIALYSIS TRIAL FOR PAIN
ASSOCIATED HEMODIALYSIS WITH
PEOPLE WITH LATE STAGE KIDNEY
DISEASE, THAT STUDY IS ONE BIG
STUDY AT MULTIPLE SITES ACROSS
THE COUNTRY. IS UP AND RUNNING
AND I THINK ABOUT HALFWAY
THROUGH RECRUITMENT SO HOPEFULLY
THE NEXT FEW YEARS WE WILL HAVE
GOOD DATA ON THAT. THE
EFFECTIVENESS RESEARCH NETWORK
IS RUNNING A NUMBER OF DIFFERENT
STAGE 3 CLINICAL TRIALS, WE HAVE
PRAGMATIC STUDIES GOING ON
THROUGH ANOTHER PROGR PROGRAM. E
ARE HYBRID EFFECTIVEN 'T
IMPLEMENTATION STUDIES TO BRING
EVIDENCE BASED TREATMENT INTO
HEALTHCARE SYSTEMS M. WE HAVE A
NEW PROGRAM LAUNCHED LAST YEAR
INTEGRATED MANAGEMENT CHRONIC
PAIN AND OCTOBERUD. THESE ARE
SPECIALIZED -- OUD. THESE COVER
TREATMENT FOR PAIN AND OUD AT
THE SAME TIME. THEN WE HAVE ONE
NUMBER OF PROGRAMS TO ENHANCE
THE CLINICAL PAIN RESEARCH WORK
FORCE, THE BIOMARKER PROGRAM WE
TOLD YOU ABOUT EARLIER IS WELL
UNDERWAY. WE REALIGNED THE
BIOMARKER PROGRAM. TO FOCUS ON
BIOMARKERS FOR CLINICAL TRIALS
AND ALSO A NEW PROGRAM ON
BIOMARKERS FOR MY TISSUES AND A
NEW PROGRAM ABOUT TO LAUNCH
ADVANCING HEALTH EQUITY IN PAIN
CARE MANAGEMENT. STARTING AT THE
BEGINNING AS FAR AS THE EARLY
PART OF THE CLINICAL TRIAL
NETWORK, THE EARLY PHASE
PRE-CLINICAL NETWORK IS THE EPIC
NET AND IT IS IN PLANNING STAGES
FOR TWO NEW TRIALS ON DIABETIC
NEUROPATHY BUT HAS FINISHED OUT
MOST OF THE PLANNING AND IS
READY TO LAUNCH A STUDY FOR
NEOOSTEOARTHRITIS, THEY ARE
ABOUT TO RECRUIT, THEY HAVE BEEN
DOING FAIR BIT OF SCREENING TO
GET TO THAT LEVEL. THIS WILL
LOOK AT EFFECT OF THE EFFICACY
OF CCR 2 ANTAGONIST BEFORE
ADULTS WITH OSTEOARTHRITIS KNEE
PAIN. THIS IS A REALLY IMPORTANT
STUDY GIVEN HOW MANY PEOPLE
ESPECIALLY THOSE OVER AGE 40,
HAVE KNEE PAIN DUE TO
OSTEOARTHRITIS. THE DIABETIC
NEUROPATHY TRIALS WILL BE RUN
UNDER A MASTER PROTOCOL SO DONE
IN A SIMILAR WAY WITH SOME
TAILORED COMPONENTS IN THEM THAT
ARE UNIQUE TO ASSET THAT IS
UNDERSTUDY, ONE IS TOPICAL AND
ONE IS AN ORAL INDICATION. SO
THESE ARE STILL IN THE PLANNING
PHASE BUT WE HOPE LATER THIS
YEAR THAT THEY WILL ALSO LAUNCH.
BACPAC IS A COMPLEX PROGRAM, AN
INITIATIVE IN ITSELF. SO IT HAS
SEVERAL COMPONENTS WHICH
INCLUDES MECHANISTIC CENTER
WHERE TRYING TO BETTER
UNDERSTAND THE ETIOLOGY OF LOW
BACK PAIN AND THE DIFFERENT
COMPONENTS THAT CONTRIBUTE TO
IT. THEY GOT OTHER CENTERS THAT
ARE WORKING TO DEVELOP DEVICES
THAT CAN HELP WITH TREATMENT OR
DIAGNOSIS AND THEY ARE RUNNING
SOME CLINICAL TRIALS. THIS SLIDE
GIVES YOU A COUPLE OF EXAMPLES
OF SOME OF THE WORK COMING OUT
OF THE DEVICE ACTIVITY AND HOW
SOME OF THE DEVICES ARE BEING
APPLIED TO EITHER DIAGNOSTICS OR
TO BACK PAIN THERAPIES. ONE OF
THE BIG GOALS OVERALL GOALS FOR
BACK PACK WAS TO AND IS TO
DEVELOP A THEORETICAL MODEL FOR
LOW BACK MAYBE INCLUDE
MECHANISMS PHENOTYPING
BIOMECHANICS AND THAT MODEL
WOULD BE BROUGHT INTO BACKPACK
STUDIES OVER TIME, IT WOULD BE
REFINED REDEFINED AS DATA FROM
BACPAC COMES IN. SO ONE THING I
WANT TO HIGHLIGHT AS AN
ACCOMPLISHMENT FOR BACPAC IS
THAT THE THEORETICAL MODEL FOR
LOW BACK PAIN DURING THE FIRST
FEW YEARS OF PLANNING IN THE
BACPAC PROGRAM HAS BEEN
DEVELOPED AND IT IS NOW IT WILL
GO AS USEFUL TOOL INTO THE
CLINICAL TRIALS AND BE REFINED
AS THEY MOVE FORWARD. THERE IS
ALSO FDA BREAK THROUGH APPROVAL
FOR DEVICE DESIGNATION FOR A
PLATFORM THAT WAS DEVELOPED
THROUGH ONE OF THE DEVICE
TECHNOLOGY PROGRAMS IN BACPAC.
THIS IS A DIGITAL HEALTH
PLATFORM THAT PULSING TO
INFORMATION ON BIOMECHANICS
SPINE SIGNATURES PATIENT
REPORTED OUTCOMES AND ELECTRONIC
HEALTH RECORD DATA, PULSE THOSE
ALL TOGETHER AS TO HOW THEY CAN
BE USED IN RESEARCH OR IN THE
CLINIC, SO THIS IS GOING TO BE
HUGE HELP FOR RESEARCH PROGRAMS
AND BACPAC MOVES FORWARD. THEN
WE MOVE INTO THE PAIN MANAGEMENT
EFFECTIVENESS RESEARCH NETWORK,
WE CURRENTLY HAVE 8 TRIALS
UNDERWAY. THEY ARE ALL PAST
THEIR PLANNING YEAR AND ALL ITS
RECRUITSMENT, SOME PHENOMENALLY
WELL RECRUITING DESPITE SLOW
DOWNS FROM COVID, THEY HAVE HAD
TO MAKE BECAUSE OF COVID A
NUMBER OF CHANGES AND SOME OF
THE PROGRAMS MOVING THEM TO
TELEHEALTH OR OTHER DIFFERENT
TYPES OF VIRTUAL INTERACTIONS
AND SO I THINK SOME THOSE WILL
BE HELPFUL IN DETERMINING
WHETHER INTERVENTIONS THAT ARE
USEFUL IN FACE TO FACE SITUATION
IS ALSO USEFUL IN AREAS SUCH AS
RURAL SETTINGS, IN AREAS POST
COVID WHERE TELEHEALTH COULD BE
DELIVERED IN MORE EFFECTIVE
WAYS. THIS SLIDE GIVES YOU THE
IDEA THAT THIS DIFFERENT
INTERVENTIONS THAT ARE BEING
TESTED, THROUGH THE
>> ETHICAL NON-PHARMACOLOGICAL
FILES GOING ON AND STRAIGHT UP
DRUG OR STRAIGHT UP
NON-PHARMACOLOGICAL
INTERVENTIONS IN ALL OF THE
DIFFERENT PAIN CONDITIONS THAT
YOU SEE ON THE RIGHT SIDE OF THE
TRIAL. ONE THING TO NOTE FROM
HERE, THESE ARE ALL -- WE WON'T
HAVE DATA,COMPLETED DATA ON THE
TRIALS FOR ANOTHER FEW YEARS BUT
ONE OF THE TRIALS WHICH WAS
LOOKING AT PRESCRIPTION OF
OPIOIDS, AND DECISION MAKINGS
WITH PATIENTS ON THE OPIOID,
GIVING THEM A STANDARD 20 DOSES
THAT MOST CAESAREAN PATIENTS GET
WHEN THEY GO HOME OR WHETHER
THEY GET A TAILORED DOSE
DEPENDING ON EDUCATION BETWEEN
THE PATIENT AND THE PROVIDER, AS
TO WHAT THE NEEDS ARE AND THE
DECISIONS OF THE PATIENT. THEY
ARE FULLY ENROLLED AND HAVE BEEN
FOR FEW MONTHS NOW DESPITE COVID
5,000 PLUS PARTICIPANTS SO WE
LOOK FORWARD TO SOME INFORMATION
FROM THAT TRIAL. IN THE NOT SO
DISTANT FUTURE. WE CAN MOVE INTO
THE PRAGMATIC TRIALS, THESE ARE
THE IMPLEMENTATION TRIALS, DONE
IN HEALTHCARE SYSTEMS, THEY HAVE
TO BE DONE IN AT LEAST TWO. THEY
ARE LOOKING ALL AT
NON-PHARMACOLOGICAL APPROACH TO
PAIN MANAGEMENT. SO ON THE LEFT
YOU SEE DIFFERENCE TYPES
COMBINATIONS OF THERAPIES THAT
ARE BEING EVALUATED AND ON THE
RIGHT HAND SIDE YOU SEE PAIN
CONDITIONS BEING -- INCLUDED AS
PART OF THE COHORTS IN THESE
STUDIES. WE HAVE SIX TRIALS
GOING ON THREE THOSE LOW BACK
PAIN SO NUMBERS ADD TO SIX. FOR
WHAT WE CALL PRISM FOR THIS
IMPLEMENTATION PROGRAM THEY
AGAIN WON'T HAVE CLINICAL
OUTCOMES DATA FOR SOME TIME.
THEY GOT TOGETHER WITH A
COLLABORATORY THAT WE HAD AT NIH
FOR SOME TIME WITH PRAGMATIC
TRIALS AND PUBLISHED A SURVEY ON
THE DIFFERENT CHALLENGES OF
USING ELECTRONIC HEALTHCARE
RECORD DATA IN LARGE TRIALS.
THESE STUDIES ARE VERY RELIANT
ON EHR DATA AND THEY WENT TO
REALLY CONSENSUS ON
PRE-REQUISITES HOW THAT DATA
SHOULD BE ENTERED IN MAKING SURE
ALL THE PROs ARE IN, DATA IS
COLLECTED, CONSISTENTLY AND
NUMBERS OF DATA POINTS TO TO BE
USED IN THESE TRIALS TO MAKE
THEM MORE EFFECTIVE. SO THIS IS
THE NEW PROGRAM THAT I MENTION
LOOKING AT INTEGRATIVE
MANAGEMENT FOR BOTH CHRONIC PAIN
AND OUD. IF YOU LOOK AT THE NEED
FOR THIS AT THE POPULATION LEVEL
IT IS HUGE. SO AS I MENTION WE
HAVE GOT 50 MILLION PEOPLE,
ADULT MS. THE U.S. EVERY YEAR
THAT REPORT CHRONIC PAIN OPIOID
MISUSE OF POPULATION LEVEL IS
ABOUT 10 MILLION PEOPLE. THOSE
WITH OUD WHICH IS ABOUT 2
MILLION PEOPLE, MOST OF THEM 40
TO 60% WHO HAVE OUD ALSO HAVE
CHRONIC PAIN. WHEN THEY GO FOR
TREATMENT IT IS EITHER ONE OR
THE OTHER TREATMENTS MAYBE CUT
OFF BY THEIR PROVIDER. OR IS
FRAGMENTED IN THAT THEY MAY END
UP IN WITH PAIN CARE AND JUST
REFERRAL FOR OUD OR VICE VERSA
OR MAYBE DROP BY THEIR PHYSICIAN
SO THE NEED FOR INTEGRATED CARE
IS REALLY HIGH. WE NEED TO KNOW
WHICH STRATEGIES ARE BEST FOR
WHICH PEOPLE ONE OF THE OTHER
PROBLEMS IS THERE ARE LIMITED
RESOURCES, SPECIALTY CLINICS, ET
CETERA WHO CAN PROVIDE
INTEGRATED CARE. SO IN POWER
WHICH IS INTEGRATED MANAGEMENT
OF PAIN OUD FOR FULL RECOVERY IN
A SINGLE PERSON, HAS DEVELOPED
THROUGH A NUMBER OF TRIALS. WE
HAVE NINE TRIALS RUNNING THROUGH
THE NEW PROGRAMS, LOOKING AT
DIFFERENT APPROACH AT MULTIPLE
LEVELS, EITHER INDIVIDUAL
HEALTHCARE SYSTEM OR PROVIDER,
TO BETTER TREAT PEOPLE WHO HAVE
BOTH PAIN AND OUD. THIS INCLUDES
DEALING WITH STIGMA AND HEALTH
DISPARITIES MANY THE CLINIC.
AGAIN, THIS PROGRAM IS BRAND
NEW, THEY ARE GETTING THROUGH
THERE. I'M STUCK AGAIN. THEY ARE
GETTING TRUE THEIR PLANNING YEAR
AND WHAT THEY HAVE DONE IN THE
PLANNING YEAR WHICH IS REQUIRED
MANY THE FOA IS TO SET UP
APPROPRIATE DOMAINS FOR INQUIRY
OF PATIENTS THROUGH PATIENT
REPORTED OUTCOMES, ON BOTH PAIN
AND OUD WHICH WILL GIVE US A
GOOD DATA SET TO BE ABLE TO
CAPTURE THE FEATURES OF PEOPLE
WHO HAVE PAIN AND OUD AND
APPROACH THEM WITH INTEGRATED
HEALTHCARE PLAN. THEN WE MOVE TO
THE BIOMARKER PROGRAMS. SO ON
CHEVRON SLIDE I MENTIONED WE
HAVE A NEW PROGRAM LOOKING AT
BIOMARKERS OF MYOFACIAL TISSUES.
THIS ONE IS A NEW IDEA THAT CAME
UP A COUPLE OF YEARS BACK WITH
THE RECOGNITION THAT MYOFACIAL
PAIN IS PROBABLY ASSOCIATED WITH
OR UNDERLYING MANY, MANY
DIFFERENCE TYPES OF CHRONIC
PAIN, SO MYOFACIAL PAIN COULD BE
PAIN ASSOCIATED MANY THE MUSCLE
TISSUE, THE OTHER SOFT TISSUES,
IT PROBABLY HAS AN INTERACTION
WITH NEUROIMMUNE SYSTEMS, IF YOU
THINK OF THE CONDITIONS WHERE IT
WOULD BE MOST LIKELY A LARGE
CONTRIBUTOR, MAY INCLUDE BACK
PAIN, TEMPORAL MANDIBULAR KISS
ORDERS, NECK PAIN SHOULDER PAIN
HEADACHE. SO IT SEEMED LIKE AN
IMPORTANT AREA OF RESEARCH AND
THESE BIOMARKERS WILL BE
PREDICTIVE AND PROGNOSTIC
HELPFUL IN CLINICAL TRIALS, AND
ARE BEING LOOKING FOR BIOMARKERS
THAT WOULD BE FOUND THROUGH
FAIRLY NOT INVASIVE TYPES OF
IMAGING AND OTHER WAYS TO
COLLECT BIOMARKERS. WE HAD --
MOVING THE RIGHT HAND SIDE OF
THE SLIDE, EARLY BIOMARKERS
PROGRAM, WHERE WE FUNDED EIGHT
DIFFERENT PROJECTS TO LOOK AT
EIGHT DIFFERENT TYPES OF PAIN.
MOST OF THESE WERE FOR
PROGNOSTIC BIOMARKERS, ONE FOR
DIAGNOSTIC AND BECAUSE WE GOT SO
MANY, WE HAVE SO MANY UNDERWAY,
AND FOR OTHER REASONS WE HAVE
REALIGNED THE PROGRAM TO LOOK AT
BIOMARKERS THAT WILL BE TARGETED
MORE FOR USE IN EARLY CLINICAL
TRIALS. THESE WILL BE RESPONSE
PREDICTION MONITORING
SIGNATURES, THAT COULD BE
ALIGNED WITH COMING THROUGH FOR
EVALUATION IN EPIC NET. ONE OF
THE REALLY EXCITING
ACCOMPLISHMENTS I THINK FROM THE
EARLY BIOMARKER PROGRAM IS THERE
IS A DIAGNOSTIC BIOMARKER DOING
WELL IN ITS FIRST PHASE OF
STUDY, THAT WILL HELP
DIFFERENTIATE FROM NEUROPATHIC
CORNEAL PAIN, THEY ARE HARD TO
DIAGNOSE, ONE FROM THE -- THAT
NEED TO BE TREATED DIFFERENTLY.
SO THIS IS CONFOCAL MICROSCOPY,
RAPID COLLECTION COLLECTION OF
IMAGING AND DEEP LEARNING SYSTEM
TO LOOK AT THOSE IMAGES AND BE
ABLE TO DETECT MICRONEUROMAS IN
THE CORNEAL AREA AND GIVE A
POSITIVE DIAGNOSTIC FOR IT BEING
ACTUALLY NEUROPATHIC CORNEAL
PAIN.
>> LINDA, I DON'T KNOW IF YOU
ARE NEARING THE END BUT WE ARE
-- I WANT TO MAKE SURE THERE'S
TIME FOR QUESTIONS AND I KNOW
MICHAEL HAS A LOT AS WELL.
>> I'M GOING TO BE RIGHT IN MY
20 MINUTES, BOB.
>> ACTUALLY IT'S -- OKAY. GO.
>> SO WE HAVE ADVANCING HEALTH
EQUITY, THIS PROGRAM LOOKS AT
WHY WE HAVE DISPARITIES IN
HEALTHCARE BECAUSE OF INDIVIDUAL
FACTORS INTERPERSONAL FACTOR,
HEALTHCARE SYSTEM FACTORS AND WE
ARE LOOKING TO FUND ABOUT 4 TO 6
TRIALS LATER THIS YEAR THAT
COVER A NUMBER OF DIFFERENT
RACIAL ETHNIC GROUPS
MARGINALIZED AND HAVE HEALTHCARE
DISPARITIES. I'M STUCK AGAIN.
WE HAVE A NEW PROGRAM THROUGH
HEAL ON PATIENT ENGAGEMENT WHERE
WE HAVE AN ADVISORY BOARD OF
PATIENTS ADVOCATES, FAMILY
MEMBERS TO HELP US WORK THROUGH
HOW WE CAN BETTER MAKE OUR
TRIALS AND OUR PROGRAMS MORE
MEANINGFUL TO PATIENTS AND OTHER
STAKEHOLDERS AS FAR AS OUTCOMES
GO. THEY HAVE BEEN HUGELY
HELPFUL. CHRIS VEASLEY THANK YOU
FOR JOINING US ON THIS PANEL AS
WELL AS ON THE COUNCIL HERE.
THIS SLIDE YOU SAW THIS IS JUST
A QUICK REMINDER OF THE KIND OF
EFFORTS WE ARE PUTTING INTO DATA
HARMONIZATION FOR ALL THE
CLINICAL STUDIES WE HAVE A
NUMBER OF DOMAINS, WHERE PATH TO
COLLECT CERTAIN PROs FOR THE
STUDIES, THEY ARE ALL
HARMONIZED. THEY WILL BE GREAT
FOR LATER EVALUATION OF DATA IN
A VERY MEANINGFUL WAY. THIS
SLIDE SUMS UP WHAT WHAT WE HAVE
ACROSS THE DISCOVERY, THE PHASE
2 COMPARATIVE EFFECTIVENESS AND
IMPLEMENTATION TYPE OF RESEARCH
ACROSS THE DIFFERENT PROGRAMS.
WE ARE LOOKING AT TWO BRAND NEW
PROGRAMS IN FY 23, FOUR, TWO ON
EACH SLIDE, ONE TO LOOK AT
BETTER PAIN MANAGEMENT AND RURAL
POPULATIONS. AND SO ANOTHER IS
SICKLE CELL DISEASE, WE THINK
THESE WILL BOTH REALLY BE
APPLICABLE TO UNDER-REPRESENTED
POPULATIONS AND THOSE WITH
HEALTH DISPARITIES. WE ARE ALSO
LOOKING AT A PROGRAM FOR
COORDINATED CARE IN HEALTHCARE
SYSTEMS WE INTEGRATE PRIMARY
CARE WITH SPECIALTY CARE SYSTEMS
AND HEALTHCARE SYSTEMS WHERE
THIS COORDINATED CARE DOESN'T
EXIST. IT WILL BE
MULTI-DISCIPLINARY BASED ON
BIOPSYCHOSOCIAL MODEL OF PAIN.
SIMILAR TO THE EMPOWER ACCEPT
THIS WILL BE PAIN AND INTEGRATED
THERAPY FOR THOSE AT RISK. FOR
OUD. VERY COMPLICATED PROGRAM.
THE ONLY OTHER THING I WANT TO
MENTION IS THAT WE HAVE SOME
REALLY IMPORTANT PROGRAMS THAT
ARE PROVING TOWARDS IMPROVING
THE WORK FORCE WE HAVE A
MENTORING PROGRAM WE MADE FOUR
AWARDS TO INVESTIGATORS TO SERVE
PROTECTED TIME TO SERVE AS
MENTORS. WE HAVE A TRAINING
PROGRAM FOR YOUNG SCHOLARS TO
MOVE INTO CLINICAL PAIN RESEARCH
AND WE HAVE A NATIONAL K 12
COMING UP WHICH WE RA REALLY
EXCITED ABOUT WHERE WE WILL
BRING IN SCHOLARS, PROVIDE THEM
WITH SUPPORT FOR RESEARCH BUT
ALSO HAVE A NETWORKING SYSTEM
WHERE WE CAN LINK UP
PRE-CLINICAL TRANSLATIONAL AND
CLINICAL RESEARCHERS TO HAVE
THEIR CONVERSATIONS TO APPROVE
OUTCOMES. IN THE RESEARCH
ENDEAVORS AND SO I THINK AT THIS
POINT I WILL TURN TO MICHAEL, IF
WE HAVE TIME FOR QUESTIONS AT
THE END WE CAN DO IT SO MICHAEL,
GO PICK UP FROM HERE.
>> ANY QUESTIONS YOU HAVE YOU
CAN ASK THEM AT THE END.
>> THANK YOU, LINDA. SLIDE HERE
THEN SHARE, THAT LOOK OKAY FOR
EVERYBODY?
>> YES, IT DOES.
>> I CAN'T SPEAK FOR EVERYBODY.
>> I HAVE A LOT TO SPEAK ABOUT
SO I WILL SPEAK QUICKLY. AS
LINDA MENTIONED WILL SAVE ALL
THE QUESTIONS FOR THE END SO WE
CAN GET THROUGH ALL THESE MANY
PROGRAMS THAT WE ARE PROUD OF
HERE IN THE ANYONE HEAL
INITIATIVE, SPECIFICALLY IN THIS
CASE IN THE PRE-CLINICAL AND
TRANSLATIONAL WORK GROUP. NINDS
PARTICIPATION IN HEAL IS MAINLY
IN THE ENHANCING PAIN MANAGEMENT
GOAL PORTION OF HEAL. THAT IS
REALLY BROKEN INTO FOUR PIECES,
UNDERSTANDING THE BIOLOGICAL
UNDERPINNINGS OF CHRONIC
PLANNING AN ACCELERATING THE
DISCOVERY AND CLINICAL
DEVELOPMENT OF NON-ADDICTIVE
PAIN TREATMENT FIRST TWO BULLET
POINTS IS WHAT WE ARE FOCUSING
ON IN THE INITIATIVES AND
PROGRESS IN HOSE INITIATIVES I
WILL SPEAK ABOUT NOW. THE LAST
TWO BULLET POINTS, LINDA,
ADDRESSED IN HER PRESENTATION.
SO LET'S TALK ABOUT A FEW OF THE
WINS THAT WE HAVE SEEN SO FAR
INSIDE THE PROJECTS AND
INITIATIVES THAT WE HAVE BEEN
SUPPORTING IN THE HEAL
PRE-CLINICAL TRANSLATIONAL PAIN
RESEARCH PORTION. INITIAL
AWARDS CAME OUT IN FY 18 BUT
THAT WAS A SMALL AMOUNT OF MONEY
SO WE ARE TALKING ABOUT THE
RESEARCH THAT WAS AND FUNDING
GONE OUT IN FY 19 THROUGH 21,
THAT'S $335 MILLION, TWO OF
THOSE YEARS WERE DURING COVID.
BUT WE HAVE ONE NEW DRUG IND FOR
A FIRST IN CLASS NON-ADDICTIVE
DRUG TO TREAT PAIN, WE HAVE FIVE
NEW IDEs FOR DEVICES, TO
CLINICAL TRIALS AND CLINICAL
RESEARCH TO STUDY DEVICES FOR
TREATING PAIN, WE HAVE SEVEN
PATENTS ON THE SBIR FUNDING,
THAT IS FOCUSED ON THERAPEUTICS
AND ANALGESIC DEVELOPMENT. WE
HAVE TWO PATENTS FOR SMALL
MOLECULE MODULATORS AN PANDORE
ACCEPTORS FROM OUR TARGET
DISCOVERY PROGRAM THAT, IS IN
OUR RO1 POOL SUPPORTED BY THESE
PROGRAMS. WE HAVE FIVE SMALL
BUSINESS THERAPIES THAT PRECEDED
TO THE CLINICAL STAGE AND ONE
PHASE 1 TRIAL COMPLETED DURING
-- IN ONE OF THE THERAPEUTICS
DEVELOPMENT PROJECTS BUT THAT IS
A LOT OF WINS IN TWO PLUS YEARS,
WE ARE VERY PROUD OF THAT. WE
ALSO SUPPORTED IN COLLABORATION
WITH THE INTRAMURAL RESEARCHERS
AT NCATS DEVELOPING NEW
SCREENING PLATFORMS, TESTING
PLATFORMS, DISCOVERING
ANALGESICS FOR PAIN, DEVELOPING
TISSUE CHIPS USED FOR SIMILAR
PURPOSES, AND FOR OPTIMIZATION
RESEARCH ON THESE THERAPEUTICS
ELEMENT. A LOT OF THE PROGRAMS
WE HAVE ONGOING INSIDE OF HEAL
MANY THE PRE-CLINICAL SPACE AND
THE ONES THAT WE LIKE TO BRING
TO YOU FOR CONCEPT CLEARANCE ARE
TEAM BASED, BRINGING INDIVIDUALS
WITH DIFFERENT TYPES OF
EXPERTISE THAT SOME OF THAT WAS
MENTIONED EARLIER IN CASE OF
DISCUSSIONS HAVING CLINICS
COLLABORATING WITH BASIC
SCIENTIST AROUND PARTICULAR
THERAPEUTIC CONDITION. THAT'S
WHAT WE ARE SUPPORTIVE OF AND
INCLUDING IN THE FUNDING
ANNOUNCEMENTS FOR HEAL. OF
COURSE THE PAIN WORK FORCE
ENHANCEMENT IN GETTING MORE
PEOPLE IN AND EARLIER STAGES
SPORING THEM SO THEY CAN GET
THEIR RO1s IN AND THERAPEUTIC
DEVELOPMENT PROGRAMS STARTED. SO
THIS IS ANOTHER VARIATION OF
THAT CHEVRON DIAGRAM, LITTLE
MORE DETAIL THAN WE HAVE SEEN
BEFORE, CON ENTRAIT ON UPPER
LEFT HAND CORNER HERE, THE
TARGET DISCOVERY VALIDATION
PROJECT, THESE HAVE BEEN FEEDING
AND LEADING TO PLANNING STUDY
FOR INITIAL ANALGESIC
DEVELOPMENT, WE HAVE SEEN THAT
HAPPEN. THESE PLANNING STUDIES
ARE WHO YEAR STUDIES THAT THEN
PREPARE INDIVIDUALS TO APPLY FOR
THESE FIVE YEAR PROGRAMS FOR THE
INITIAL TRANSLATIONAL EFFORTS
AND NON-ADDICTIVE ANALGESIC
THERAPEUTIC DEVELOPMENT, THEN WE
HAVE THE PTDP PROGRAM, THE PAIN
THERAPEUTIC DEVELOPMENT PROGRAM
WHICH MIRRORS NIH VERY
SUCCESSFUL BLUE
NEURONEUROTHERAPEUTIC PROGRAM,
OPTIMIZING GETTING READY FOR IND
SESSION IN PHASE 1 CLINICAL
TRIALS, IN THIS CASE SUPPORT
THOSE STUDIES IN PHASE 1
CLINICAL TRIALS INSIDE THERE.
THERE ARE DEVICE PROGRAMS WITH
SEVERAL FUNDING ANNOUNCEMENTS.
ONE OF THE STREET HERE BUT HAS
MANY COMPONENTS, VERY PROUD OF
THE WORK THAT IS GOING ON IN
THERE, PRE-CLINICAL DEVELOPMENT
AND EVEN CLINICAL TRIALS IN
THESE REALLY PROJECTS THAT ARE
BASED ON DEVICES THAT HAVE
TREMENDOUS POTENTIAL TO HAVE LOW
ADDICTION LIABILITY BUT CHANGE
THE LIVES OF THESE PATIENTS. WE
ALSO HAVE THE PRE-CLINICAL
STREAMING PAIN, I WILL GIVE YOU
DETAILS WITH SLIDES LATER ON FOR
THAT AND EPIC NET IS OUR PHASE 2
CLINICAL TRIALS PROGRAM THAT
LINDA GAVE YOU DETAILS ON WHAT
STAGE THEY ARE AT.
LET'S NOT FORGET WE HAVE THE
INTRAMURAL RESEARCHERS AT NCATS
IN COLLABORATION WITH EXTERNAL
COMMUNITY SUPPORTING THE
DEVELOPMENT OF TISSUE CHIPS.
IPSC CELLS, BASED ON NOCICEPTORS
TO REALLY THESE IPSC CELLS THAT
MIMIC NOCICEPTORS TO PROVIDE
PLATFORMS FOR SCREENING TENS OR
HUNDREDS OF THOUSANDS OF
POTENTIAL COMPOUNDS FOR TREATING
PAIN. WE HAVE NEW PROGRAMS
PRECISION HUMAN PAIN NETWORK AND
ALSO THE REJOIN PROGRAM, I WILL
GIVE YOU SOME DETAILS ON. SO LET
ME SHOW YOU HOW THESE PROGRAMS
FIT TOGETHER AND HOW THE PAIN
DISCOVERY AND TARGET PROGRAM
WHICH IS AN RO1 THERE IS AN OPEN
ENDED BUT FOCUS ON VALIDATING
PARTICULAR TARGET TO THEN LEAD
TO THIS PLANNING STUDY TO BUILD
A TEAM AROUND DEVELOPING A
THERAPEUTIC PROGRAM, BRINGING
THOSE INDIVIDUALS IN, WHO HAVE
EXPERTISE IN DEVELOPING SMALL
MOLECULES OR BIOLOGICS AND
DEVELOPING SCREENING TO ASK THE
QUESTION WHETHER OR NOT THEY CAN
HAPPEN, WHETHER OR NOT THEY CAN
BE EFFECT, BIOLOGICAL EFFECT OF
PARTICULAR MOLECULE OR ASSET
THEY DEVELOPING, AROUND
PARTICULAR RECEPTOR AND THEN
ALSO INCLUDING EXPERTS IN USING
ANIMAL MODELS FOR ASKING
QUESTIONS ABOUT THE EFFICACY OF
PAIN THERAPEUTICS. BUILDING THAT
TEAM TOGETHER AND THEN
INITIATING THERAPEUTICS
DISCOVERY PROGRAM AROUND A
PARTICULAR TARGET. THEN WHEN
THEY FOUND HIT TO LEAD AND THEY
HAVE A STRONG BIOLOGICAL
RATIONALE THEY CAN SUBMIT TO THE
PTTP PROGRAM, PAIN THERAPEUTIC
DISCOVERY PROGRAM, DEVELOPMENT
PROGRAM, THAT WILL TAKE THEM
THROUGH IND AND PHASE 1 CLINICAL
TRIALS AND GET READY FOR EPIC
NET. THE PSDP PROGRAM CAN HELP
AT ANY STAGE HERE AND THE SBIR
WE SEE A LOT OF WORK IN THAT
AREA, AND A LOT OF INTEREST IN
THE SDIRs AND THEY CAN ALSO
TAKE ADVANTAGE OF EITHER THE
INITIAL THERAPEUTICS PROGRAM OR
LATER STAGE AFTER THEY GET THEIR
HIT TO LEAD. WE SEE INTEGRATING.
RIGHT NOW INSIDE THERAPEUTIC
VALIDATION OF THESE POTENTIAL
THERAPEUTIC TARGETS TO TREAT
PAIN THESE RO1s TO WORK UP THE
BIOLOGY BUT WORK UP BIOLOGY IN
THE CONTEXT OF VALIDATED TARGET,
I SEE YOU HAVE YOUR HAND UP DID
YOU WANT THE SAY SOMETHIN SOMETE
CURRENTLY HAVE WE HAVE 26 RO1s
FUNDED, TWO AND EIGHT
ADMINISTRATIVE SUPPLEMENTS THOSE
ARE PROJECTS BACK IN 2018, THOSE
WERE EASIEST ON THE STREET AND
WE ALREADY SEE AT LEAST ONE OF
THOSE PROGRAMS TAKING ADVANTAGE
OF LATER DEVELOPMENT FUNDING
OPPORTUNITIES INSIDE HEAL AND WE
HAVE SEVERAL PATENTS FROM THESE
GROUPS, ALREADY SUBMITTED. WE
HAVE THE PLANNING GRANT AND THE
TEAM BASED RESEARCH FOR THAT
INITIAL THERAPEUTICS DEVELOPMENT
AND WHAT IS INTERESTING ABOUT
THIS PROGRAM, IT SUPPORTS
MULTIPLE PARTS OF THERAPEUTICS
DEVELOPMENT IN THE SAME
APPLICATION. SO THE GOAL HERE IS
THE GROUPS DON'T HAVE TO WRITE A
GRANT IN ORDER TO DEVELOP ASSAY,
BRIGHT A SEPARATE GRANT IN ORDER
FOR THEM TO DEVELOP PARTICULAR
ANIMAL MODEL THEY NEED IN ORDER
TO GET THEIR PROGRAM UP AND
RUNNING. SEPARATE AWARD TO
DEVELOP PHARMACODYNAMIC
BIOMARKERS WHICH ARE HELPFUL FOR
THESE SMALL MOLECULE AND
BIOLOGICAL DEVELOPMENT PROJECTS.
WE SPORT THE PKPD EFFICACY
STUDIES INSIDE ALL THIS ONE
PROJECT AND WE ARE EXCITED ABOUT
THAT PROGRAM, WE HOPE THAT WE
CAN GET MORE APPLICATIONS. I
WILL GIVE A REPORT HOW MANY
PROJECTS WE HAVE RUNNING BUT
RIGHT NOW WE HAVE SEVEN PROJECTS
SIX ARE PLANNING GRANTS AND ONE
IS A FUNDED U I, YOU SEE IF YOU
LOOK IN THE YELLOW HERE, WE HAVE
MULTIPLE SITES, THESE ARE
COLLABORATORY PROJECTS, AND WE
DON'T REQUIRE THEM TO BE AT THE
SAME INSTITUTION, WE ENCOURAGE
THEM TO USE THE BEST SCIENTISTS
IN ORDER TO CONTRIBUTE TO THAT
COMPONENT OF THE GRANT TO MAKE
IT THE MOST SUCCESSFUL. WE DON'T
SEE THAT IN THE APPLICATIONS AND
SOMETHING THAT REALLY EXCITES
US. THAT THIS COLLABORATION
OVER LONG DISTANCES WITH THESE
ELECTRONIC PLATFORMS, AND
SHARING OF DATA, IS REALLY
POSSIBLE AND THEY ARE TAKING
ADVANTAGE OF THAT. THAT IS WHAT
I WILL TALK ABOUT THE PTDP HEAL
PAIN DEVELOPMENT THERAPEUTICS
DEVELOPMENT PROGRAM, THIS IS A
VIRTUAL PHARMA MODEL FOR
SUPPORTING A PROJECT. NINDS, NIH
THROUGH THE HEAL INITIATIVE AND
THIS IS A STRUCTURE WE LEARNED
FROM THE BLUEPRINT THERAPEUTICS
PROGRAM, HAS CLINICAL TRIALS
FROM MEDICINAL CHEMISTRY, PK AND
TOX STUDIES DATA MANAGEMENT,
MANUFACTURING AND POPULATION,
SUPPORT FOR CLINICAL TRIALS. SO
THE WAY THESE PROJECTS WORK
AFTER THEY ARE ACCEPTED INTO THE
PROGRAM THERE IS A CORE
CONSULTANT GROUP THAT'S
DEVELOPED TO SUPPORT THESE
PROJECTS. AND THEY DON'T HAVE TO
HAVE EXPERTISE FOR DOING
MEDICINAL CHEMISTRY OR THE
FORMULATION IN THEIR PARTICULAR
RESEARCH GROUP BUT THEY WILL
HAVE -- DEVELOP FOR THEM AND
ALSO THEY CAN TAKE ADVANTAGE OF
CLINICAL TRIALS IN ORDER TO GET
THESE DONE. SO WE HAVE A FEW
REALLY EXCITING BIG WINS FROM
THIS PROGRAM SO FAR WE HAVE ONE
PHASE 1 CLINICAL TRIAL COMPLETE
AND WE HAVE TWO LICENSING
AGREEMENTS WITH BIG PHARMA TO
HELP IN THE DEVELOPMENT OF THESE
PROJECTS WITH THESE GROUPS AND
IS CURRENTLY SEVEN PROJECTS
ONGOING IN THIS PARTICULAR
PROGRAM. THERE IS A NEW PROGRAM
THAT WE STARTED. THIS WAS
APPROVED LAST YEAR, WITH MDWG,
THE FUNDING ANNOUNCEMENTS WENT
ON THE STREET AND WE RECEIVED
APPLICATIONS. THIS IS CALLED
REJOIN. THIS IS RESTORING JOINT
HEALTH AND FUNCTION TO REDUCE
PAIN. THE GOAL OF THIS PROGRAM
IS TO REALLY LOOK AT THE
INNOVATION OF THE DIFFERENT
TYPES OF ARTICULAR AN
PERIARTICULAR TISSUES. THAT
COLLECTIVELY MAKE UP THE JOINT.
AND ASK HOW THAT INNERVATION PAN
THOSE PARTICULAR TISSUES
CONTRIBUTE TO THE VARIOUS TYPES
OF ACUTE AND CHRONIC PAIN MANY
THE JOINT. WE ARE TALKING
CARTILAGE, INTRASYNOVIAL SPACE,
THE BONE, THE MUSCLE, THE
TISSUE, FROM THE MUSCLE
INSERTING ON TO THE BONE, ET
CETERA, ET CETERA. THEN OF
COURSE THE FASCIA THERE. SO
THERE ARE PARTICULAR JOINTS THAT
WE KNOW CONTRIBUTE TO LOTS OF
DIFFERENT CHRONIC PAIN
CONDITIONS LIKE TEMPORAL
MANDIBULAR JOINT AND THE KNEE,
THAT IS KIND OF A FOCUS INZOOID
THE FUNDING ANNOUNCEMENT TO HELP
US UNDERSTAND THOSE PARTICULAR,
AGAIN NEURAL INNOVATION IN THERE
AND HOW THAT CONTRIBUTE TO PAIN
AND THOSE APPLICATIONS GOING
THROUGH REVIEW. I'M SORRY. THE
NEXT PART OF TO DISCUSS IS
REALLY EXCITING. THE PRECISION
HUMAN -- EVALUATE CELLS TO GENE
INFORMATION THAT SPECIFY
INTRICACIES ORIGINS IN NATURE OF
HUMAN PAIN, THAT IS A MOUTHFUL
BUT STILL A PROGRAM THAT VERY
EXCITED ABOUT. THIS IS TO LOOK
AT HUMAN TISSUE. FROM HUMANS
WITH CHRONIC PAIN. THE SOURCES
FOR THE TISSUES WILL BE LOCAL
TRANSPLANT CENTERS, CONSORTIUM
OF TRANSPLANT CENTERS PROVIDED
TO DIFFERENT GROUPS, WE HAVE THE
NATIONAL DISEASE RESEARCH
INTERCHANGE, THE NDRI NINDS
SUPPORTS AND NEUROBIOBANK ET
CETERA. COLLABORATIONS WITH
LOCAL SURGEONS. TO TAKE THAT
TISSUE FROM PATIENTS, GET VERY
GOOD PHENOTYPE OF THOSE TISSUES
OF THE PAIN DISORDER AND MAYBE
ADDICTION, INDIVIDUALS HAVE,
THEN ASK WHAT CHANGES ARE THERE
IN THE GENES, WHAT PROTEIN
EXPRESSION, ET CETERA. MAYBE THE
FUNCTIONAL IMAGING OR EVEN
ELECTROPHYSIOLOGY ON CELLS WHICH
WE HAVE SEEN GROUPS DO. SO YOU
MIGHT HAVE SEEN SOME PAPERS
COMING OUT IN THIS DOMAIN. BUT
THE BENEFIT OF THIS PARTICULAR,
GOING TO EMPHASIZE, NETWORK, IS
THAT THERE IS A COORDINATION OF
-- WITH DATA CENTER SO THAT THE
DATA HAS TO COME IN IN THE SAME
FORMAT AND MORE IMPORTANTLY, IT
HAVE TO BE STANDARDIZATION
WITHOUT PROCESSING THE TISSUES.
>> MICHAEL.
>> YOU CAN'T HEAR ME?
>> EVERYTHING IS OKAY MICHAEL.
>> THE BENEFIT OF THIS IS
COORDINATION OF DATA PROCESSING
AND DATA STORING AND THE GOAL IS
TO MAKE ALL THIS DATA AVAILABLE
SO GOAL OF THIS PROGRAM IS NOT
PUBLICATION, THE GOAL OF THIS
PROGRAM IS CREATE A DATA SET
THAT CAN BE MINED BY THOSE DOING
THERAPEUTICS DEVELOPMENT STUDIES
AND OTHER TYPES OF PROJECTS TO
GET US TO UNDERSTAND HUMAN PAIN.
ALL HUMAN TISSUE. NEXT SLIDE.
SO THE THIS TRANSLATED
DISCOVERIES FOR DEVICES IS THE
MULTI-FACETED DEVICE PROGRAM
THAT WE HAVE INSIDE OF HEAL TO
SUPPORT CLINICAL TRIALS AS WELL
AS BASIC SCIENCE STUDIES TO
UNDERSTAND MECHANISM OF ACTION
OF THESE DEVICES IN ORDER TO
OPTIMIZE THEM FOR PEOPLE WHO ARE
ALREADY RECEIVING BENEFIT FROM
THEM ALSO HOW TO GET DEVICES
OPTIMIZED FOR THOSE WHO AREN'T
GETTING BENEFITS. WE HAVE EIGHT
CLINICAL TRIALS GOING AND SIX
DEVELOPMENTAL PROJECTS, LOOKING
AT FOCUS ULTRASOUND, SPINAL CORD
STIMULATION, TRG STIMULATION,
AND PERIPHERAL NERVE
STIMULATION, ET CETERA, ET
CETERA. THERE ARE -- FUNDING
ANNOUNCEMENT THAT IS STILL ON
THE STREET IS WE ARE LOOKING
FORWARD TO FUNDING OUR FIRST SET
OF PROJECTS THIS SUMMER IS THIS
RFA NS 22016 AND THERE WILL BE
NEW RECEIPT DATES HOPEFULLY
COMING AVAILABLE FOR THAT ONE
TOO. THIS PROGRAM IS SOMETHING
YOU WERE REALLY EXCITED WITH IN
OUR WORK GROUP. THIS IS THE
DIVERSITY BASED SUPPLEMENT,
THESE ARE SUPPLEMENTS TO SUPPORT
THE CAREER DEVELOPMENT AND
RESEARCH FOR APPLICANTS FROM
DIVERSE BACKGROUNDS INSIDE THESE
STUDIES THAT ARE CURRENTLY
FUNDED IN HEAL. NOT JUST BASIC
SCIENCE IN PAIN BUT OUD. YOU CAN
LOOK AT NUMBER OF AWARDS, 19
DIVERSE CANDIDATES SUPPORTED, IT
IS STILL OPEN AND ON THE STREET.
IF YOU KNOW HEAL PROGRAMS TELL
THEM AND THESE ARE ALL HEAL
PROGRAMS ON THE LIFT LIST ON
THIS TABLE THAT CURRENTLY HAVE
SUPPLEMENTS SUPPORTING THESE
DIVERSE CANDIDATES IN THEIR
PROJECTS. GEOGRAPHIC
DISTRIBUTION IS ON THE RIGHT.
THE NEXT RECEIPT DATE IS
NOVEMBER 15, 2022. YOU CAN SEE
THERE IS A SMALL AMOUNT OF MONEY
GOING TO THIS BUT WE ARE
SUPPORTING A LOT OF DIVERSE
CANDIDATES WITH THIS EARLY IN
CAREER, 11 GRADUATE STUDENTS AND
EIGHT OTHER INVESTIGATORS AT
OTHER STAGES. AS I MENTION AT
THE BEGINNING THE SBI ARE SBIR M
IS SUCCESSFUL AND INTERESTINGLY
TO THE APPLICANTS FOR THEM TO
TAKE ADVANTAGE OF HEAL MONEY TO
SUPPORT COMPANIES DEVELOPING,
THERAPEUTIC INTERVENTION FOR
PAIN CONDITIONS THAT HAVE LITTLE
ABUSE LIABILITY. WE HAD A TOTAL
OF 42 AWARDS AT THIS POINT AND
THAT IS DISTRIBUTED AMONG 19 NIH
INSTITUTES AND CENTERS. A LOT OF
REALLY GREAT ACCOMPLISHMENTS, WE
HAVE FOUR HEAL FUNDED PROJECTS
IDENTIFIED AND VALIDATED NEW
TARGETS, WE SUPPORTED VIRTUAL
REALITY THERAPIES, FIVE HEAL
PROGRAM SBIR PROGRAMS THAT
ADVANCE PAIN MANAGEMENT TO
CLINICAL STAGE AND SEVEN PATENTS
HERE. THESE ARE BIG WINS AND
EMILY CAPIRELLO DIRECTOR OF THE
PROGRAM IS DOING PHENOMENAL JOB
WITH HER TEAM THE PSPP PROGRAM
PRE-CLINICAL SCREENING PLATFORM
FOR PAIN, MISSION IS TO
ACCELERATE DISCOVERY AND
DEVELOPMENT OF NON-OPIOID
ADDICTIVE TREATMENT. THE
APPLICANTS ARE COMPANIES AND
ACADEMIC IN THE U.S. AND IF THE
INTERNATIONAL COMMUNITY THAT
HAVE ASSETS THAT MAY HAVE
DEVELOPING OTHER THERAPEUTIC
CONDITIONS. THEY MAY ASK THE
QUESTION IT IS WORTH INVESTING
IN TAKING ADVANTAGE OF THIS
ASSET FOR THE TREATING OF PAIN
ACUTE OR CHRONIC PAIN OR
DIFFERENT PAIN MODALITIES. THE
PSPP HAS A CONTRACT WITH A
COMPANIES FOR DOING PRE-CLINICAL
SCREENING OR TESTING IN ANIMAL
MODELS THEY HAVE RIGOROUS
CONDITIONS FOR TESTING THOSE
MODELS SO MAYBE REPRODUCE THE
DATA THEY CURRENTLY HAVE OR GET
DATA IN OTHER PAIN CONDITIONS OR
PAIN CONDITIONS THEY NEVER
LOOKED AT. SO THEY -- THIS IS
DONE IN A PRIVATE WAY AND THE
DATA IS ALL CONTROLLED IN THE
COMMUNECATION BETWEEN APPLICANT
AND THE NIH AND THE INTELLECTUAL
PROPERTY STAYS WITH THE COMPANY.
THEY HAVE 30 PLUS ASSETS IN THE
PROGRAM AND THEY HAVE MORE THAN
20 ASSETS CURRENTLY STILL UNDER
EVALUATION. THIS IS DIVERSITY OF
DIFFERENT TARGET CLASSES YOU SEE
MT. MIDDLE IN THE GRAPH THERE.
NINDS IS NOT MOST OF THE
PROGRAMS I SHOWED YOU PREVIOUSLY
ALL OF THEM WERE LED BY NINDS
PEOPLE. IN COLLABORATION WITH
MANY INDIVIDUALS AT NIH HEAL
INITIATIVE. BUT NCATS ALSO HAS A
BIG ROLE THE PLAY HERE IN THE
PRE-CLINICAL TRANSLATIONAL
SPACE. JUST IN THE MISSION OF
NCATS FOR THOSE FAMILIAR WITH
IT, YOU UNDERSTAND WHAT I MEAN.
BUT THIS IS A SLIDE OR CHEVRON
DIAGRAM THAT DESCRIBE IT IS MANY
PROGRAMS THAT NCATS HAS IN THE
-- THAT ARE SUPPORTED BY THE
HEAL INITIATIVE. LOOK DOWN AT
THE PURPLE HERE, DEVELOPING NEW
TISSUE MODELS FOR SCREEN FOR
PAIN OR IPSC CELLS HERE IN THE
GREEN AND THEN DEVELOPMENT OF
INVESTIGATIONAL DRUGS FOR
CLINICAL TESTING ET CETERA. THEY
HAVE 65 TOTAL PROJECTS. AND THEN
THEY HAVE CHALLENGE GRANTS AND
THINGS SUPPORTED, 22 WINNERS FOR
THOSE AND COLLABORATION BETWEEN
INTRAMURAL AND EXTRAMURAL, THEY
HAVE 43 ONGOING CURRENTLY
SUPPORTED BY THE HEAL
INITIATIVE. SO THEREFORE 3
FUNDING ANNOUNCEMENTS THAT ARE
STILL FOR PROGRAMS THAT ARE RUN
BY NCATS AT NINDS PARTICIPATES
IN THAT ARE STILL ON THE STREET.
THEY ARE EMERGENCY REWARDS FOR K
18, THAT IS TO HAVE BASIC
SCIENCE RESEARCHER, SPEND SOME
TIME IN TRANSLATIONAL LAB EITHER
ACADEMIA OR INDUSTRY TO LEARN
TRANSLATIONAL RESEARCH. WE HAVE
THE DP 2 AWARDS, INNOVATOR
AWARDS SIMILAR TO THE NIH OD DP
2 INVEIGH FOR AWARDS, FOCUS OF
RESEARCH HAS TO BE AROUND
SCIENCE. THEN WE ALSO HAVE THE
R21 FOR VALIDATING OR
IDENTIFYING TARGETS IN THE
DRUGGABLE GENOME WHICH IS A
DATABASE OF UNIDENTIFIED GENES
AND PROTEINS AND WHAT THEY DO
BUT TO UNDERSTAND FROM RESEARCH
STANDPOINT WHETHER OR NOT THEY
CAN BE USED AS TARGETS FOR
TREATING PAIN. SO THERE ARE TWO
PARTICULAR COLLABORATION BETWEEN
HEAL AND NIH BLUEPRINT
NEUROTHERAPEUTIC PROGRAM WE
FUNDED ASPECT OF THESE PROJECTS
WHICH HAVE HAD BIG WINS. ONE ON
THE RIGHT IS COMPLETED PHASE 1A
CLINICAL TRIAL FOR THEIR EC 502C
WHICH IS SEH INHIBITOR HYPOXY
HYDROXYLASE INHIBITOR, WHICH IS
NOVEL COMPOUND FOR WHICH HAS
POTENTIAL IN TREATING PAIN AND
THEN WE HAVE THERAPEUTICS AS
PARTNER, A LARGE PARTNERSHIP
WITH SIGNIFICANT PHARMACEUTICAL
COMPANY TO DEVELOP THEIR NAV 1.7
INHIBITORS, THEY SITE ONE MOST
OF THE OTHER NAV, 1.7 INHIBITORS
LOOKING AT OTHER BINDING SITES
SO THEY THINK THEY HAVE A
POTENTIAL HERE TO BE SUCCESSFUL
FOR THAT. THIS IS PROJECT
CO-FUNDED BY HEAL AND BPN
PROGRAM. THIS SUMMARY SLIDE WILL
GIVE YOU A FEEL FOR THE NUMBER
ON THE RIGHT PAIN CONDITIONS
THAT ARE BEING SUPPORTED
CURRENTLY BY HEAL FUNDED
PROJECTS. OR THE TARGETS THAT
THESE PARTICULAR PROJECTS ARE
LOOKING AT EITHER IN THE CASE OF
RECEPTORS OR CHANNELS OR
PARTICULAR CELL TYPES OR PAIN
PATHWAYS. THERE ARE 34 AWARDS
FOR TARGET DISCOVERY AND
VALIDATION, 14 DEVICE PROGRAMS
AND 16 THERAPEUTICS PROGRAMS.
EITHER WITH SMALL MOLECULE AND
BIOLOGICS CURRENTLY BEING FUNDED
BY THESE HEAL PROGRAMS. SO
MISPOINT CHANGE GEAR AND TALK
THREE CONCEPTS. A AND FOR FY 23
WE WOULD LIKE TO ADD TO OUR
PORTFOLIO OF FUNDING
OPPORTUNITIES INSIDE OF HEAL.
THE FIRST ONE IS THE CONCEPT OF
INTEGRATED BASIC AND CLINICAL
RESEARCH IN PAIN SO THIS IS A --
WE ARE GOING TO USE PLAN HERE IS
TO USE AN RO1 AND THERE WILL BE
A COLLABORATION AS WAS MENTIONED
EARLIER BETWEEN THIS NEED FOR
COLLABORATION BETWEEN A
CLINICIAN AND A BASIC SCIENTIST
IN ORDER TO UNDERSTAND THE
UNDERLYING BIOLOGY AND GET
MECHANISTIC UNDERSTANDING OF THE
PAINFUL CONDITION. AND THAT IS
BEST DONE WITH THIS
COLLABORATION BETWEEN BASIC
SCIENCE AN CLINICIAN. THE REASON
FOR THE NEED FOR THIS CONCEPT IS
BECAUSE APPLICATIONS IN OUR
EXPERIENCE AS PROGRAM STAFF THAT
CONTAIN BOTH CLINICAL AND BASIC
SCIENCE COMPONENT HAVE A
DIFFICULTY IN REVIEW BECAUSE OF
THE FOCUS OF THE STUDY SECTION
IS USUALLY EITHER BASIC SCIENCE
OR CLINICAL. THESE PARTICULAR
APPLICATIONS WILL HAVE THE TEAM
BASED REVIEW UNDERSTANDING THAT
THAT IS A GOAL OF THE PROGRAM
AND WE ARE HOPING FOCUS PROGRAM
LIKE THIS IS MORE SUCCESSFUL
THAN THE STANDARD STUDY
SECTIONS. THIS NEXT CONCEPT IS
AROUND DEVELOPMENT OF ANIMAL
MODELS WITH NON-RODENT SPECIES
FOR THE TREATMENT OF PAIN. SO
THE GOAL HERE IS TO DEVELOP
VALIDATE THOSE MODELS AROUND
PARTICULAR NATIONALLY OCCURRING
DISEASE NATURALLY OCCURRING
DISEASE IN THOSE ANIMAL
POPULATIONS IN ORDER THE USE FOR
BIOMARKER OR BASIC SCIENCE
STUDIES IN ORDER TO GET A BETTER
FUNDAMENTAL UNDERSTANDING OF
PATHOPHYSIOLOGY OF THAT PAIN
CONDITION. THAT IS A SECOND
CONCEPT. THE THIRD ONE IS TO
SUPPLEMENT TO ONGOING HEAL
PROJECTS TO EMBED AN EXPERT IN
BUSINESS DEVELOPMENT ALONG WITH
THESE TEAMS TO GET THEM TO TAKE
THEIR IDEAS FROM THE BASIC
SCIENCE STAGE OR THE EARLY
TRANSLATIONAL PHASE TO
UNDERSTAND WHAT IT MEANS TO
START A BUSINESS AND REALLY
DEVELOP A THERAPEUTIC SO THAT IT
CAN GET INTO THE HANDS OF THE BY
IN ADDITION AND THEN EVENTUALLY
THE PATIENTS THEMSELVES SO WE
UNDERSTAND THAT THIS TRANSITION
FROM THE SCIENTIFIC ASPECT OF
THE PROJECT TO BUSINESS ASPECT
OF THE PROJECT COULD BE HARD.
AND THEIR EXPERIENCE AT NIH WITH
SIMILAR PROGRAMS THAT HAVE BEEN
SUCCESSFUL SO WE WANT TO TAKE
ADVANTAGE OF THAT IN THE HEAL
SPACE BECAUSE OF THE IDEA OF --
AND OVERALL GOAL OF HEAL IS TO
ENHANCE PAIN MANAGEMENT WE KNOW
THAT CAN'T HAPPEN WITHOUT
GETTING NEW TREATMENT AND
OPPORTUNITIES IN THE HANDS OF
PHYSICIAN AND PATIENTS TO TREAT
THEIR PAIN. THIS LAST SLIDE IS
JUST TO SHOW YOU THE TEAM OF
PEOPLE ON THE PAIN HEAL PAIN
PRE-CLINICAL TRANSLATIONAL TEAM
THAT CONTRIBUTED TO THESE MANY
DIFFERENT FUNDING OPPORTUNITIES
AND CONTRACT PROGRAMS ET CETERA,
REALLY A BIG TEAM AN
COLLABORATIVE. THANK YOU SO
MUCH.
>> VERY IMPRESSIVE, YOU MANAGED
TO GIVE AN HOUR LONG TALK IN
ABOUT 25 MINUTES. SO WE ARE
GOING TO DO THIS IN REVERSE
ORDER. MICHAEL PROPOSED THE
CONCEPTS THREE INITIATIVES
FORMALLY WE DON'T NEED TO
ACTUALLY VOTE ON HEAL INITIATIVE
CONCEPTS TO COUNCIL BUT IF THERE
ARE ANY SIGNIFICANT COMMENTS YOU
WANT TO MAKE ABOUT ANY OF THOSE
OR QUESTIONS ABOUT ANY OF THOSE
THREE INITIATIVES NOW WOULD BE A
GOOD TIME TO DO THAT.
>> WE ACTUALLY BEFORE THE
MEETING GOT SOME QUESTIONS, I
GOT SOME QUESTIONS ABOUT THE USE
OF THE RM 1 MECHANISM WHICH IS A
NEW COLLABORATIVE MECHANISM THAT
WE DEVELOPED AND HEAL SEEMS LIKE
REALLY EXCELLENT PLACE TO PILOT
THOSE KINDS OF COLLABORATIONS.
MECHANISM IS ALREADY BEEN USED,
VERY SIMILAR MECHANISM BY NIGMS
AND IS ACTUALLY BEEN I WOULD SAY
MUCH MORE SUCCESSFUL STANDARD
PROGRAM PROJECT MULTI-PI RO1.
THAT'S KIND OF A PRELIMINARY
RESULT. ARE THERE ANYTHING --
ANYTHING -- ANY OTHER QUESTIONS
ABOUT THESE INITIATIVE CONCEPTS?
IF IF NOT, GREAT, NOW I CAN SEE
EVERYBODY. IF NOT I SEE KEN HAS
-- IF NOT JUST SOMETHING FOR TWO
OR THREE GENERAL QUESTIONS. KE .
>> MICHAEL, LINDA, THIS IS
TREMENDOUS, I WASN'T SURE IF I'M
IN A PHARMA COMPANY
PRESENTATION. YOU GUYS ARE GOING
TO STOP GETTING PHARMA
COMPETITION SOON. I LOVE THE
THREE POLES FOR FISCAL YEAR 23.
PARTICULARLY THE BUSINESS SIDE.
I SPENT FOUR AND A HALF YEARS IN
THE EXTERNAL INNOVATION SPACE
WHICH IS BRIDGING DUE DILIGENCE
SPACE WHERE YOU BRINGING THE
SCIENCE BUT YOU ARE WORKING WITH
THE BUSINESS DEVELOPMENT PEOPLE,
AND THE KINDS OF THINGS YOU NEED
TO THINK ABOUT THERE, THE
BUSINESS ACUMEN YOU NEED TO
COMBINE WITH THE SCIENCE IN
ORDER TO MAKE SOMETHING FLY IS
COMPLETELY DIFFERENT SKILL SET.
SO I LOVE IT. THAT SUMS UP
TREMENDOUS PROGRAM GOING --
PROGRAMS HERE IN HEAL, BOTH
LINDA AND MICHAEL. THANK YOU.
EXCELLENT.
>> BY WAY I CAN SHORTEN THE NEXT
SECTION A LITTLE BIT SO I THINK
I CAN MAKE UP A LITTLE BIT OF
TIME. HEAL IS IMPORTANT. SO IF
YOU HAVE -- DAVID.
>> WONDERFUL WORK VERY EXCITING,
WHAT SORT OF NON-RODENT MODELS
ARE BEING CONSIDERED AND HOW
WILL ONE VET WHICH MODELS ARE
CHOSEN AMONG THE MANY OPTIONS?
>> DAVID, THAT IS AN EXCELLENT
QUESTION. SO THIS IS A CONCEPT
FOR CLEARANCE WE BRINGING BEFORE
COUNCIL. INSIDE FUNDING
ANNOUNCEMENT WE DON'T ANTICIPATE
SAYING WE EXPECT MODEL X Y OR Z.
EXCEPT TO SAY NON-RODENT
SPECIES. WITH THAT SAID THERE
ARE CONSIDERATIONS THAT ARE
GOING TO NATURALLY COME OUT OF
THE PROJECT IF THERE IS AN
EMPHASIS ON NATURALLY OCCURRING
PAIN DISEASE INSIDE THE ANIMALS
WE KNOW THERE ARE GROUPS USING
LARGE ANIMALS SUCH AS SWINE AND
THERE ARE INDIVIDUALS USING
COMPANION SPECIES SUCH AS DOGS
AND CATS IN NATURALLY OCCURRING
DISORDERS PAIN DISORDERS IN
THEM. WE IMAGINE THOSE GROUPS
WILL TAKE ADVANTAGE OF THIS
POTENTIAL FUNDING OPPORTUNITY.
>> IT WAS STUDY IN MY
NEIGHBORHOOD, WE HAD A LOT OF
OLD DOGS WITH CHRONIC HIP PAIN.
>> THERE YOU GO. NATURALLY
OCCURRING.
>> CHRIS.
>> SORRY HIT THE WRONG BUTTON.
CERTAINLY SUPPORTIVE OF ALL THE
CONCEPTS THAT HAVE BEEN
DISCUSSED AT HEAL AND VETTED AND
MDWG WE ARE SUPPORTIVE OF THESE
MOVING FORWARD. I PARTICULARLY
LIKE THE RO1 PROPOSALS, IN THE
BACK OF MY MIND SOMETHING SAYS
TO ME DO WE HAVE ENOUGH MATURE
PAIN RESEARCH GROUPS THAT HAVE
THAT EXPERTISE IN HOUSE. THAT
WILL BE ABLE TO SUBMIT
COMPETITIVE APPLICATIONS.
WONDERING IF YOU ARE CONCERNED
ABOUT THAT AND THEN MY SECOND
QUESTION WOULD BE IF WE DON'T
GET THE TYPE OF APPLICATIONS WE
ARE LOOKING FOR THERE, IS IT
POSSIBLE THAT HEAL WILL CONSIDER
ANOTHER FUNDING MECHANISM THAT'S
MORE COLLABORATIVE WITH NIH
WHERE YOU ACTUALLY PUT THE TEAMS
TOGETHER BRING PEOPLE IN FROM
DIFFERENT UNIVERSITIES WITH
DIFFERENT EXPERTISE AND PUT
TEAMS TOGETHER LIKE BROADER
INITIATIVES WITHIN BRAIN FOR
EXAMPLE.
>> CHRIS, THAT IS A PERCEPTIVE
QUESTION. YOU REALLY HAVE A VERY
GOOD UNDERSTAND OF THE PAIN
FIELD. WE THINK THERE ARE
POTENTIAL FOR AN INITIAL STAGE
OF APPLICATIONS AND
COLLABORATIONS THAT ARE ALREADY
NASCENT OR ALREADY ONGOING. SO
WE EXPECT PEOPLE TAKING
ADVANTAGE OF US, OUR GOAL IS
MULTIPLE RECEIPT DATES AND HAVE
THIS BE ONGOING PROGRAM AND
INSPIRE NEW COLLABORATIONS. IT
WOULD BE BEST FOR THOSE TO
ORGANICALLY HAPPEN BUT WE
UNDERSTAND THAT AS PROGRAM
DIRECTORS AND PROGRAM STAFF AT
NIH IT IS HELPFUL FOR US TO
STAND BEFORE INDIVIDUALS MAYBE
NOT ZOOM MEETINGS BUT
CONFERENCES, AND EXPLAIN
COLLABORATIONS AND HEN TALK TO
AT THE UASP OR CONFERENCE, ET
CETERA AND ENCOURAGE THOSE
CLINICS TO REACH OUT TO BASIC
SCIENCE COLLEAGUES OR BASIC
SCIENCE COLLEAGUES TO REACH TOUT
CLINICIANS, IN ORDER TO BUILD
THESE COLLABORATIONS. SOME WAY
NIH HAS TO TEACH THEM HOW TO DO
IT, SOME THEY ALREADY KNOW HOW
TO DO IT, THEY NEED A MECHANISM
TO FUND IT SO I GUESS THAT IS A
SUMMARY OF MY ANSWER.
>> ALLAN.
>> I HAVE WRITTEN TO YOU ABOUT
THIS, AND DECIDES WORTH JUST
MENTIONING, THE CONCEPT TOO I
CERTAINLY AM IN FAVOR OF IT,
BRINGING DIFFERENT STRENGTHS AND
TALENTS AND TECHNOLOGIES
TOGETHER WITH CLINICAL BASIC
SCIENCE. BUT THOSE OFTEN DON'T
EXIST AT ONE CAMPUS. AND
CERTAINLY NOT IN ONE LAB. I'M
NOT SURE TO WHAT EXTENT IS IT
REASONABLE TO BRING IN THE
TALENT ACROSS THE COUNTRY FOR
THAT MATTER IN ANOTHER COUNTRY
WHERE SOMEONE HAS A PARTICULAR
STRENGTH WHATEVER IT IS THAT
WOULD BE EXACTLY APPROPRIATE FOR
THIS PARTICULAR APPROACH, THAT
DOESN'T EXIST AT UCSF FOR
EXAMPLE.
>> I THINK AGAIN GREAT QUESTION,
WE TRIED TO ADDRESS THAT WITH
SOME OF OUR OTHER PROPOSALS AND
INITIATIVES INSIDE OF HEAL. FOR
INSTANCE, THE PLANNING STUDIES,
AND THE U 19 FOR THAT INITIAL
THERAPEUTICS DEVELOPMENT WE
INSIDE THE FUNDING APPLICATION
AND IN OUR WEBINARS HAVE SAID WE
DON'T EXPECT THE EXPERTISE TO BE
AT ONE INSTITUTION. WE EXPECT
THERE TO BE COLLABORATION ACROSS
INSTITUTIONS AND EVEN
INTERNATIONALLY. WE HAVE TWO
INTERNATIONAL COLLABORATIONS
CURRENTLY HAPPENING INSIDE THOSE
PROGRAMS AND AS I SHOWED YOU IN
THAT LITTLE MAP ON THE RIGHT
SIDE OF THE SLIDE, WE HAVE SOME
OF THEM THREE OR MOROSITIES
INSIDE THAT SAME PROJECT USING
THE BEST TALENT AT DIFFERENT
INSTITUTIONS TO SOLVE THE GOALS
OF THE SAME PROJECT. SO INSIDE
THE FUNDING ANNOUNCEMENT AND IN
THOSE WEBINARS TEACHING THE
APPLICANTS THAT THIS IS A
POSSIBILITY REALLY CAN BRING THE
PEOPLE TOGETHER.
>> WHY DON'T WE STOP THERE, IF
THERE ARE MORE QUESTIONS THOUGH
WHY DON'T YOU JUST EMAIL EITHER
MICHAEL OR LINDA DIRECTLY AND
PERHAPS COPY WALTER SO HE'S IN
THAT LOOP. YOU CAN COPY ME AS
WELL AND USUALLY COPY ALL
COUNCIL RELATED STUFF SO FEEL
FREE TO ASK THEM ANY OTHER
QUESTIONS YOU HAVE OR ANY
CONCERNS YOU HAVE AND I
APOLOGIZE FOR THE AGENDA BEING
SO CRAMMED AT MOMENT. I'M GOING
TO TRY TO MAKE UP TIME BY
SKIPPING ALL THE NONSENSE I
STUFF SAID IN INTRODUCTIONS. WE
ARE DOING CONCEPT CLEARANCE NOW
AND ROD, OUR POINT PERSON FOR
ALZHEIMERS AND ADRD IS GOING TO
PRESENT SOME CONCEPTS. HI ROD.
CORRIVEAU. OKAY. GO FOR U IT
>> THANK YOU, BOB. GOOD TO BE
HERE TO SAY A FEW WORDS ABOUT
THE ADRD PROGRAM AND THE CONTEXT
OF CONCEPT CLEARANCE FOR THIS
COUNCIL ROUND. THE ALLS MYERS
DISEASE AND ALSO HAMMERER'S
DISEASE RELATED DEMENTIA AS I
DON'T HAVE TO TELL THIS AUDIENCE
OF COURSE IS IRREVERSIBLE
PROGRESSIVE BRAIN DISEASE THAT
AFFECT ALMOST 6 MILLION PEOPLE
IN THE UNITED STATES. SO MAJOR
PUBLIC HEALTH ISSUE. AFFECTS THE
HEALTH AND FINANCES OF
INDIVIDUALS FAMILIES,
COMMUNITIES AND SOCIETY.
CONGRESS IS CHOSEN TO ACT ON
THIS NATIONAL ALZHEIMER'S
PROJECT ACT LAW OF 2011,
PROVIDES AN OPPORTUNITY TO
ADDRESS ALZHEIMER'S DISEASE AND
RELATED DEMENTIAS WITH GOAL ONE.
BEING TO TREAT OR PREVENT AD
ADRD BY 2025. AT THE NIH NIA
LEADS THE RESPONSE TO THE
NATIONAL PLAN TO ADDRESS
ALZHEIMER'S DISEASE. AD ADRD AND
NINDS LEADS ACROSS THE NIH, LEWY
BODY DEMENTIA, FRONTOTEMPORAL
DEMANE SHAH AND ALZHEIMER'S
DISEASE RELATED SUMMIT. THE
NINDS AND THE NIA WORKING TO
CLOSELY ON FUNDING OPPORTUNITIES
SUPPLEMENT PROGRAMS TO EXPAND
THE FIELD PAY LINES YOU HAVE
SHARED PAY LINES, AS WELL AS
TRIENNIAL SUMMITS IF YOU LOOK AT
THE BAR ACROSS THE TOP HERE,
THERE ARE SUMMIT EACH YEAR WITH
THE NIA LEADING THE ALZHEIMER'S
DISEASE SUMMITS, CARE SUMMITS,
THE NINDS LEADING ALZHEIMER'S
DISEASE RELATED DEMENTIA
SUMMITS. THESE PRODUCE RESEARCH
RECOMMENDATIONS FOR THE ADRD
SUMMIT, THEY BECOME MILESTONES,
IT IS A FACA PROCESS, I WANT TO
THANK GINA CO-AND TOM CARMICHAEL
FOR BEING PART OF THAT PROCESS
AND LOOK TOWARD SCIENTIFIC
ADVANCES TO WORK ON A GOAL ON TO
TREAT AD ADRD BY 2025. A PREVIEW
OF THE OCTOBER COUNCIL, WE WILL
DO A PRESENTATION ON NIH ADRD
SUMMIT THAT WAS THIS PAST MARCH
AND WILL WILL BE A FORMAL REPORT
TO COUNCIL THAT WILL BE
PRESENTED, THE SCIENTIFIC CHAIR
WAS DR.NATELY ROAST WE GRATEFUL
TO HER FOR THAT WORK THAT SHE
DID. AND THE TOPICS OF THE
SUMMIT ARE THE TOPICS THAT ARE
DESIGNATED BY THE NATIONAL PLAN
HEALTH EQUITY AND ADRD
FRONTOTEMPORAL DEGENERATION.
VASCULAR CONTRIBUTION TO
COGNITIVE IMPAIRMENT DEMENTIA
VCID, LEWY BODY AND MULTIPLE
ETIOLOGY DEMENTIAS. UNDER
MULTIPLE ETIOLOGY WE HAVE SUB
TOPICS BECAUSE THEY ALL RELATE
TO AND ARE RISK FACTORS FOR
DIDEMENTIA. IT WAS THE FIRST
TIME WE HAD A VIRTUAL SUMMIT
THIS PAST MARCH OUT OF
NECESSITY. AND WE HAD MORE THAN
1500 ATTENDEES, 400 TO 700
DURING MOST SESSIONS WITH BROAD
REPRESENTATION AMONG ACADEMIC
CLINICAL, GOVERNMENT INDUSTRY
AND NOT FOR PROFIT AND PUBLIC
STAKEHOLDERS. I WILL BE TELLING
YOU MORE ABOUT SUMMIT ALONG WITH
NATALIA IN SEPTEMBER, THERE ARE
LINKS AVAILABLE FOR DAY ONE FOR
BOTH DAYS OF THE SUMMIT AND YOU
CAN WATCH SUMMIT IF YOU DIDN'T
HAVE THE OPPORTUNITY. IT WAS
NICE TO SEE ALL THE OPEN MIC
TIME THAT WE HAD AVAILABLE
DURING THE TWO DAYS, 210 MINUTES
USED VERY WELL I WILL ADD, IT IS
WONDERFUL THAT WE GOT ALL THAT
INPUT. FUNDING FOR NINDS AD ADRD
PROGRAMS IS THROUGH OUR
PARTNERSHIP WITH THE NIA. AND IF
YOU LOOK AT THE BLUE HERE ON
THIS PLOT, YOU CAN SEE NINDS
INVESTMENT IN AD ADR RESEARCH
REGULAR NINDS BUDGET AND IN
YELLOW OR GOLD YOU SEE
ADDITIONAL FUNDS FROM THE NIA
FROM CONGRESS AND EARMARKED
FUNDS FOR AD ADRD RESEARCH. THE
ADDITIONAL FUNDS FROM NIA ARE
USED BY THE NINDS TO INCREASE
INVESTIGATOR INITIATED RESEARCH
AS WELL AS RESEARCH RESPONSIVE
TO THE ALZHEIMER'S DISEASE AND
RELATED DEMENTIA INITIATIVES.
THREE OF WHICH ARE ON THE AGENDA
FOR CONCEPT CLEARANCE TODAY. A
VERY THUMBNAIL SUMMARY OF THE
PROGRAM IS THAT THE NINDS HAS
LED FOUR SUMMITS THAT HAVE SET
NATIONAL RESEARCH PRIORITIES.
AND THERE HAVE BEEN MORE THAN 60
NINDS ALZHEIMER'S DISEASE FUND
INITIATIVES AND THESE SUPPORTED
MAJOR PROGRAMS AND CONSORTIA AND
I DON'T HAVE TIME TO GO OVER
THEM TODAY BUT YOU CAN SEE LOGOS
FOR MANY AND MANY FAMILIAR TO
YOU. THE NIH ALZHEIMER'S DISEASE
RELATED DEMENTIA RESEARCH
FUNDING IS INCREASE MORE THAN
FIVE FOLD SINCE 2015. AND THAT
IS ALLOWED US TO DO SOME SUPPORT
TREMENDOUS PROGRAMS THAT ARE
MOVING FIELD FORWARD. IN TERMS
OF CONCEPT CLEARANCE, I JUST
WANTED TO MENTION THAT BEFORE
THE CONCEPTS COME TO COUNCIL
THEY GO THROUGH A PRETTY
RIGOROUS PROCESS. THE SUMMIT
MILESTONES ARE DELIVERED TO THE
DEPARTMENT OF HEALTH AND HUMAN
SERVICES, AND THEY INFORM ALL OF
US REALLY AT THE NINDS PROGRAM
STAFF LEADERSHIP AND
DISCUSSIONS, ABOUT THE CONCEPTS,
ANNUALLY, THAT STARTED IN SPRING
OR SUMMER AND CONTINUED THROUGH
THE FALL, DIRECTOR IS INVOLVED,
THE NIA IS INVOLVED, AND
ULTIMATELY THESE CONCEPTS ARE
DEVELOPED AND DISCUSSED AND HAVE
BEEN VETTED BY THE NINDS
DIRECTOR AS WELL AS THE NIA
DIRECTOR BEFORE THEY COME TO
COUNCIL HERE. ONCE WE HOPE THE
CONCEPTS ARE APPROVED, THEY ARE
FURTHER WORKEDDED UP FOR
IMPLEMENTATION, TYPICALLY IN THE
FOLLOWING FISCAL YEAR. SOMETIMES
WE ARE ABLE TO PLAN, WE HOPE TO
PLAN MORE UP TO TWO YEARS IN
ADVANCE AND JUST MAKES A LOT OF
THINGS WORK VERY SMOOTHLY IF WE
CAN PLAN THAT FAR IN ADVANCE.
THIS IS A LARGE PROGRAM WITH A
LOT OF EFFORT BY LOT OF PEOPLE,
AND IT IS HARD TO DO JUSTICE TO
IT BUT I AM GRATEFUL TO
EVERYBODY FOR THEIR TREMENDOUS
EFFORTS CREATIVE EFFORTS IN
MAKING THIS PROGRAM A SUCCESS.
WE HAVE THREE CONCEPTS THAT ARE
FOR CONCEPT CLEARANCE. ONE OF
THEM, YOU CAN SEE THAT I HAVE
NAMED THE PROGRAM LEAD WILL
DAILY IS THE LEAD OF A CONCEPT
CALLED CELLULAR MOLECULAR
MECHANISMS OF PRYION LIKE
SEEDING AGGREGATION AN
NEUROTOXICITY IN ADRD, REBECCA
HUMMER IS LEAD FOR AMYLOID FOR
POPULATIONS WITH VASCULAR RISK
OF COGNITIVE IMPAIRMENT AND
DEMENTIA AND (INAUDIBLE) IS THE
LEAD FOR NEUROPATHOLOGICAL
ASSESSMENT OF TBI RELATED
NEURODEGENERATION AND
NEUROCOGNITIVE DECLINE. WITH
THAT I WILL PAUSE. I KNOW YOU
HAVE SEEN THE MATERIALS AND SEE
IF ANYBODY HAS ANY QUESTIONS
ABOUT THESE.
>> OKAY. ARE THERE ANY QUESTIONS
FOR ROD? FOR THEIR RESPECTIVE
PROGRAM DIRECTORS? DID YOU HAVE
MORE, THAT IS ALL.
>> WHAT WE NEED IS A MOTION TO
APPROVE OR DISAPPROVE THESE
THREE INITIATIVE CONCEPTS, THEY
ARE COMING FROM THE ALZHEIMER
DIRECTED FUNDS SO WE NEED A
MOTION TO APPROVE.
>> MOTION TO APPROVE.
>> SECOND. OKAY. LET'S USE THE
CHAT TO VOTE ON THESE THREE
TOGETHER. THANKS A LOT ROD,
APPRECIATE YOUR BREVERY AS WELL
IF THERE ARE QUESTIONS OR ROD,
OUR STAFF IS GETTING SLICK WE
ARE REALLY ARE SOUNDING LIKE A
DRUG COMPANY NOWADAYS. IF THERE
ARE QUESTIONS FOR ROD FEEL FREE
TO REACH OUT TO HIM AND HE CAN
RELAY QUESTIONS TO THE RELEVANT
PROGRAM PEOPLE. THE OTHER
INITIATIVE TALK ABOUT
SPECIFICALLY IS REISSUES ON A
SLIDE THAT WE WON'T TALK ABOUT
UNLESS YOU HAVE QUESTIONS. IS
DAN MILLER, DAN DO YOU HAVE YOUR
SLIDE READY TO PUT UP? WELCOME,
BOB BROWN.
>> ARE WE SUPPOSED TO VOTE ON
THE HEAL CONCEPT?
>> THE HEAL CONCEPT WE WANTED
YOU YOU ARE FEEDBACK FORMALLY
SPEAKING WE DON'T NEED TO
APPROVE CONCEPTS FOR HEAL.
CREATE NATIONAL EMERGENCY, WE
HAVE AUTOMATIC APPROVAL BUT
WALTER WANTS THE SEE EVERYTHING
YOU ARE PROPOSING TO DO. I
APOLOGIZE FOR THINGS BEING
RUSHED TODAY.
>> THANKS.
>> SO DAN, KELLY, TONY, HE
DOESN'T HAVE ACCESS TO SHARE HIS
SLIDE. T WE WILL HAVE A COPY OF
YOUR SLIDE. IS ACCESS SOMETHING
TO GRANT TIM OR BROOK?
>> YOU HAVE TO CLICK THE PROMOTE
BUTTON. DID YOU HEAR THAT, CLICK
THE PROMOTE BUTTON. WHATEVER
THAT MEANS.
>> THERE WE GO. WE SEE IT. WE
DON'T SEE OR HEAR YOU.
>> THANKS DAN.
>> IS THIS IN PROPER MODE?
>> NOT IN PRESENTATION MODE. IT
IS THE OTHER SIDE OF THE SCREEN.
THAT IS RIGHT. GO FOR IT.
>> THANKS, EVERYBODY. I'M DAN
MILLER, THIS IS A CONCEPT THAT
I'M BRINGING TO YOU FOR
ACCORDANCE THAT WAS PUT TOGETHER
BY A NUMBER OF US AT NINDS.
FOCUSED ON STRATEGIES TO
INCREASE DIVERSE NEUROTYPICAL
BRAIN DONATION. SO IT IS
CONCEIVED AS A MULTI-IC
INITIATIVE THAT REALLY AIMS TO
ADDRESS TWO OF THE TOP
CHALLENGES THAT BRAIN BANKS HAVE
BEEN FACED TO HAVE
REPRESENTATIVE TUSH SHOE
ESSENTIALLY IN OUR BANKS THAT
REPRESENT ALL VARIATION THAT
EXISTS IN US SOCIETY.
IMPORTANTLY ACROSS ALL DISEASE
TYPES. IT IS ONE THING TO HAVE A
PERCENTAGE OF CERTAIN ANCESTRY
OR RACE IN YOUR BANK THAT LOOKS
DECENT OR LOOKS REPRESENTATIVE.
IT IS ANOTHER THING TO HAVE THAT
REPRESENTATION ACROSS REALLY
DISEASE TYPES IN WHICH TISSUE IS
-- NEEDS TO BE STUDIED. THE
OTHER MAIN CHALLENGE WE HAVE IS
ACCESS TO NEUROTYPICAL TISSUE. I
THINK YOU ARE PROBABLY ALL AWARE
THAT IT IS CRITICAL TO HAVE
NORMAL HUMAN BRAIN TISSUE
AVAILABLE TO UNDERSTAND HOW THE
BRAIN WORKS. IT IS ALSO EXREAMLY
IMPORTANT AS ESSENTIALLY CONTROL
OR COMPARATIVE TISSUE FOR
DISEASE FOCUS STUDIES. SO
EARLIER LAST YEAR WE HELD A
WORKSHOP CALLED TISSUE QUALITY
PIPELINE FOR HUMAN BRAIN CENSUS
WORKSHOP, ESSENTIALLY DEALT WITH
HUMAN BRAIN TISSUE NEEDS THAT WE
ARE FACING GIVEN BRAIN
INITIATIVE RAMP UP IN THE HUMAN
CELL CENSUS. AND EVEN THOUGH
REALLY THE WORKSHOP WAS FOCUSED
ATLASSING AND NEED FOR ATLASSING
THESE TWO TOPICS BUBBLED TO THE
TOP. I THINK YOU WILL SEE WHY
LATER. AND THE TWO TOPICS THAT
THEY IDENTIFIED AND MADE A
RECOMMENDATION ON ARE REALLY
DONOR DIVERSITY HOW WE GET OUR
HANDS ON DIVERSE TISSUE. HOW CAN
WE MAKE SURE THAT WE HAVE
SUFFICIENT NEUROTYPICAL TISSUE
IN OUR BANKS. THEY MAKE SPECIFIC
RECOMMENDATIONS, THE FIRST ONE
FOR DONATION IS SOMEWHAT
OBVIOUS, BUT VERY IMPORTANT,
TARGETED OUTREACH, ENGAGEMENT TO
COMMUNITIES CURRENTLY
UNDERBANKED. TO INCREASE ACCESS
AND COLLECTION OF NEUROTYPICAL
TISSUES THEY SUGGEST THAT WE DO
THINGS THAT SUPPORT NEW
COLLABORATION BETWEEN BANKS
TISSUE BANKS AND LOCATIONS WHERE
THESE TISSUES ARE COLLECTED SO
MEDICAL EXAMINERS OFFICE,
OPOs. I DON'T KNOW HOW
NECESSARY IT IS BUT I WANT THE
GIVE YOU A QUICK IDEA OF WHY
DIVERSITY IS AN ISSUE IN BRAIN
BANKING AND THERE IS A LOT SAID
ABOUT UNDERREPRESENTATION
CLINICAL STUDIES, THERE'S
ACTUALLY A LOT PUBLISHED OR
IMPORTANT PAPERS PUBLISHED ON
THE LACK OF REPRESENTATIVE
DIVERSITY AND BRAIN BANKING
ACTUALLY SPECIFICALLY. BUT I
WILL GIVE YOU SOME NUMBERS THAT
SHOW WHAT IS GOING ON IN THE NIH
BIOBANK WHICH IS PROBABLY
NATION'S LARGEST HUMAN BRAIN
BANK. SO THESE ARE -- WE COLLECT
THIS DATA IN TWO WAYS RACE AND
ETHNICITY SO I'M SHOWING IT IN
TWO WAYS BUT I THINK THE POINT
CAN BE MADE, IN THIS WAY. SO IN
BLUE IS THE DATA WE COLLECT ON
RACE AND ORANGE IS DATA WE
COLLECT ON ETHNICITY AND WHAT IT
SHOWS US IS THAT OUR NUMBERS FOR
BLACK OR AFRICAN AMERICAN DONORS
IN BIOBANK IS DECENT. IT IS
NUMBER THAT NEUROBIOBANK IS
PROUD OF AND OVER YEARS AND IS
HAPPY TO SHOW. I THINK THE DEVIL
IS IN THE DETAILS AND IF I HAVE
TIME I WILL GO INTO THAT LATER.
IF WE LOOK AT ASIAN DONORS OR
HISPANIC AND LATINO DONORS THE
NUMBERS ARE QUITE BAD IF NOT
ABYSMAL, THIS IS REALLY
SOMETHING THAT I THINK WE NEED
TO ADDRESS. AND THAT THIS EFFORT
WANTS TO ADDRESS, LET ME LOOK AT
TIME HERE. I WANT TO TALK ABOUT
THE BLACK AFRICAN AMERICAN
COMPONENT IN THE NEUROBIOBANK.
IF YOU TAKE A LOOK AT WHERE
TISSUE BLACK AFRICAN AMERICAN
DONORS IS BANKED, I GAVE A BIG
SORT OF EAGLE EYE OVERVIEW TO
MAKE MY POINT, YOU WILL FIND
THAT MORE THAN HALF OF THE
TISSUE IS BANKED IN THESE THREE
SITES, HPCC, MARYLAND, AND
MARYLAND PSYCHIATRIC BANK. THE
HPCC IS INTRAMURAL NIH BANK AND
MARYLAND PSYCHIATRIC BANK LIKE
THE NIMH BANK ARE HEAVILY
FOCUSED ON PSYCHIATRIC
DISORDERS. THE MARYLAND BANK IS
OUR PEDIATRIC BANK SO THEY ARE
AGENTS OF DONORS ARE VERY YOUNG.
SO IF YOU LOOK AT THE AGE
DISTRIBUTION, ESSENTIALLY WHAT
THIS TELLS US IS THAT HBCC AND
MARYLAND PSYCHIATRIC HAVE A VERY
LARGE COMPONENT PROPORTIONALLY
OF BLACK AFRICAN AMERICAN TISSUE
BUT IT IS GOING TO BE HEAVILY
SKEWED TOWARDS PSYCHIATRIC
DISORDERS. WHAT THE MARYLAND
COLLECTION ESSENTIALLY TELLS US
IS THAT THE AFRICAN AMERICAN
DONORS THAT WE HAVE WILL BE
ADDITIONALLY SKEWED TOWARDS
YOUNG DONORS. THAT IS
ESSENTIALLY WHAT THE DATA SHOWS
IF YOU LOOK AT THE GRAPH ON THE
RIGHT THE BLUE BARS ARE THE
NEUROBIOBANK AND IF YOU IGNORE 0
TO 10 THAT IS ESSENTIALLY THE
AGE DISTRIBUTION ONE WOULD
EXPECT OF A BRAIN BANK, THE
OLDER THE MORE. WE DO HAVE A LOT
OF 0 TO 10 BECAUSE MARYLAND IS
VERY FOCUSED ON PEDIATRIC CASES.
AND EVEN HPCC AND MARYLAND
PSYCHIATRIC BANK IS ALSO GOING
TO BE VERY SKEWED HEAVILY
TOWARDS YOUNGER CASES. SO I
THINK WHAT IT TELLS US IS HOE
THE BLACK AFRICAN AMERICAN
NUMBER LOOKS GOOD, AND IS
ACTUALLY GOOD COMPARED TO OTHER
BANKS WE STILL HAVE WORK TO DO
TO MAKE SURE THAT WE HAVE
REPRESENTATION OF BLACK AND
AFRICAN AMERICAN AND ALL
ANCESTRIES RACE ACROSS ALL THE
DISEASE TYPES THAT ARE IMPORTANT
TO BE STUDIED. I WANT TO QUICKLY
ALSO GIVE YOU AN IDEA OF WHY
NEUROTYPICAL COLLECTION IS
REALLY COMING TO THE FORE FRONT
FOR COLLECTION OF NEUROTYPICAL
TISSUE COMING THE FOREFRONT NOW.
AND THAT MANY OF YOU ARE AWARE
COMES FROM SET OF RFAs AND
GROUP OF INITIATIVES THAT ARE
COMING OUT OF THE BRAIN
INITIATIVE CALLED BUY CAN, THE
BRAIN CELL CENSUS BRAIN
INITIATIVE CELL ATLAS NETWORK.
WHERE A LOT OF MONEY IS BEING
SPENT TO DEVELOP A ATLAS ALL
CELL TYPES IN THE HUMAN BRAIN.
NORMAL HUMAN BRAIN. THIS REALLY
REQUIRES SOME SPECIAL
CONSIDERATIONS, SO IT IS A CLEAR
GOAL OF THE CELL CENSUS THAT
ATLAS REPRESENTS HUMAN DIVERSITY
AS WE FIND IT NOT CELL TYPES,
SOME LOOKS LIKE ME OLDS BLACK
GUY BUT REFLECT IT IS DIVERSITY
THAT WE HAVE. AND WE WILL NEED
NORMAL OR NON-DISEASE TISSUE FOR
THIS, THAT IS PREPARED IN A WAY
THAT SUITS THESE VERY MODERN
ASSAYS THAT WILL BE APPLIED.
FOR THAT THE BRAIN INITIATIVE
HAS TEAMED UP WITH THE
NEUROBIOBANK AND CREATED THE
HUMAN BRAIN CELL ATLAS
COLLECTION CALLED HBCAC. WE ARE
TASKED WITH OVER THE NEXT FOUR
TO FIVE YEARS COLLECTING 200 TO
300F PREPARED
AND PROCESSED NEUROTYPICAL
BRAINS FOR THE ATLASSING EFFORT.
SO THAT INVOLVES THE
STANDARDIZED COLLECTION PROCESS,
SPECIALIZED METHODS FOR THE
ASSAYS THAT WILL BE APPLIED
IMAGING SAMPLES CAN BE
REGISTERED BACK ON TO ATLAS. AND
WE HAVE TO MEET THE INCLUSION
GOALS WHICH IS BROAD DIVERSITY
OF NEUROTYPICAL DONORS. SO THE
EFFORT WE ARE PROPOSING HERE
ISN'T REALLY -- IT IS MORE LONG
TERM, IT IS NOT NECESSARILY
GOING TO HELP US ACHIEVE THOSE
GOALS THAT WE HAVE, IT WILL HELP
US BACK FILL, THIS WILL
ESSENTIALLY SOMEWHAT -- THIS
WILL PUT A LARGE BURDEN ON
COLLECTION OF NEUROTYPICAL
TISSUE THAT WILL NOT THEN BE
AVAILABLE FOR PEOPLE STUDYING
ALZHEIMER'S PD SCHIZOPHRENIA, SO
ON SO WE NEED TO BACK FILL THOSE
BRAINS AND THAT IS WHAT WE HOPE
WILL BE HELPING US TO DO. SO I
WANT TO GIVE A LITTLE DETAIL ON
EXACTLY HOW WE WERE RECOMMENDED
TO DO THIS. WE WILL TALK ABOUT
OUTREACH ENGAGEMENT PART, WE
WANT TO LEVERAGE ONGOING NIH
STUDIES, CLINICAL STUDIES THAT
HAVE ACTIVE ENGAGEMENT PARTNERS
THAT ARE CURRENTLY TALKING TO
THOSE UNDERSERVED COMMUNITIES
THAT ARE NOT BANKING. WE WOULD
LIKE TO SUPPLEMENT AND ADD FUNDS
TO THEIR PROGRAMS, WE WOULD LIKE
THE ADD TRAINING AND MESSAGING
TO THEIR OUTREACH PROGRAMS SO
THEY CAN TALK ABOUT OUR TOPIC
WHICH IS BRAIN DONATION, TO THE
PEOPLE THAT THEY ARE ENGAGED
WITH AND OF COURSE WE WOULD WANT
THOSE AND IT WILL REQUIRE
CLINICAL STUDIES THAT WE WORK
WITH TO REALLY HAVE VERY ACTIVE
OUTREACH ARMS IN THOSE
COMMUNITIES. LATINO COMMUNITIES
AND ASIAN COMMUNITIES NATIVE
AMERICAN COMMUNITIES, AND THERE
ARE MANY OTHER COMMUNITIES THAT
ARE I BELIEVE UNDERREPRESENTED
BUT THE DATA IS TRICKY TO GET.
SO THEY ARE TASKED WITH NEED TO
IDENTIFY BARRIERS TO BRAIN
DONATION AND TO ALSO EDUCATE US
ABOUT WHY FOLKS DON'T KNOW ABOUT
BRAIN DONATION AND WHY FOLKS
DON'T -- WHY CERTAIN COMMUNITIES
HESITATE TO DONATE BRAIN. WE
ALSO WANT TO REACH OUT TO THEM
AND ESSENTIALLY EDUCATE OR HELP
COMMUNITIES UNDERSTAND WHY IT IS
SO IMPORTANT TO THEIR
COMMUNITIES AND TO THE HEALTH OF
THEIR COMMUNITIES THAT WE HAVE
REPRESENTATION FROM THEM IN THE
BRAIN BANKS. THIS SHOULD HAVE TO
BE COORDINATED CLOSELY WITH THE
COMMUNICATIONS CONTRACT WHO THEN
PROVIDE HAIR MNIZED MESSAGING
TRAINING, ONE THING TO REACH OUT
TO COMMUNITIES TO SAY HEY IT IS
IMPORTANT FOR YOU TO ENROLL IN
THIS STUDY FOR KIDNEY HEALTH, IT
IS DIFFERENT TO APPROACH THEM ON
DONATING A LOVED ONES BRAIN
AFTER THEY PASS. THERE IS
MESSAGING AND TRAINING THAT IS
REQUIRED IN THE COMMUNICATIONS
CONTRACTOR WILL HELP US DO THAT.
THEY HELP WITH PRE-REGISTERING
FOLKS THAT REST INTERESTED IN
DONATION. AND INTERESTED IN
LEARNING MOREMENT THE OTHER
PRONG EFFORT IS TO STRENGTHEN
COLLABORATION WITH BRAIN BANKS
AND SITES OF TISSUE COLLECTION.
THIS WAS SPECIFICALLY A
RECOMMENDATION FROM THE WORKSHOP
ON HOW WE CAN GAIN MORE ACCESS
TO NORMAL OR NEUROTYPICAL
NON-DISEASE BRAIN. SPECIFIC
RECOMMENDATIONS THEY HAD WAS TO
PROVIDE PONDS TO SUPPORT
CLINICAL STAFF EMBEDDED IN
MEDICAL EXAMINERS OFFICE AND
FUNERAL HOMES, HOSPITAL
AUTOPSIES AND SO ON. TASKED
WOULD BE TO AID IN DONOR
PRE-SELECTION EARLY ON TO
LIAISON WITH FAMILIES, INFORMED
CONCEPT AND PROVIDE INFORMATION
THEY NEED ON THE DONATION
PROCESS AND ALSO LIAISON WITH
THE BANK, TO HAND OFF TISSUE AND
RETURN TO FOR EXAMPLE MEDICAL
EXAMINERS OFFICE WHAT IS
IMPORTANT TO THEM AND THAT IS
THE NEUROPATHOLOGICAL REPORT.
PART OF THE EFFORT WOULD INCLUDE
COMMUNITY OUTREACH ENGAGEMENT
BECAUSE THESE WOULD BE VERY
LOCAL EFFORTS, IF IT IS MEDICAL
EXAMINERS OFFICE AND ACCOUNTING,
IT WOULD BE EXTREMELY IMPORTANT
FOR THOSE THAT SHOW UP IN THAT
OFFICE HAVE SOME PRIOR KNOWLEDGE
OF BRAIN DONATION AND WHY IT IS
IMPORTANT. IF POSSIBLE WE LIKE
TO MAKE EFFORTS TO TARGET IDEA
STATES AND MINORITY SERVING
INSTITUTIONS.
>> CLOSE TO WRAPPING UP?
>> I'M DONE. I WAS GOING TO SAY
THANK YOU AND TAKE QUESTIONS.
>> OKAY. ANY QUESTIONS ABOUT
THIS FOR DAN? THANKS A LOT.
GREAT JOB. OKAY. WANT TO MAKE
SURE THERE'S NO QUESTIONS. IN
THAT CASE --
>> THERE WAS A POINT ABOUT
APPROACHING PALLIATIVE TEAMS,
DID YOU MENTION THAT?
>> I DID NOT. COULD YOU
ELABORATE?
>> IT WAS IN THE CHAT. IT WASN'T
FROM ME.
>> IT WAS FROM ME, JUST CURIOUS
LOOKING AT COLLABORATIVE
PARTNERS IF YOU THOUGHT ABOUT
REACHING OUT TO PALLIATIVE CARE
TEAMS, TYPICALLY ALREADY ENGAGED
IN SENSITIVE CONVERSATION. MIGHT
BE A NATURAL PARTNER.
>> GREAT POINT. THANK YOU.
>> OKAY. AT THIS POINT IT WOULD
BE GREAT TO HAVE A MOTION TO
APPROVE OR DISAPPROVE THIS
PARTICULAR IDEA.
>> SO MOVED.
>> SECOND. OKAY. YOU CAN GO TO
THE CHAT AND THANKS AGAIN, DAN.
CAN SOMEBODY PUT UP MY SLIDE AND
MISCELLANEOUS INITIATIVES?
>> THIS SLIDE WHICH YOU ARE
ABOUT TO SEE MOSTLY CONSISTS OF
REISSUES OF EXISTING INITIATIVES
THAT WE WERE INCLINED TO TALK
ABOUT UNLESS YOU HAVE QUESTIONS.
I SEE THAT OUR SPEAKERS AND
PARTICIPANTS FOR THE LAST
SEGMENT OF COUNCIL ARE NOW ON.
THE INITIATIVE? GREAT. OKAY. IF
YOU LOOK AT THIS NUMBERS FOUR
THROUGH 9 ESSENTIALLY REISSUES
OF EXISTING INITIATIVES. JUST
SAY IMBIBINGLY THIS FIRST
COUNTER ACT INITIATIVE, THIS IS
USING DEDICATED STREAM OF
COUNTER ACT MONEY IS MORE T POO
FOCUSED ON EARLY FACE PHASES OF
CHEMICAL THREATS. IF YOU READ
THE MISSION THAT SPRIGGS WROTE,
TO UNDERSTAND THE FUNDAMENTAL
MECHANISMS OF TOXICITY OF
CHEMICAL -- IN THE SUPPORT
RESEARCH DEVELOPMENT OF
THERAPEUTICS THAT REDUCE
MORTALITY AND MORBIDITY IN THE
EVENT OF THE RELEASE OF THESE
KINDS OF -- SO THIS IS FOCUSING
PARTICULARLY ON THE EARLY PHASE
OF THAT PROCESS WHICH IS A
LITTLE UNDERFOCUSED ON. THE NEXT
INITIATIVE HALFWAY DOWN IS EARLY
STAGE ESTABLISHED BIOMEDICAL
DATA REPOSITORIES OR KNOWLEDGE
BASES, AND ESSENTIALLY THIS IS
TWO COMPANION IF I RECALL TWO
COMPANION FUNDING ANNOUNCEMENTS,
ONE FOR NEW OR EARLY STAGE
BIOREPOSITORIES AND OTHER ONE
FOR EXISTING BIOREPOSITORIES OR
KNOWLEDGE BASES. THIS CONCEPT
WAS APPROVED BY TRANS-NIH
COUNCILS BACK IN JANUARY AND
WHAT WE WANT TO DO IS SIGN ON TO
THIS. THE IDEA IS TO MAKE SURE
THERE ARE HIGH QUALITY DATABASES
THAT ALLOW THE SHARING OF
REAGENTS AND KNOWLEDGE WE TALKED
ABOUT EARLIER. SO THAT IS PRETTY
MUCH IT FOR THAT ONE. THE THIRD
ONE IS PART OF THE AMPD PROJECT
THAT I THINK MOST OF YOU KNOW
WHAT THAT IS. IT IS ESSENTIALLY
A COLLABORATION BETWEEN NINDS
AND INDUSTRY FOCUSED ON
PARKINSON DISEASE, THE GOAL HERE
IS TO TAKE EXTRA CELLULAR
VESICALES, PLEASE JUMP IN IF I
GET THIS WRONG, AND TO SEQUENCE
THE RNA FROM THEM IN ORDER TO
GET COMPREHENSIVE RESOURCE OF
RNA SEQUENCING DATA FROM PEOPLE
WITH PARKINSON AND NORMAL
CONTROLS. ALL THESE PEOPLE WHO
ARE BEING WHOSE DNA RNA
SEQUENCED WE CURRENTLY HAVE
WHOLE GENOMIC TRANSCRIPTOMIC AND
PROTEOMIC SEQUENCING AVAILABLE
DATA ON THEM. SO THIS IS
INTENDED TO COMPLIMENT THAT.
TAKE IT A STEP FURTHER. THOSE
ARE THE THREE NEWISH INITIATIVES
THE REST YOU CAN SEE HERE IS AN
INITIATIVE ABOUT FOR RO1s FOR
NEW AT RISK INVESTIGATORS, THIS
IS WHAT WALTER TALKED ABOUT IN
DIRECTIVES TALK. THE REST,
THESE ARISH ISSUE OF BRAIN AND
HEAL INITIATIVES THAT YOU SAW IN
THE PAST. THIS CONTRACT WE ARE
LOOKING TO RENEW. ANY PRESSING
QUESTIONS, AARON?
>> NUMBER 3 I WAS WONDERING WHAT
IS THE PLAN FOR CELL OR TISSUE
TYPE? WHAT WILL BE SEQUENCED?
WHERE IS THE RNA COMING FROM?
>> I TOLD YOU IT IS EXTRA
CELLULAR VESICLES BUT IN TERMS
OF TISSUE -- I GUESS THIS IS DEB
BABBCOCK. DO YOU WANT THE TALK
ABOUT THAT?
>> I CAN ANSWER THAT QUESTION.
THANK YOU. SO THIS IS BASED ON A
PILOT PROJECT THAT BRAND WHERE
WE LOOK AT EXTRA CELLULAR
VESICLES IN BLOOD AND CSF. THE
YIELD WAS SO LOW IN CSF THE
COMMITTEE WANTED TO GO AHEAD AND
DO IT IN BLOCK. AS BOB MENTIONED
WE HAVE WHOLE GENOME SEQUENCING
AND PROTEOMICS AND
TRANSCRIPTOMICS IN BLOOD. THIS
IS A NICE COMPANION TO THE
EXISTING SEQUENCES BECAUSE EXTRA
CELLULAR VESICALES ACROSS THE
BLOOD BRAIN -- CROSS THE BLOOD
BRAIN BARRIER.
>> SO IS THE IDEA THAT THE RNA
IN THESE VESICALES WILL SOMEHOW
CONTRIBUTE TO THE DISEASE? I'M
WONDERING WHAT WAS LEARNED FROM
THE GENOME SEQUENCING OF BLOOD
AND THE RNA SEQUENCING OF
PROTEOMICS AND BLOOD SO FAR.
>> RIGHT NOW IT IS ALL BEING
USED TO IDENTIFY BIOMARKERS.
THAT WAS THE OVERARCHING GOAL OF
THE PROJECT. WE HAVE HAD A
NUMBER OF BIOMARKER PROJECTS
PUBLISHED AND WE HAVE HAD A
NUMBER OF GENES AND TRANSCRIPTS
IDENTIFIED THAT ARE NEW FOR
PARKINSON'S DISEASE. WHAT WE ARE
INTERESTED IN IS TRYING TO GET
SOMETHING THAT IS A LITTLE MORE
REPRESENTATIVE OF WHAT IS GOING
ON IN THE BRAIN. WE ARE GOING TO
BE DOING A PILOT PROJECT ON --
WE ARE IN FACT CURRENTLY DOING A
PILOT PROJECT ON SINGLE NUCLEUS
RNA SEQUENCING AND BRAIN TISSUE
AND WHOLE GENOME SEQUENCING IN
BRAIN TISSUE. WE ARE TRYING TO
SEE IF THERE IS -- IF THE -- IF
THE EXTRA CELLULAR VESICALES CAN
BE A BRIDGE INSTEAD OF HAVING TO
OBVIOUSLY WE DON'T DO BRAIN
BIOPSIES IN PEOPLE. SO I THINK
ALL OF THESE SAMPLES ARE
SEQUENCED LONGITUDINALLY EXCEPT
WHOLE GENOME SEQUENCING BUT THE
OTHER ONES SEQUENCED
LONGITUDINALLY SO OUR HOPE IS TO
BE ABLE TO GET A CLEAR PICTURE
OF DISEASE PROGRESSION. . WHAT
IS CHANGING IN THE TRANSCRIPTS,
WHAT IS CHANGING IN THE PROTEINS
AS THE DISEASE WORSENS.
>> ARE THERE NEURONAL
TRANSCRIPTS PRESENT IN THE EXTRA
CELLULAR VESICLES FROM BLOOD?
>> WE MIGHT TAKE THIS UNLESS
INTRINSIC TO YOUR APPROVING OR
DISAPPROVING.
>> DEFINITELY, IT IS EXTREMELY
INTERESTING, FEEL FREE TO EMAIL
THEM WE HAVE PRELIMINARY DATA
THAT I'M HAPPY TO SHARE ON WHAT
-- BLOOD IN THE CSF.
>> YES. OKAY. IF THERE ARE NO
OTHER QUESTIONS, I WILL PAUSE
FOR A SECOND. I NEED A MOTION
FOR THIS GROUP OF NINE
INITIATIVE CONCEPTS. I SEE A
MOTION FROM GENE NET AND SECOND
FROM TIM. EMPTY YOUR VOTES IN
THE CHAT. SORRY WE WERE SO
RUSHED TODAY. THERE IS AN ECHO.
THE VERY LAST THING ON THE
AGENDA IS AN IMPORTANT
DISCUSSION OF OPEN ACCESS
PUBLISHING OR PERHAPS THE WHOLE
MORE GENERAL OPEN ACCESS
ENVIRONMENT CONCEPT. TIM RYAN
PROPOSED THAT WE HAVE THIS
DISCUSSION, SOMETHING LIKE A
YEAR AGO AND WE DECIDED TO
POSTPONE IT WHILE WE FIGURED
WHAT THE LANDSCAPE AROUND OPEN
ACCESS WAS AT NIH AND HHS. WHICH
PERHAPS OUR FIRST SPEAKER CAN
TALK ABOUT. SO IN ANY CASE I
WILL PASS IT TO AMY ADAMS WHO IS
THE NINDS DEPUTY DIRECTOR FOR
SCIENCE MANAGEMENT AND
OPERATIONS AND SHE WILL
INTRODUCE THE SPEAKERS. WE WILL
-- I'M CERTAIN WE WILL PASS THE
TENTATIVE 5:45 TIME, I IMAGINE
WE WILL GO TO ABOUT SIX O'CLOCK
FOR THOSE THAT NEED TO MAKE
PLANS.
>> THANK YOU SO MUCH, BOB. I'M
GOING TO TAKE A MINUTE OR TWO TO
FRAME THIS DISCUSSION. AND THEN
I'M VERY EXCITED TO INTRODUCE
OUR SPEAKERS. SO AS WE LIKE TO
SAY THAT SCIENCE ISN'T FINISHED
UNTIL IT IS COMMUNICATED BUT THE
QUESTION HOW TO SHARE SCIENTIFIC
RESULTS SO THEY PROVIDE THE MOST
BENEFIT AND ADVANCE KNOWLEDGE
MOST EFFECTIVELY HAS BEEN AN
ACTIVE AREA OF DEBATE FOR
DECADES. THERE ARE ARGUMENTS
THAT OPEN ACCESS WHICH REFERS TO
POLICY ENSURING RESEARCH
LITERATURE IS DIGITAL ONLINE
FREE OF CHARGE AND FREE OF MOST
COPYRIGHT AND LICENSING
RESTRICTIONS, IS THE BEST
APPROACH. MANY OF THOSE
RESTRICTIONS ACTUALLY ARE
CRITICAL FOR SUPPORTING
INFRASTRUCTURE FOR CURRENT
MODELS OF PUBLISHING AND PEER
REVIEW. JUST TO TAKE AN NIH
LENS TO THIS AS WE ARE ADVISORY
COUNCIL OF NIH AS MANY OF YOU
KNOW IN 2008 NIH PUBLIC ACCESS
POLICY WENT INTO EFFECT AND IN
2013 THE WHITE HOUSE OFFICE OF
SCIENCE AND TECHNOLOGY POLICY
ISSUED A POLICY MEMORANDUM AT
MOST FEDERAL AGENCIES MAKING
THEM MAKE SURE THAT PUBLICATIONS
AND DATA RESULTING FROM FUNDED
-- FEDERALLY FUNDED RESEARCH WAS
FREELY AVAILABLE TO THE PUBLIC
WITHIN ONE YEAR OF PUBLICATION.
SINCE THEN THERE'S EXPANSION OF
ONLINE PUBLISHING CONTINUED
EXPERIMENTS AND PUBLISHING AND
PRE-PUBLISHING ALONG WITH RECENT
POLICY CHANGES BY MAJOR FUNDERS
AND WE HAD THE EXPERIENCE OVER
TWO YEARS URGENT IMMEDIATE NEED
FOR ACCESS TO DATA RELATING TO
COVID-19. THESE ARE A FEW
EXAMPLES OF THIS THAT RAISE THE
QUESTION FOR US WHAT IS THE
RIGHT ACCESS POLICY FOR NIH AND
HOW CAN NINDS NEUROSCIENCE
COMMUNITY ACT TO ENSURE
SCIENTIFIC RESULTS ARE
DISSEMINATED. SO TODAY WE
BROUGHT TOGETHER A NUMBER OF
DIFFERENT PERSPECTIVES FROM THE
NIH FROM THE SCIENTIFIC
PUBLISHING WORLD AND DIFFERENT
NON-FEDERAL FUNDING AGENCIES,
HMHMI AND ASAP TO DISCUSS
EXPERIENCING WITH THE EVOLVING
LANDSCAPE AROUND OPEN ACCESS TO
GATHER IDEAS PERSPECTIVES AN
FEEDBACK TO SHARE WITH NIH AS IT
CONSIDERS IF POSSIBLY HOW IT
MIGHT SHIFT ITS OWN POLICIES.
WE ARE NOT SAYING MINI NIH IS
PLANNING ANY JUST GATHERING
POINTS TO CONSIDER TO INFORM
THAT DISCUSSION. SO LOOK
FORWARD TOKER THATTING FROM THEM
AND FROM YOU. WE ARE GOING TO
TRY TO MAXIMIZE THE TIME FOR
FULL DISCUSSION SO WE REALLY ASK
THAT AFTER EACH SPEAKER PLEASE
FEEL FREE TO ASK ANY CLARIFYING
QUESTIONS BUT SAVE YOUR
DISCUSSION QUESTIONS FOR AFTER
THE LAST SPEAKER: SO WITH THAT,
I WILL START BY INTRODUCING OUR
FIRST SPEAKER WHO I SEE ON OUR
SCREEN, TERRIFIC. SO IT IS WITH
TREMENDOUS PLEASURE THAT I
INTRODUCE JERRY SHEEHAN, DEPUTY
DIRECTOR FOR THE NATIONAL
LIBRARY OF MEDICINE HE HAS
SERVED DEPUTY DIRECTOR OF NLM
SINCE 2017, BEFORE THAT IN THE
ROLE OF ASSISTANT DIRECTOR FOR
POLICY DEVELOPMENT AND NLM, HE
WAS IN THAT ROLE FROM 2006.
DURING THAT PERIOD HE HAS TWICE
SERVED ON EXTENDED DETAIL WHITE
HOUSE OFFICE OF SCIENCE AND
TECHNOLOGY POTSY WHERE HE WORKS
TO ADVANCE OPEN SCIENCE POLICIES
ACROSS THE FEDERAL GOVERNMENT.
HERE AT NIH HE PLAY AD PIVOTAL
ROLE IN FORMULATION AND
IMPLEMENTATION OF NUMEROUS NIH
LEVEL POLICIES, RELATED TO
SCIENTIFIC GENOMIC DATA SHARING
AS WELL AS PUBLIC ACCESS TOLL
NIH FUNDED PUBLICATIONS. WE ARE
LOOKING FORWARD TO HEARING FROM
YOU JERRY. PLEASE FEEL FREE.
>> I WILL SAY ONE QUICK THING,
WHEN I PUT DOWN THE LIST OF
SPEAKERS ON AGENDA, I PUT
OUTSIDE SPEAKERS BUT OUR COUNCIL
MEMBER HAS A REAL STAKE IN THIS
WHOLE ISSUE. YOU WILL HEAR MORE
ABOUT THAT SOON. HI JERRY,
SORRY TO INTERRUPT.
>> AMY, CAN YOU HEAR ME OKAY?
USUALLY A DIFFERENT MICROPHONE
SET UP TODAY.
>> LOUD AND CLEAR.
>> I'M GLAD IT IS WORKING.
>> THANK YOU FOR INVITING ME TO
SPEAK TO YOUR COUNCIL TODAY. AS
DEPUTY DIRECTOR PART OF NIH THAT
HAS THE EXPLICIT MISSION OF
COLLECTING ORGANIZING AND
DISSEMINATING INFORMATION NIH
PUBLIC ACCESS POLICY ARE AREA OF
GREAT INTEREST AND WE HAVE GREAT
ENGAGEMENT IN OVER THE LAST TWO
DECADES. WE ARE ALSO OPERATING
ARM OF NIH PUBLIC ACCESS POLICY,
I WILL SHOW YOU MOVE SOME OF THE
OTHER FEDERAL AGENCY AND
NON-FEDERAL PUBLIC ACCESS
POLICIES BECAUSE WE OPERATE IT
NATIONAL LIBRARY OF MEDICINE
PUBMED CENTRAL REPOSITORY OR
ARCHIVE FULL TEXT JOURNAL
LITERATURE WHICH GIVES US
ANOTHER ENTRY POINT INTO THIS
DISCUSSION AND DEBATE. I HAVE
SOME SLIDES THAT MIGHT BE
EASIEST FOR ME TO SHARE FROM
HERE IF THAT IS FINE. ARE Y'ALL
SEEING THAT NOW?
>> GREAT. LET ME JUST STATE AS
MY SAID THERE WAS OSTP MEMO,
WHITE HOUSE OFFICE OF SCIENCE
TECHNOLOGY MEMO IN 2013 THAT
SPREAD PUBLIC ACCESS WHICH IS
OUR TERMINOLOGY FOR IT HERE AT
NIH
>> YOUR SLIDES ARE NOT SHOWING.
SOMETHING YOU DID PRESENTATION
BLUE IT.
>> IF IT IS SHOWING FULL SCREEN.
HOW IS IS THAT?
>> WE CAN SEE THAT. NOT IN SLIDE
SHOW MODE BUT WE CAN SEE I.
>> SOON AS IT GOES THE SLIDE
SHOW MODE IT WILL BE ON SCREEN
3. (OVERLAPPING SPEAKERS)
>> OUR WORK AT NIH ON THIS ISSUE
IS FRAMED AROUND PUBLIC ACCESS.
ENSURING THAT THE PUBLIC HAS
FREE AND TIMELY ACCESS TO THE
RESULTSES OF PUBLISHED RESEARCH
THAT THAT NIH FUNDED. IT COMES
FROM A LEGISLATIVE REQUIREMENT
BACK TO 2008, THE TEXT OF THAT
REQUIREMENT IS HERE. THAT IS
WHAT WE HAVE BEEN IMPLEMENTING
NOW OVER LAST 14 YEARS. T THIS
APPLIES TO ANY ARTICLES THAT
WERE ACCEPTED FOR PUBLICATION
AFTER EARLY APRIL OF 2008. IF
NIH FUNDS YOU, YOUR ARTICLE OR
THE FINAL PEER REVIEWED
MANUSCRIPT REFLECTING ALL THE
CHANGES FROM PEER REVIEW
PROCESS, NEEDS TO MAKE INTO
PUBMED CENTRAL AT NLM WHERE IT
WILL BE RELEASED NO LATER THAN
12 MONTHS AFTER THE PUBLICATION
DATE. THAT IS WHAT OUR POLICY
IS BASED ON. JUST TO GIVE A SNAP
SHOT ABOUT WHERE WE ARE 18 YEARS
LATER -- 14 YEARS LATER WE HAVE
IN PUBMED CENTRAL 1.3 MILLION
NIH SUPPORTED ARTICLES THAT DATE
FROM THAT 2008 YEAR TO PRESENT.
WE ADD MORE THAN 100,000 SUCH
ARTICLES EVERY YEAR SO MAKING
MORE THAN 100,000 ARTICLES
REPORTING ON NIH FUNDED RESEARCH
EVERY YEAR. DEPENDING HOW YOU
LOOK AT THINGS IF YOU ARE
OPTIMIST OR PESSIMIST, A LITTLE
OVER HALF THOSE ARTICLES USE THE
MAXIMUM 12 MONTH EMBARGO PERIOD
THAT IS ALLOWED SO CURRENTLY
ABOUT 22,000 PLUS ARTICLES THAT
ARE UNDER EMBARGO. THE OTHER WAY
OF LOOKING AT IT IS JUST UNDER
HALF CHOOSE SHORTER EMBARGO
PERIOD WHICH IS NO EMBARGO,
OTHER CASES THREE MONTHS OR SIX
MONTHS, I DON'T THINK WE HAVE
TOO MANY THAT ARE BETWEEN SIX
AND 12. THE COMPLIANCE RATE WE
ASK TO MEASURE AND REPORT ON IS
90%. THAT MEANS THAT OVER THE
COURSE -- SINCE 2008 OF ALL
ARTICLES SUBJECT TO POLICY WE
THINK WE HAVE 90% OF THEM IN
PUBMED CENTRAL NOW ACCESSIBLE TO
PUBLIC. THE ARTICLES ARE
COMPRISED A FRACTION, THAT IS A
FIFTH OF ALL THE CONSENT
WEEVILEDDABLE IN PUBMED CENTRAL.
BUT THEY ARE HIGHLY USED. SO
THEY ATTRACT MORE THAN TWICE
THEIR PROPORTION OF VIEWS AND
DOWNLOADS ANNUALLY SO THEY COUNT
FOR 42% OF THOSE. THEY COME TO
US IN TWO WAYS. CURRENTLY IN THE
BLUE IN THE CHART, ABOUT 54% OF
THE ARTICLES COME AS MANUSCRIPTS
DIRECTLY FROM THE AUTHORS. WE
HAVE BEEN WORKING WITH
PUBLISHERS FOR MANY YEARS MANY
WHO WILL SUBMIT ARTICLES ON
BEHALF OF NIH FUNDED RESEARCHERS
AND AUTHORS SO WE ARE GETTING
46% OF THOSE FROM PUBLISHER
THEMSELVES, WHICH WORKS BETTER
FOR EVERYONE, WORKS BETTER FOR
US BECAUSE WE GET THEM IN FORMAT
TYPICALLY THAT WE WANT. EASIER
FOR RESEARCHERS AS WELL BECAUSE
WE DON'T DO ANY CHECKING WE
CONVERTED THESE INTO A STANDARD
FORMAT THAT WE HAVEN'T MADE
ERRORS THAT NEED TO BE
CORRECTED. SO WE ARE DOING WELL
WILL POLICY IMPLEMENTATION.
1.3 MILLION ARTICLES IN PUBMED
CENTRAL FROM NIH FUNDING DURING
THE TIME PERIOD, CLOSE TO 8
MILLION FULL TEXT ARTICLES IN
PUBMED CENTRAL NOW. OF A THAT
1.310 MILLION% ARE SITE NINDS
FUNDING OR COULD COME FROM
INTRAMURAL RESEARCH PROGRAM SO I
THINK NINDS IS WELL REPRESENTED
IN THAT MIX. WE ARE MEETING ONE
OF THE AMBITIONS OF THIS EFFORT
WHICH WAS TO ENSURE THAT THE
PUBLIC INCLUDING RESEARCH EARS,
STUDENTS, CLINICS, FRIENDS AND
FAMILY PATIENTS AND THEIR
FAMILIES HAVE ACCESS TO THIS
CONTENT, WE HAVE 3 MILLION
UNIQUE USERS OF PUBMED CENTRAL
EVERY DAY. THEY DOWNLOAD
BETWEEN 7 1/2 AND 8 MILLION
ARTICLES ON TYPICAL DAY. YOU CAN
SEE IT WAXES AND WANES A LITTLE
BIT WITH THE SEASONS. SOME OF
THAT BEING AROUND ACADEMIC
CALENDAR AS WELL. IT IS FAIRLY
STEADY GROWTH IN CONTENT AND
COMMENSURATE GROWTH IN THE
AMOUNT OF USAGE IN PMC. AS I
MENTIONED WE HAVE BEEN USING
PUBMED SENTRA L TO SUPPORT OTHER
INSTITUTIONS WITH PUBLIC ACCESS
POLICIES. AMY MENTIONED THIS
OSTP MEMO FROM TEN YEARS AGO
THAT REQUIRES EVERY AGENCY WITH
MORE THAN $100.000000 IN ADD
EXPENDITURES TO HAVE A SIMILAR
POLICY, WE SUPPORT NINE AGENCIES
INCLUDING THE MAJOR COMPONENTS
OF THE DEPARTMENT OF HEALTH AND
HUMAN SERVICES AS WELL AS EAR
AGENCIES HERE INCLUDING THE EPA
NIST AND THE VA. WE ALSO HAVE
DONE SOME SUPPORT FOR OTHER
PRIVATE FUNDERS, SO WE HAVE
HOWARD HUGHES AND GATES
FOUNDATION WITH PUBLIC ACCESS
POLICIES THAT USE PMC AS
PLATFORM, HEALTH RESEARCH
ALLIANCE BRINGS TOGETHER A
CONSORTIUM OF OTHER HEALTH
RELATED BIOMEDICAL RESEARCH
FUNDERS, SMALLER FUNDERS AND WE
HAVE BEEN WORKING WITH EUROPEAN
FUNDERS AS WELL. THERE IS A MERE
SITE OF PUBMED CENTRAL IN
EUROPE. WE WORKED WITH A FEW NIH
INITIATIVES THAT HAVE MORE
AGGRESSIVE PUBLIC ACCESS
POLICIES CALLING FOR ACCESS TO
PUBLISHED RESULTS OF RESEARCH
LIKE CANCER MOON SHOT OR HEAL
INITIATIVE ENDING ADDICTION AND
THE ALL OF US PROGRAM WHICH IS
DIFFERENT AS WELL IN THAT THE
POLICY IS NOT JUST FUNDED
RESEARCHERS BUT USER OF THE ALL
OF US DATA. MOST CURRENTLY ARE
FUNDED BY NIH. SO WE HAVE WORKED
OUT SOME WAYS TO SUPPORT THOSE
VARIATIONS IN POLICIES. WE HAVE
ALSO DONE SOME THINGS PEOPLE
VIEW PUBMED AS PLACE TO COME
READ THE LITERATURE. THAT IS
OFTEN WHAT THOSE 3 MILLION
PEOPLE PER DAY USE. BUT WE ALSO
KNOW THERE IS A LOT OF INTEREST
IN USING ARTIFICIAL INTELLIGENCE
MACHINE LEARNING OTHER TEXT
MINING ALGORITHMS TO HELP YOU
SORT THROUGH OR FIND NEW THINGS
IN THE LITERATURE. SO WE MADE
SUB SETS OPEN FOR DOWNLOADING
FOR COMPUTATIONAL USE. IN BULK
AUDIENCE WITH BROAD CURE RAYTIVE
LICENSE WITH BROAD RIGHTS GIVEN,
CAN BE DOWN LOADED ABOUT 4
MILLION NOW, ANY NIH AUTHOR
MANUSCRIPTS THAT WE ACCEPT,
750,000 OF THEM NOW ARE ALSO
AVAILABLE FOR TEXT MINING
APPLICATION AS WELL AS
HISTORICAL COLLECTIONS OF BOOK
AND BOOK CHAPTERS. WE HAVE ALSO
BEEN DOING WORK TO SUPPORT DATA
DISCOVERY THROUGH PUBMED
CENTRAL. THERE IS A LOT OF OTHER
WORK THAT WE CAN TALK ABOUT TO
SUPPORT DATA MANAGEMENT SHARING
AND DISCOVERY, WE HAVE 3 MILLION
USER EVER DAY FINDING THE
LITERATURE WHICH IS OFTEN A
STEPPINGSTONE TO FINDING DATA.
WE HAVE BEEN DOING WORK TO HELP
MAKE THAT ASSOCIATED DATA MORE
VISIBLE IN PUBMED, WE CALL IT
THE DATA BO BO BOX. SO THERE ISA
CITATION WE COLLECT
SUPPLEMENTARY MATERIALS WHICH
INCLUDE DATA FINDING DATA
AVAILABILITY STATEMENTS IN
JOURNAL ARTICLES, WE WILL DO
MORE TO SURFACE THOSE AND
PROVIDE LINKS TO THOSE AND THERE
IS A DATA CITATION WITH A LINK
OUT TO ASSOCIATED DATA. WE HAVE
SEEN INCREASE IN THIS OVER THE
YEARS. CURRENTLY ABOUT 40% OF
THE MATERIAL WE HAVE IN PMC HAS
SUPPLEMENTAL MATERIAL. MUCH OF
OF WHICH IS SUPPLEMENTARY DATA,
UP FROM 27% TEN PLUS YEARS AGO.
YOU CAN SEE STILL A FRACTION OF
THE OVERALL CONTEMPT BUT GREATER
EFFORTS AROUND DATA MANAGEMENT
AND SHARING INCLUDING THE FOURTH
COMING NIH POLICY WE EXPECT TO
SEE THOSE NUMBERS CONTINUE TO
GROW. WE DID SOMETHING
DIFFERENT MORE AGGRESSIVE AND
SPECIAL DURING THE COVID
PANDEMIC. SO WITHIN BEFORE WE
LEFT TO GO ON MASS TELEWORK FROM
THE NIH IN MARCH, WE WORKED WITH
THE WHITE HOUSE OFFICE OF
SCIENCE AND TECHNOLOGY POLICY
AND LEADERS FROM OTHER COUNTRIES
TO CALL ON THE PUBLISHERS OF THE
WORLD TO MAKE THEIR CONTENT
AROUND THEM WHICH IS LARGELY
HISTORICAL CORONA VIRUS
LITERATURE FREELY AND
IMMEDIATELY ACCESSIBLE THROUGH
PLATFORMS LIKE PUBMED CENTRAL
NOT JUST PDF VERSION TO POST FOR
READING BUT ALSO MACHINE
READABLE FORMS. WE THEN ALSO
WORK IN 50 PUBLISHERS INCLUDING
MAJOR SOCIETIES AND COMMERCIAL
PUBLISHERS BEGAN WORKING WITH US
TO DO THAT. WE LAUNCHED A DATA
SET IN MARCH THAT HAD ABOUT
30,000 ARTICLES IN IT. THAT IS
NOW OVER THE ENSUING 2 PLUS
YEARS GROWN TO 400,000
PUBLICATIONS THAT DOWNLOADABLE
SET WE COLLABORATE WITH OUTSIDE
PARTNERS WHO BROUGHT IN MORE
CONTENT AND USE TO GENERATE TO
GENERATE AI MACHINE LEARNING
NATURAL LANGUAGE PROCESSING
CHALLENGES AND COMPETITIONS.
SOMETHING ABOUT IMPROVING SEARCH
CAPABILITIES, SOMETHING ABOUT WE
LEARN NEW THINGS HABIT COVID
FROM THE LITERATURE. THE MEDIA
SHY OF CONSEN CONSENT TENT. WE D
TWO YEARS AGO JUNE OF 2020 A
PRE-PRINT PILOT. UNTIL WE
LAUNCHED THIS EVERYTHING IN
PUBMED CENTRAL CAME FROM A
JOURNAL WE AT NLM REVIEWED. IT
WAS CONTENT THAT HAD BEEN PEERRY
REVIEWED AN CONCERNS ABOUT FEW
ARE TRUSTED HIGHLY TRUSTED MLM
LITERATURE SERVICES OFFERING
NON-PEER REVIEWED CONTENT AND
WITH ARRIVAL OF THE COVID MANY
OF THOSE CONCERNS IN THE MEDIA
SHY DESIRE FOR MEDIA SHY OF
CONTENT MADE US LAUNCH PROMPTED
US TO LAUNCH THIS PILOT EFFORT
WHICH MAKES AVAILABLE THROUGH
PUBMED CENTRAL WITH CITATION IN
PUBMED WHICH YOU ARE FAMILIAR
WITH TOO, PREPRINTS RESULTING
FROM NIH FUNDED COVID-19
RESEARCH. WE HAVE DONE THIS IN
COLLABORATION WITH SOME OF THE
MAJOR PRE-PRINT SERVERS, WE TOOK
GREAT PAINS TO MAKE SURE IF YOU
COME ACROSS A PRE-PRINT IN
PUBMED CENTRAL OR CITATION IN
PUBMED, YOU KNOW IT IS A
PRE-PRINT. BECAUSE YOU SEE THE
BANNER, WE HAVE GIVEN SOME
SMALLER PRINT IN INDICATORS IN
CITATION INFORMATION, WE HAVE
ALSO ARE PROVIDING LINKS TO A
PEER REVIEWED VERSION OF THE
ARTICLE WHERE IT IS POSSIBLE. T
OVER THE LAST TWO PLUS YEARS WE
HAVE COLLECTED ABOUT 3200 NOW
NIH FUNDED COVID-19 RELATED
PREPRINTS, WHICH IS LESS THAN
10% OF ALL THE PRE-PRINTS YOU
MIGHT FIND AROUND COVID-19 YOU
CAN SEE WHO WE HAVE BEEN
COLLABORATING WITH. WHAT WE ARE
BEGINNING TO SEE IS HOW
PUBLICATION PATTERNS WORKED
DURING THE PANDEMIC BUT MAYBE
MORE BROADLY. EVEN FROM TWO
YEARS AGO ARE STILL AVAILABLE
ONLY AS A PRE-PRINT AND HAVE NOT
BEEN ASSOCIATED YET WITH A PEER
REVIEW JOURNAL ARTICLE. THAT
NUMBER IS STILL AS HIGH AS 40%.
GOING BACK COUPLE OF YEARS. WE
WILL DO WORK TO UNDERSTAND
BETTER WHAT HAPPENED WITH THOSE.
IS THAT BECAUSE THERE WAS
INTEREST IN RAPIDLY REPORTING
RESULTS BUT NOT AS MUCH PURSUING
PUBLICATION, WAS IT THAT THEY
PURSUED PUBLICATION AND RESULTS
DIDN'T STAND, THERE A LOT TO
LEARN ABOUT PRE-PRINT NOW AND
WHAT IT MEANS. IN THE TITLE OF
THE SLIDE WE ARE NOT ONLY
ACCELERATING ACCESS TO RESEARCH
BY THROUGH PREPRINTS BUT MAYBE
BROADENING THE ACCESS TO
RESEARCH THAT HAS NOT YET BEEN
PUBLISHED. SO MAYBE WE CAN
UNDERSTAND AND SEE MORE CASE
REPORTS OR SOMETHING ALONG THOSE
LINES, THAT IS WHAT WE WANT TO
UNDERSTAND. OUR NLM CONCERN WAS
DID WE DIMINISH TRUST IN OUR
RESOURCES BY DOING THIS. WE HAVE
TAKE AN NUMBER OF APPROACHES TO
MEASURING IT, I WILL SHARE
SURVEY RESULTS HERE. MOST PEOPLE
DID CHANGE IN OUR RESOURCES AT
ALL. IF ANYTHING A THIRD OF THE
PEOPLE THOUGHT IT INCREASE TRUST
BECAUSE THEY COULD NOW SEE INTO
THE RESEARCH PROCESS. WHAT
HAPPENED IN CHANGE DURING PEER
REVIEW PROCESS. YOU ARE SAYING
THAT IS A POSITIVE SIGNAL WE ARE
THINKING AT NLM WHETHER OUR
APPROPRIATE NEXT STEPS WITH
PREPRINTS DO WE WANT TO EXPAND
TO BROADER SET OF NIH FUNDED
RESEARCH, SEE IF THE PATTERNS
ARE DIFFERENT. THE KEY IS TO
MAINTAIN TRUSTABILITY OF NLM
RESOURCES MAKE USE OF PLATFORMS
WE HAVE THAT SEEM TO BE HIGHLY
USED. AND PROVIDE CONNECTIONS TO
OTHER INFORMATION TO HELP PEOPLE
MAKE GOOD INFORMED RESEARCH
PROGRAMS, CLINICAL DECISION
PERSONAL DECISIONS AND B INFORM
PUBLIC HEALTH. I WILL STOP
THERE, I WILL TAKE ANY QUESTIONS
AND I KNOW WE WANT TO MOVE ON BE
THE DISCUSSION, LOOK FORWARD TO
HEARING FROM THE OTHER SPEAKERS
>> THANK YOU SO MUCH, JOHN IF
THERE IS CLARIFYING QUESTIONS,
OR WE CAN MOVE TO NEXT SPEAKER
AND HAVE DISCUSSION QUESTIONS
LATER.
>> LET'S MOVE ON.
>> THAT WAS FABULOUS. AS WE MOVE
ON I WOULD LIKE TO ENTER DEUCE
DR. BODO STERN, CHIEF OF
STRATEGIC INITIATIVES AT THE
HOWARD HUGHES MEDICAL INSTITUTE
HE BECAME HHMI CHIEF STRATEGIC
INITIATIVES IN P 2018 AND BEFORE
THAT HE SERVED Z THE CHIEF
DEVELOPMENT AND STRATEGY
OFFICER. BEFORE JOINING HHMI
HEED AS EIGHT YEARS AS DIRECTOR
OF RESEARCH AFFAIRS AT HARVARD
SYSTEMS BIOLOGY AND SENIOR
SCIENTIFIC EDITOR T A CELL. --
AT CELL. HE PLAY AD PIVOTAL ROLE
DEVELOPING HHMI OPEN ACCESS TO
PUBLICATIONS POLICY AND I LOOK
FORWARD TO HEARING FROM HIM NOW.
THANK YOU SO MUCH.
>> THANK YOU VERY MUCH FOR THE
INVITATION AND FOR THE
INTRODUCTION. CAN YOU HEAR ME?
AND SEE THE SLIDES. SO I WANT TO
SPEND THE NEXT FEW MINUTES TO
INTRODUCE YOU TO OUR PUBLISHING
INITIATIVE, WITH A FOCUS ON OUR
NEW OPEN ACCESS POLICY, THIS
POLICY JUST WENT INTO AFFECT
EARLIER THIS YEAR AND IT
REQUIRES IMMEDIATE OPEN ACCESS
SO THERE IS NOT A 12 MONTH
EMBARGO, WE REQUIRE OUR ARTICLES
TO BE OPEN ACCESS. I WANT TO
TELL YOU A LITTLE BIT HOW THIS
IS GOING BUT ALSO HOW WE WANT TO
BUILD ON THIS POLICY TO REFORM
SCIENTIFIC PUBLISHING FURTHER.
OUR OPEN ACCESS POLICY IS
ALIGNED WITH PLAN S. WE JOINED
COALITION S IN 2020 WHEN WE
ANNOUNCE POLICY H. POLICY GO
INTO EFFECT, THIS COALITION IS
SORT OF THE GROUP FORMULATED
PLAN S AND WE LEARNED
TREMENDOUSLY FROM THAT OPEN
ACCESS POLICY AND HAVE ADOPTED
IT IN TO LARGE EXTENT. A FEW
WORDS ABOUT THIS COALITION, IT
IS NOW GROWN TO INCLUDE 26
ORGANIZATIONS WORLDWIDE, STATED
IN EUROPE AND INCLUDES MANY
NATIONAL FUNDERS FROM URINE UK
BUT ALSO FLOW FROM CANADA AND
AFRICAN COUNTRIES. IT INCLUDES
EUROPEAN COMMISSION SO IT COVERS
A LOT OF THE EUROPEAN FUNDING,
RESEARCH FUNDING. BUT ALSO
INCLUDES A LOT OF CHARITABLE
ORGANIZATIONS, INCLUDES WELCOME
GATES AND US I THINK THE MALES
TALK ABOUT EXPERIENCE OF
COALITION AND OPEN ACCESS
POLICY. COALITION S HAS $40
BILLION RESEARCH FUNDS AND THAT
COVERS 150,000 ARTICLES, I DON'T
KNOW EXACTLY, PROBABLY AROUND 5%
GLOBAL OUTPUT. BUT MUCH HIGHER
PERCENTAGE IN PRESTIGIOUS
JOURNALS. THAT HAPPENS TO BE AS
WE KNOW NOW HAPPENS TO BE ENOUGH
TO CONVINCE ENOUGH TO CONVINCE
MANY PUBLISHERS TO AT LEAST
COMPLY AND OFFER PUBLISHING
OPTIONS THAT ARE CONSISTENT WITH
PLAN S AND WITH CELL OPEN ACCESS
POLICY. THE CORE FEATURE OF
PLAN S AND HMI POLICY IS THAT IT
REQUIRES ARTICLES TO PUBLISH TO
BE PUBLISHED WITH OPEN ACCESS --
WITH AN OPEN LICENSE CALLED CC
BY. THAT ALLOWS ANYBODY TO READ
ACCESS THIS ARTICLE BUT ALSO TO
REUSE THE ARTIC ARTICLE. THIS LE
CONDITION ON THE LICENSE IS THAT
THE AUTHORS NEEDS TO BE
ACKNOWLEDGED. AND THERE ARE TWO
WAYS THAT OUR SCIENTISTS CAN
APPLY OPEN LICENSE. THE FIRST
OPTION IS LICENSE APPLIED TO
JOURNAL RECORD THAT IS REFERRED
TO AS GOLD OPEN ACCESS, THAT
COMES WITH OPEN ACCESS
PUBLICATION FEES AND ALL MEMBERS
OF THE COALITION S HAVE AGREED
THAT THEY WOULD ONLY PAY THESE
FEES IF ASSOCIATED WITH A
JOURNAL THAT HAS FULLY ADOPTED
OPEN ACCESS MODEL OR AT LEAST
HAS COMMITTED TO TRANSITIONING
TO OPEN ACCESS BUSINESS MODEL.
THAT MEANS WE ARE NOT PAYING
OPEN ACCESS FEES IN HYBRID
JOURNALS THAT ARE SUBSCRIPTION
JOURNALS THAT CHARGE EXTRA FOR
OFFERING OPEN ACCESS. THE REASON
IS HAPPY TO GO INTO DETAILS BUT
THE REASON IS THAT THIS
SUBSCRIPTION JOURNALS CAN STILL
PUT THE JOURNAL VERSION BEHIND
SUBSCRIPTION PAY WALL, THEY CAN
STILL MAKE MONEY FROM THATTINGS
VERSION BUT OFFICE COMPLIES
UNDER CCBY LICEN LICENSE. WE ARE
GRATEFUL FORE PUBMED TO HOST OUR
MANUSCRIPT, WE HAVE HAD A GREAT
RELATIONSHIP WITH PUBMED
SUPPORTING THIS TRANSITION AND
IT IS FUN TO WORK. WITH THEM.
MANY COALITION MEMBERS HAVE ALSO
STRENGTHENED THIS GREEN OPTION
BY ESTABLISHING RIGHTS
RETENTION. WE HAVE ASKED OUR
SCIENTISTS TO SIGN AGREEMENT
THAT MAKES SURE THAT THEY RETAIN
THE RIGHTS TO THEIR ARTICLES SO
THEY CAN ALWAYS SHARE AUTHOR
MANUSCRIPT UNDER CCBY LICENSE IF
PUBLISHED IN JOURNAL SO THAT
RIGHT RETENTION IS REALLY AN
APPROACH TO ENSURE THAT NOT
HANDING OVER ALL COPYRIGHT TO
THE PUBLISHERS SO AT LEAST THEY
CAN STILL HAVE EXCLUSIVE
COPYRIGHT ON FINAL VERSION BUT
AUTHOR MANUSCRIPT IS NO LONGER
EXCLUSIVE LICENSED TO PUBLISHER.
A FEW WORDS ON THE IMPACT HHMI
THIS POLICY HAS BEEN IN THE WORK
FOR YEARS AND BEFORE WE ANNOUNCE
IN 2020 WE ASK OUR SCIENTISTS,
WE DID A BIG SURVEY, TURNS OUT
MOST OF OUR SCIENTISTS ARE
SUPPORTIVE OF OPEN ACCESS IN
PRINCIPLE AND THEY ALSO TOLLS
THERE ARE PROBLEMS WITH
SCIENTIFIC PUBLISHING AT THE --
THEY DEFINITELY THINK PUBLISHING
ISN'T WORKING AS IT SHOULD. BUT
THEY WERE ORIGINALLY A SPLIT
ABOUT PULLING A TRIGGER ON AN
IMMEDIATE OPEN ACCESS -- MAYBE
THAT IS AN EXPERIENCE THAT YOU
HAVE SEEN AS WELL. 50%, LIKE
POLITICS, 50% SCIENTISTS WERE
STRONGLY IN FAVOR OF MANDATE AND
50% WERE STRONGLY AGAINST. THE
MAIN BARRIER IS PEOPLE WITH
WORRIED WITH PUBLISHING CERTAIN
JOURNAL AND TRAINEES NOT GOING
TO GET THEIR JOBS THAT THEY
SHOULD GET. SO THAT WAS THE MAIN
FEAR AND AFTER WE ANNOUNCED
AFTER THIS POLICY IS NOW INTO
EFFECT, THIS PARTICULAR IS
PROBABLY NOT ANY MORE SO MUCH ON
THE FOREFRONT BECAUSE A LOT OF
THE PUBLISHERS HAVE ACCEPTED
PUBLISHING OPTION THAT ARE
COMPLIANT SO THAT PRESTIGIOUS
JOURNALS OUTS OF REACH, THAT
HASN'T MATERIALIZED. THE
CHALLENGE WE FACE NOW THAT I GET
A LOT OF EMAILS FROM SCIENCE
WHAT I CAN TELL IS THE POLICY IS
COMPLEX. IT HAS TWO OPTIONS.
PUBLISHING LICENSE, GOD FORD BY
THEY NEED TO LOOK AT THE
PUBLISHING CONTRACT. THAT'S
SOMETHING SCIENTISTS DIDN'T NEED
TO DO. THEY JUST SIGNED THEIR
RIGHTS IN THE PAST. SO I GET A
LOT OF QUESTIONS LIKE CAN YOU
TELL ME JOURNALS TO PUBLISH IN
AND IT IS NOT THAT SIMPLE, SO
THAT IS ONE PROBLEM WE ARE
FACING BUT I THINK THE BIGGEST
COMPLAINT I HERE IS ABOUT HIGH
OPEN ACCESS PUBLISHING PEES. I
SYMPATHIZE THAT, I DON'T THINK
PUBLISHING SHOULD COST $11,000
BUT ITS WILL NOT I WILL SAY ALSO
NOT A PROBLEM OF OPEN ACCESS, IT
IS A PROBLEM OF JOURNAL BASED
PUBLISHING SYSTEM THAT IS
INCREDIBLY EXPENSIVE SO THAT IS
SOMETHING I WILL COVER -- I WANT
TO SAY A FEW WORDS ABOUT HOW WE
THINK THIS WE NEED TO MOVE AWAY
FROM THIS CURRENT MODEL. I THINK
WE WON'T ACHIEVE FULL OPEN
ACCESS IF WE JUST FOCUS ON OPEN
ACCESS TO THE PRODUCTS. OPEN
ACCESS TO ARTICLES. WE HAVE
REALLY NEED TO CONSIDER THE
PROCESS OF PUBLISHING AND ALSO
MAKE THAT PROCESS MORE OPEN. SO
I'M GOING TO SPEND A FEW MORE
MINUTES ON THIS FIRST NEXT STEP,
WE WANT TO MOVE BEYOND OPEN
ACCESS AND WANT TO PROMOTE WHAT
WE REFER TO AS A FLIP PUBLISHING
PROCESS. IT IS A LITTLE BIT LIKE
JERRY ALREADY STARTED TALKING
ABOUT PRE-PRINTS. WE THINK THIS
SHOULD BE THE DEFAULT. PEOPLE
SHARE THEIR WORK AS A PRE-PRINT
AND THEN JOURNALS AND REVIEW
SERVICES, DO PEER REVIEW
AFTERWARDS. THAT IS -- IT
HAPPENS ALREADY A LITTLE BIT BUT
WE THINK THIS NEEDS TO BECOME
DEFAULT. JUST A LITTLE NOTE ON
ANOTHER NEXT STEP THAT WE ARE
EXCITED ABOUT BUT REALLY ONLY IN
PLANNING PHASES RIGHT NOW, WE DO
WANT TO CREATE AN HHMI
REPOSITORY THAT WE HOST ALL OPEN
ACCESS CONTENT ON. DON'T THINK
OF THIS AS JUST SORT OF AN
ARCHIVE FOLLOW-UP, WE WANT THIS
TO BE A DISCOVERY PLATFOR PLATFE
WANT IT TO BE A PLACE WE
EXPERIMENT HOW SCIENCE IS
DISSEMINATE AND ENHANCE THE WORK
THAT IS ALREADY PUBLISHED IN
PRE-PRINT SERVICE ARTICLES. I
CAN TALK MORE LATER BUT THIS IS
ONLY POSSIBLE IF YOU HAVE AN
IMMEDIATE OPEN ACCESS POLICY
ONLY THEN DO YOU HAVE RIGHTS TO
PLAY AROUND WITH CONTENT SO THAT
IS WHAT WE REALLY INTEND TO DO.
SO FLIPPING THE PUBLISHING
PROCESS, IS SOMETHING WE THINK
WE REALLY WANT TO ENGAGE THE
COMMUNITY ON EMBRACING. WHERE
ARTICLES ARE FIRST PUBLISHED AS
PREPRINTS AND THEN YOU LAYER ON
TOP OF THIS LAYER TRANSPARENT
PEER REVIEW PROCESS. ONE OF THE
CRITICAL FEATURES THAT
DIFFERENCES WEAN CURRENT SYSTEM
AND THIS NEW SYSTEM, IN THE NEW
SYSTEM WHERE YOU FLIP THE
PROCESS THERE IS NO LONGER
REJECTION AS WE KNOW IT TODAY.
REJECTION AS IN JOURNAL ACCEPTS
OR REJECTS ARTICLE FOR
PUBLICATION. THERE IS NO
REJECTION BECAUSE THE ARTICLE IS
ALREADY PUBLISHED. AND SO IN
THIS SYSTEM RIGOR AND RELEVANCE
OF PIECE OF WORK IS GOING TO BE
SIGNAL THROUGH A TRANSPARENT
POST PUBLICATION REVIEW PROCESS
AND A CURATION PROCESS, THAT CAN
INCLUDE ENDORSEMENT BY JOURNALS
BUT IT IS NOT NOW MORE JOURNALS
REJECT OR ACCEPT PUBLICATION. I
WANT TO MOTIVATE THIS CHANGE
WITH A LITTLENY OF COSTS THAT I
THINK THIS CURRENT REJECTION
RESUBMISSION CYCLE IMPOSES ON
OUR SCIENTIFIC ENTERPRISE. I
MENTIONED THE HIGH PUBLISHING
COST. IF YOU -- THE JOURNALS ARE
BUILDING REPUTATION BY BEING
SELECTIVE. REJECTION RATE
INCREASED FOR DECADES. THAT
INCREASE COST. ESPECIALLY AT THE
HIGHLY PRESTIGIOUS JOURNALS, IT
ALSO WAISTS REVIEWER AND AUTHOR
RESOURCES. IT IS HARDER TO FIND
REVIEWERS, IF AN ARTICLE NEEDS
TO BE REVIEWED TWO OR THREE
TIMES BY TWO OR THREE JOURNALS,
IT WASTES A LOT OF REVIEW OF
RESOURCE AND BECOME MORE
DIFFICULT TO FIND. ALSO DELAYS
PUBLICATION. POINT JERRY ALSO
MADE, PREPRINTS ACCELERATE
PUBLICATION. IT TAKES LONGER TO
-- IT IS BIZARRE, TAKES LONGER
TODAY TO PUBLISH A JOURNAL
ARTICLE THAN IT TOOK WHEN
JOURNAL WAS PRINTED BECAUSE OF
THIS REJECTION RESUBMISSION
CYCLE.
THIS PROCESS CAN BE -- AN AUTHOR
WHO IS DETERMINED CAN TURN
AROUND AND RESUBMIT REJECTED
ARTICLE TO NEW -- BECAUSE
JOURNALS DON'T SHARE ANY
INFORMATION ON REJECTED
ARTICLES. THE WORST COST WE ARE
PAYING IS IT DEMORALIZES OUR
TRAINEES. IF A GRADUATE STUDENT
SPENDS FIVE YEARS ON THEIR PAPER
AND THEN IT GETS REJECTED WITH
COMMENTS LIKE THIS IS NOT
INTERESTING ENOUGH FOR JOURNAL X
OR Y, IT REALLY DRIVES I THINK
PEOPLE AWAY FROM SCIENCE. WE
REALLY FEEL STRONGLY THIS NEEDS
TO CHANGE. THIS FLIP PROCESS IS
NOT -- IT IS NOT A PIPE DREAM,
IT ALREADY EXISTS, JUST ISN'T --
IT JUST ISN'T DEFAULT, WE HAVE
TO -- I FEEL LIKE WE HAVE TO
PUSH THAT IT BECOMES MORE THE
DEFAULT. eLIFE IS DOING IT,
THEY HAVE LAST YEAR SHIFTED TO
MODEL WHERE THEY ONLY REVIEW
PREPRINT AND THEY ARE PUBLISHED
JOURNAL AGNOSTIC PEER ARE VIEW
REPORTS ON ALL PAPERS THEY
REVIEW. THERE ARE JOURNAL
INDEPENDENT REVIEW SERVICES THAT
ARE GROWING AND GETTING MORE
IMPORTANT, I HAVE LISTED A FEW
HERHERE. GRASSROOTS ORGANIZATIOS
THAT DO GREAT WORK PROMOTING
PREPRINT AND PRE-PRINT REVIEW.
THIS IS HAPPENING AND GROWING.
I WANT TO END BY LISTING A FEW
PARTNERSHIP OPPORTUNITIES, WE
CERTAINLY -- WE ARE NOT BIG
FLUFF TO DO THIS. WE REALLY -- I
MEAN WE REALLY NEED PARTNERS TO
MOVE -- REFORM SCIENTIFIC
PUBLISHING. WE WOULD LOVE IF
COALITION S GROWS, INCLUDES MORE
FEDERAL FUND IN THE U.S. BUT
THERE ARE OTHER WAYS TO PROMOTE
OPEN ACCESS, I'M LISTING ONE
HERE, RIGHTS RETENTION, TO MAKE
SURE THAT SCIENTISTS KEEP THE
RIGHTS TO SHARE AUTHOR
MANUSCRIPTS. THAT CAN BE DONE
WITHOUT EVEN ADDRESSING ALL
THESE COMPLICATIONS ABOUT
BUSINESS MODELS. IN TERMS OF
SUPPORTING PROCESS I THINK THE
TIME IS RIGHT TO BUILD A
COALITION OF FUNDERS AND MAYBE
OF SOCIETY PUBLISHERS TO DEVELOP
A PROCESS AND A BUSINESS MODEL
TO ACTUALLY SUPPORT THIS
PROCESS. AND FINALLY
RESPONSIBLE RESEARCH -- IF WE
ARE NOT ALSO CHANGING HOW WE
ASSESS RESEARCHERS. REWARDING
OPEN SCIENCE IS OF COURSE, WE
WILL TALK ABOUT THAT IN THE
CONTEXT OF WHAT I TALKED ABOUT
IN PUBLISHING THE ONE CRITICAL
STEP I WOULD RECOMMEND IS THAT
WE RECOGNIZE PRE-PRINTS PLUS
REVIEWS AS PEER REEVED ARTICLES,
IMPROVEMENT TO JOURNAL ARTICLE.
WHEN NIH AND HHMI RECOGNIZED
PREPRINTS AS SIGNS OF
PRODUCTIVITY A FEW YEARS AGO.
PREPRINTS TOOK OFF. IT IS
IMPORTANT WE ALSO SIGNAL THAT
THE PEER REVIEW OF PRI PRINTSES
IS VALUABLE. THIS IS MY
PRESENTATION. THANK YOU FOR
LISTENING. HAPPY TO DISCUSS.
>> THANK YOU FOR APPEARING ON
THE ZOOM. DO YOU HAVE A
CLARIFYING QUESTION BEFORE WE
MOVE ON?
>> I WAS WONDERING HOW YOU ARE
GOING TO GET PEOPLE TO REVIEW
PREPRINTED, RIGHT NOW NO
PREPRINT GETS COMMENTS AND --
>> I HAVE TO LOOK UP THE
INTERNET TO FIND START REVIEWING
THEM?
>> BECAUSE WE ARE RELYING ON
JOURNALS TO DO THIS -- I THINK
WHAT WE IMMEDIATE TO DO IS IS
GET ALSO JOURNALS TO COMMIT AND
PAY THEM FOR COMMITTING TO A
MORE TRANSPARENT PROCESS. IT IS
NOT JUST THAT SCIENTISTS DO IT
ON THEIR OWN, BUT ALSO THAT
JOURNALS START CONDUCTING PEER
REVIEW THAT IS FIT TO BE SHARED
IN A ATTACHED PREPRINT. IT NEEDS
TO CHANGE A LITTLE BIT. IT
SHOULDN'T BE ABOUT PEER REVIEWS
THAT JUST INFORM SUMS UP THUMBS
DOWN DECISION, IT SHOULD BE
SEPARATED FROM THAT ACCEPT
REJECT DECISION. THAT IS PART
OF THE PROBLEM. JOURNALS SHOULD
BE ABLE TO DO THAT. eLIFE IS
GOING TO DO IT BUT I HOPE WE CAN
ENCOURAGE OTHER JOURNALS TO DO
THAT AS WELL. WE CAN FIGURE HOW
TO PAY FOR THAT. AND NOT PAY FOR
THE PUBLISHING BUT PAY FOR PEER
REVIEW, THAT IS BASICALLY
FINANCIALLY WHAT WE HAVE TO
FIGURE OUT HOW TO DO IT.
>> ALLAN, QUICK RESPONSE BEFORE
WE MOVE ON?
>> THE YOU SHALL SHOE U.S. THE
ELEPHANT IN THE ROOM. WE ALL
KNOW WHICH JOURNALS ARE THE MOST
EXPENSIVPENSIVE. BECAUSE IF WE H
IN NATURE CELL, THE FACT IS IT
PROVIDES AN PERIMETER TO THE
TRAINEES, IN THE PROMOTION
PROCESS, AND UNTIL YOU SOLVE A
WAY TO REDUCE THAT COST OR
ELIMINATE IT GETTING I'M
REVIEWING EDITOR FOR eLIFE AND
I KNOW THE PROCESS BUT PEOPLE
CHOOSE TO SEND NATURE BEFORE
THEY SEND TO ELI.
>> AGREE. THAT'S WHY I PUT MY
LAST POINT WE CAN'T CHANGE THE
SYSTEM UNLESS WE IN PARALLEL
CHANGE HOW WE ASSESS SCIENTISTS.
I DIDN'T PUT IT IN THERE. BUT I
AGREE, WE NEED TO DE-EMPHASIZE
AND MAYBE EVEN REMOVE
RECOGNITION WHERE SOMETHING IS
-- HAS BEEN PUBLISHED. SO YES.
RECOGNIZING --
>> GOOD LUCK.
>> I MEAN, YEAH.
>> GOOD TOPIC FOR BROADER
DISCUSSION AFTER OUR OTHER
SPEAKERS GO SO I'M GOING TO
INTRODUCE OUR THIRD SPEAKER, DR.
MARINA PICCIOTTO. SHE WAS LISTED
ON THE AGENDA AS EDITOR AND
CHIEF PUBLIC DEFENDER'S OFFICE
JOURNAL NEURONEUROSCIENCE I WILL
GET TO IN A MOMENT BUT WE KNOW
HER AS AMAZING NEUROSCIENTIST
KNOWN FOR HER WORK IN NICOTINE
ADDICTION MEMORY AND REWARD
BEHAVIORS. SHE HAS NUMEROUS
TITLES INCLUDING THE CHARLES BG
MURPHY PROFESSOR PSYCHIATRY AND
PROFESSOR IN THE CHILD STUDY
CENTER NEUROSCIENCE PHARMACOLOGY
DEPARTMENTS AT YALE. SHE IS
DEPUTY DIRECTOR OF THE CODLY
INSTITUTE FOR NEUROSCIENCE AT
YALE AMONG OTHER POSITIONS.
WITH RESPECT TO THIS PARTICULAR
TOPIC, SHE ALSO SERVES IN A
NUMBER OF IMPORTANT EDITORIAL
POSITIONS. INCLUDING SINCE 2015
MR. EDDINS: TORR IN CHIEF FOR
JOURNAL OF NEUROSCIENCE, IN THAT
ROLE SHE'S A STRONG SUPPORTER
FOR GREATER RIGOR AND
TRANSPARENCY IN PUBLISHING
OVERSEEING A LOT OF EVOLUTION IN
THE PUBLISHING FIELD, INCLUDING
BEING AN EARLY SUPPORTER OF
PRE-PRINT PUBLISHING AND ALSO
OVERSAW THE TRANSITION AWAY FROM
PAPER PUBLISHING BECAUSE I DON'T
KNOW IF EVERYBODY IS AWARE NOW
THAT WE ARE ALL ONLINE BUT THE
JOURNAL OF NEUROSCIENCE MOVED
INTO ON LINE ONLY PUBLISHING IN
JANUARY. SO BE THAT I TURN IT
OVER TO DR. PICCIOTTO AND I LOOK
FORWARD TO HEARING COMMENTS.
>> SHE MAY HAVE JUST --
>> I FROZE AT EXACTLY THE RIGHT
MOMENT. MAGIC. SO I DON'T HAVE
SLIDES TODAY AND I AM HAPPY TO
EXPAND ON ANY OF THE POINTS THAT
I'M GOING TO MAKE BUT I COME
FROM A VERY DIFFERENT
PERSPECTIVE THAN MY COLLEAGUE
FROM HHMI. MY NAME AS YOU HEARD
IS MARINA PICCIOTTO, EDITOR IN
CHIEF FOR JOURNAL OF
NEUROSCIENCE AND IT IS A HYBRID
JOURNAL, IT PROVIDES FULL OPEN
ACCESS FOR ALL CONTENT AFTER SIX
MONTHS, IT IS COMPLETELY
COMPLIANT WITH PLAN S, AUTHORS
OWN FULL COPYRIGHT TO THEIR WORK
WE ENCOURAGE SUBMISSION TO
BIOARCHIVE AT ANY TIME BEFORE OR
DURING SUBMISSION AND ALSO HAVE
DIRECT SUBMISSION OPTION FROM
BIOARCHIVE. WE HAVE AN OPTION
FOR THOSE WHO WORK LIKE TO BE
ACCESSED IMMEDIATELY, THERE IS A
PUBLICATION COST FOR THAT. AND
WE HAVE BEEN PUBLISHED FOR THE
LAST 41 YEARS BY THE SOCIETY FOR
NEUROSCIENCE WHO IS OUR
PUBLISHER AND GIVES INCREDIBLE
EDITORIAL FREEDOM BECAUSE THEY
REALLY HAVE AN INCREDIBLE
INVESTMENT IN PEER REVIEW. I
WANT TO CALL OUT ONE OF YOUR
MEMBERS WHICH IS JOHN MANSEL WHO
INTRODUCED SOME OF THE POLICIES
THAT PLAN S PUSHED FOR MORE THAN
TEN YEARS AGO BEFORE THE OPEN
ACCESS MANDATES BECAME QUITE
BROAD. AUTHORS HAVE OWNED THEIR
OWN COPYRIGHT TO THEIR OWN
ARTICLES FINAL PUBLISHED VERSION
SINCE JOHN'S TENURE AND WE HAVE
MADE EVERYTHING ALL HISTORICAL
CONTENT IS FULLY OPEN ACCESS AND
OF COURSE AFTER SIX MONTHS NEW
CONTENT IS OPEN ACCESS. OUR
SISTER JOURNAL IS GOLD OPEN
ACCESS, IT'S PUBLISHED FOR THE
LAST SEVEN YEARS. FOR US OPEN
ACCESS IS PRIMARY GOAL, IT IS
INCREDIBLY IMPORTANT GOAL BUT
HOW WE GET SCIENTIFIC
INFORMATION TO PUBLIC IS
COMPLEX. PEER REVIEW ADDS VALUE.
I WOULD LIKE TO GO FURTHER TO
SAY BLINDED PEER RERUE IS STILL
SOMETHING THAT IS AN IMPORTANT
WAY TO GUARANTEE THAT THOSE WITH
INCREDIBLE AMOUNTS OF PRIVILEGE
ARE NOT GIVEN EXTRA CREDIT BY
PEER REVIEWERS WHO WANT TO TO
CURRY FAVOR. WE HEAR FROM
TRAINEES THEY WANT PEOPLE TO
REREVEAL THEMSELVES SO THEY ARE
FAIR TO PEOPLE WITHOUT POWER AND
IN FACT IT IS THE OPPOSITE. IT
IS THAT PEOPLE WITHOUT POWER
FEEL CRUSH AND PEOPLE WITH POWER
ARE GIVEN EXTRA BENEFIT OF THE
DOUBDOUBT. CURATION ALSO ADDS VE
AND DESPITE MY FEELINGS ABOUT
CNS JOURNALS AS COMPETITORS IN
WAYS THAT ARE HAVE TAKEN CONTENT
THAT WE WOULD LOVE TO HAVE
HOSTED AT THE JOURNAL OF
NEUROSCIENCE, THERE IS NO
QUESTION THAT OUR TRAINEES
CAREERS ARE ENHANCED BY BEING
PICKED OUT OF THE PILE NOT JUST
BY THOSE WHO ARE IN THEIR FIELD
BUT BY THOSE PROFESSIONAL
EDITORS AND THERE SOMETHING TO
BE SAID FOR PROFESSIONAL EDIT
EDITORS. THEY ARE DERIDED FOR
NOT BEING ACTIVE SCIENTIST BUT
THEY ARE CHOSEN FOR A NUMBER OF
SKILLS IN IDENTIFYING
INTERESTING NEW IDEAS THAT SOME
OF US COULD ADD AS EDITORS OF
SOCIETY JOURNALS AS WELL. BOTH
OF THESE ARE COSTLY. AND THEY
TAKE TIME. THE MAIN GOAL OF
PUBLIC ACCESS SHOULD BE TO
MAXIMIZE ACCESS WHILE
SIMULTANEOUSLY ALLOWING TIME AND
VALUE OF PEER REVIEW TO GO
FORWARD. A BIG CHANGE AT THIS
TIME IS WHO PAYS FOR PUBLIC --
PEER REVIEW. LIBRARY
SUBSCRIPTIONS ARE A SUBSTANTIAL
PROPORTION OF JOURNALS ECONOMIC
MODEL. IF THE JOURNAL WERE TO
MOVE TO BE FULLY OPEN ACCESS THE
COST TO AUTHORS WOULD INCREASE
BY MORE THAN 3 FOLD. THAT MEANS
WE ARE SHIFTING A SHARED
RESPONSIBILITY FOR COSTS OF PEER
REVIEW TO ONE THAT IS ON THE
AUTHORS ALONE. ANOTHER MODEL HAS
BEEN FOR PARTICULARLY FOR
COMMERCIAL PUBLISHERS TO
NEGOTIATE TRANSFORMATIVE
AGREEMENTS WITH GOVERNMENTS AND
FUNDING AGENCIES TO PAY FOR THE
COSTS OF PEER REVIEW. ONE
CONCERN ABOUT A SHIFT IS
NEGOTIATING WITH LARGE NUMBER OF
FUNDERS REQUIRES AN ENTIRE
OFFICE DEDICATED TO THOSE
NEGOTIATIONS. THEY ARE YEARLY
BECAUSE THEY DEPENDS ON NUMBER
OF SUBMISSIONS FROM EACH FUNDING
BODY. THEREFORE THEY JUST
NEGOTIATING THOSE AGREEMENTS IS
VERY COSTLY. I HAVE BEEN TOLD BY
OUR COUNCIL AND BY THE SFN AS
OUR PUBLISHER THAT NEGOTIATING
WITH ALL FUNDERS WOULD BE BEYOND
THE SFN BUDGET AND THEY LET US
KNOW THAT THE LIKELIHOOD WOULD
BE THAT THEY -- IT WOULD BE MORE
COST EFFECTIVE TO SELL THE
JOURNAL TO LARGE COMMERCIAL
PUBLISHER WHO HAS SCALE TO
NEGOTIATE TRANSFORMATIVE
AGREEMENTS ON A MUCH BROADER
SCALE. THAT WOULD BE ENORMOUS
LOSS TO THE JOURNAL WHICH HAS
HAD THE LUXURY OF FULL EDITORIAL
AUTONOMY. . SOME FUNDING AGENCY
SUCH AS WELLCOME TRUST AND HHMI
REQUIRE BRAN TEES TO PUBLISH
IMMEDIATELY IN FULLY OPEN ACCESS
JOURNALS AND THEY ARE REQUIRING
PEOPLE TO PUBLISH AND FULLY OPEN
ACCESS JOURNAL BECAUSE THEY
WON'T PAY OPEN ACCESS FEES AND
HYPERJOURNALS SO NOT ABLE TO
HOST MATERIAL FROM THOSE WHO
DON'T HAVE ANOTHER WAY TO PAY
OPEN ACCESS FEES TO THE JOURNAL
OF NEUROSCIENCE. THIS THEN OF
COURSE PURPOSES PEER REVIEW COST
TOTS AUTHORS AWAY FROM MIX OF
SUPPORTERS AND IN THE END ALL
JOURNALS DO BECOME FULLY OPEN
ACCESS AND THERE IS A WAY TO WE
HAVE TO FIND A WAY TO
DEMOCRATIZE THE COSTS OF
PUBLICATION INCLUDING TO
LIBRARIES AND UNIVERSITIES,
BECAUSE THAT WOULD FAVOR CHOICE
FOR AUTHOR WHOSE HAVE A ALSO OF
GRANT MONEY, AND DISFAVOR AUTHOR
WHOSE DON'T HAVE DEEP POCKETS OR
WHO COME FROM COUNTRIES OUTSIDE
OF THE U.S. AND WESTERN EUROPE
WHERE PUBLICATION BUDGETS ARE
LIMITED. ONE OF THE THINGS WE
ARE DOING RIGHT NOW IS
NEGOTIATING A PILOT AGREEMENT
WITH UK FUNDERS THAT WILL ALLOW
BRITISH AUTHORS TO PUN PUBLISH
NEUROSCIENCE FULLY OPEN ACCESS
IMMEDIATELY WITH THE COSTS BOSH
DIRECTLY BY THE FUNDING AGENT
RECEIVES. BUT IT IS NOT CLEAR
THAT OTHER FUNDING BODIES FOR
EXAMPLE, THE NIH WOULD BE ABLE
TO WOULD WANT TO ADOPT SIMILAR
TRANSFORMATIVE AGREEMENTS. SOME
ASPECT OF PUSH TO REFORM
SCIENTIFIC PUBLISHING SUCH AS
THOSE OUTLINED IN PLAN S HAVE
MADE INCREDIBLY POSITIVE
DIFFERENCE IN SCIENTIFIC
PUBLISHING AND I THINK THIS
COULD BE ASSISTED BY NIH.
GRANTING FULL COPYRIGHT TO
AUTHORS PROVIDING A CREATIVE
COMMONS LICENSE TO FULLY USE ALL
MATERIALS PUBLISHED FOR OTHER
SCIENTIFIC WORK AFTER PEER
REVIEW WOULD REALLY INCREASE
SHARING OF SCIENTIFIC
INFORMATION. A MIX OF EARLY
POSTING ON PRE-PRINT SERVERS
FOLLOWED BY FORMAL PEER REVIEW
AND THEN CURATION BY JOURNALS
AND FINALLY AVAILABILITY ON
GOVERNMENT ARCHIVES AFTER
PUBLICATION IS DEFINITELY
ALREADY CHANGED PUBLISHING. IT
IS FACILITATED AN SPEEDED UP
DISSEMINATION PUBLIC DEFENDER'S
OFFICE SCIENTIFIC INFORMATION
AND I THINK THIS COMBINATION HAS
BECOME A DE FACTO SYNERGISTIC
SOLUTION OF FINDING THE CORRECT
BALANCE BETWEEN IMMEDIATE ACCESS
TO SCIENTISTS OF SCIENTIFIC
DATA, THE VALUE OF PEER REVIEW
AND CURATION AND THEN THE
IMPORTANCE OF PUBLIC ACCESS TO
THE POOR REVIEWED ORGANISM, IT
IS NOT ONE ORGANIZATION OR MODEL
THAT DOES THIS, IT IS THE
COMBINATION OF MULTIPLE ARCHIVES
AND MULTIPLE LEVELS OF PEER
REVIEW. I WOULD REALLY LIKE TO
ADD THAT BIOARCHIVE HAS BEEN
ESSENTIAL IN GETTING INFORMATION
OUT TO OTHER SCIENTISTS AND TO
THE PUBLIC DURING THE NOT ONLY
DURING THE PANDEMIC BUT IN MANY
AREAS OF MEDICAL RESEARCH. AND
HAVING THAT DATA UNPEER REVIEWED
OF COURSE LEADS TO SOME PROBLEMS
IN PUBLIC PERCEPTION OF SCIENCE
OF THE VALUE OF THE SCIENTIFIC
DATA, HAVING SUBSEQUENT PEER
REVIEW CAN REALLY MAKE A BIG
DIFFERENCE IN HOW NON-SCIENTISTS
USE THAT INFORMATION. I CAN
LIKE TO COMMENT POST PUBLICATION
PEER REVIEW. SCIENTISTS WON'T
REVIEW UNLESS INVITE AND
RECOGNIZED FOR THAT REVIEW. AND
THAT IS WHAT COSTS MONEY, IT IS
IN FACT THE INFRASTRUCTURE TO
INVITE FOLLOW-UP WITH AND HELP
REVIEWERS GET THEIR CONTENT ON
TO A PLATFORM THAT COSTS MONEY
TO JOURNALS.S. IT IS SOMETHINGE
DON'T KNOW HAPPENS ON BIOARCHIVE
OR RARELY, I THINK THAT THE
EXPERIMENT ON PRE-PUBLICATION
REVIEW IS INTERESTING. BUT SCALE
IS MINIMAL. IT IS GOING TO BE
LESS THAN .1% OF THE SCIENTIFIC
LITERATURE. IT IS POSSIBLE
BECAUSE eLIFE IS SUPPORTED BY
PEOPLE WITH BIG POCKETS AND THAT
IS HHMI AND WELLCOME TRUST.
UNLESS WE HAVE FUNDERS THAT ARE
WILLING TO SUPPORT THAT, IT
WON'T HAPPEN ON A LARGER SCALE.
IT ALSO COMES FROM A POSITION OF
INCREDIBLE PRIVILEGE I WOULD
NOTE. THE MASS OF DATA AND MUCH
OF THE DATA THAT MANY OF OUR
TRAINEES USE TO PLAN EXPERIMENTS
ARE NOT ONLY IN HIGH PROFILE
JOURNALS NOT ONLY NATURE SCIENCE
AND CELL, THEY ARE IN
PSYCHOPHARMACOLOGY. THEY ARE IN
NEUROPHARMACOLOGY, NEUROSCIENCE,
JOURNALS WHERE A PIECE OF DATA
CAN BE EXPLORED FULLY AND
PRESENTED FULLY. THAT DOESN'T
COME INTO THE EQUATION WHEN WE
TALK ABOUT THE KINDS OF CASCADES
OF PUBLISHING YOU HEARD FROM
BODO. I THINK COALITION OF
SOCIETY PUBLISHERS WITH FUNDERS
WILL EXTREMELY WELCOME. I KNOW
THAT WELCOMES SOMETHING THAT
JOURNAL OF NEUROSCIENCE IN
SOCIETY FOR NEUROSCIENCE WILL
EMBRACE. I WANT TO AGAIN PRAISE
THE ERA COMMONS, IT WAS A
PIONEER IN ARCHIVING PUBLISHED
MATERIAL AND IT WAS REALLY ONE
OF THE FIRST TO DEMOCRATIZE
ACCESS TO SCIENTIFIC ARTICLES.
I WAS IMPRESSED BY THE DATA
SHOWN ABOUT MILLIONS OF PAPERS
DOWNLOADED EACH DAY, I
DOWNLOADED ABOUT FIVE ARTICLES
TODAY FROM ERA COMMONS I CAN
TELL YOU IT'S FANTASTIC TO BE
ABLE TO PUSH A BUTTON IN PUBMED
AND GET THE CONTENT IMMEDIATELY
EVEN IF NOT ON THE UNIVERSITY
VPN. THE FACT IS THOUGH IT IS
ONLY PULLY PEER REVIEWED
CONTENT. SO THERE IS STILL A
DELAY BETWEEN THE TIME EVEN IF
IMMEDIATELY OPEN ACCESS UNDER
ERA COMMONS, STILL BETWEEN THE
TIME A SCIENTIST FINISHING THE
EXPERIMENT AND TIME IT WOULD BE
POSTED ON ERA COMMONS. I DON'T
THINK THAT WE SHOULD NECESSARILY
HAVE ONLY ONE WAY OF ARCHIVING.
WE SHOULD ARCHIVE FULLY PEER
REVIEWED STUDIES SEPARATELY FROM
NON-PEER REVIEWED STUDIES, THEY
HAVE DIFFERENT CONTENT AND THEY
SHOULD BE REGARDED DIFFERENTLY.
I DO THINK ALSO THAT OPEN ACCESS
PUBLISHING POLICIES THAT ARE
BEING FLOATED DON'T SOLVE SOME
OF THE MAJOR PROBLEMS IN THE
SYSTEM INCLUDING THE MASSIVE
PROFITS AT LARGE COMMERCIAL
PUBLISHERS AND I DO THINK THAT
INCREASING CHOICE FOR AUTHORS
AND SUPPORTING IN INNOVATION FRM
eLIFE AND FUNDING BODIES SUCH
AS HHMI MADE A DIFFERENCE IN
WHAT IS THOUGHT TO BE
ACCEPTABLE. I THEN COMING
TOGETHER TO DO EXPERIMENTS IN
PEER REVIEW, IS SIGNISTTISES,
CONSIDER THESE EXPERIMENTS IN
PEER REVIEW NOT SIMPLY CHANGES
IN POLICY. IT IS AN IMPORTANT
THING FOR ALL OF US TO SUPPORT.
AND I WILL STOP THERE.
>> THANK YOU SO MUCH. THAT WAS
REALLY HELP.
FUL AND GOT THOUGHTS FROM OUR
GUYS AND GALS SO GRATEFUL FOR
THAT. THANK YOU. SO UNLESS THERE
ARE CLARIFYING QUESTIONS, I'M
GOING TO TURN TO OUR FINAL
PRESENTER WE ARE GRATEFUL FOR
THE OPPORTUNITY TO HEAR FROM ONE
OF OUR COUNCIL MEMBERS ON THIS
TOPIC DR. EKEMINI RILEY. WHO IS
MANAGING DIRECTOR ALIGNING
SCIENCE ACROSS PARKINSONS OR
ASAP. IT IS A RESEARCH FUNDING
KNISHTIVE ACCELERATING THE PACE
OF DISCOVERY AND INFORMING PATH
TO CURE FOR PARKINSONS. THROUGH
COLLABORATION RESEARCH ENABLING
RESOURCES AND DATA SHARING PRIOR
TO HER ROLE IN ASAP SHE WAS
DIRECTOR AT THE -- INSTITUTE
CENTER FOR STRATEGIC
PHILANTHROPY AND BELOOK FORWARD
TO HEARING HER COMMENTS ON ASAP
EXPERIENCE DEVELOPING
IMPLEMENTING OPEN ACCESS POLICY
>> THANKS, AMY. I DON'T HAVE TO
GO OVER OUR MISSION BECAUSE YOU
JUST COVERED IT BUT I WILL SAY
THAT AS Y'ALL HEARD, OPEN
SCIENCE IS CORE TO OUR
INITIATIVE. WE ARE AS BODO
MENTIONED A COALITION MEMBER AND
WE IMPLEMENT SOME OF THE
POLICIES THAT THEY HAVE
PIONEERED IN PART SO I WILL
EXPLAIN IN A MOMENT. SO JUST TO
START OFF, I WILL GO THROUGH OUR
FIVE POINT OPEN SCIENCE POLICY,
AND I WILL DESCRIBE WHY WE REFER
TO IT AS OPEN SCIENCE POLICY IN
A MOMENT BECAUSE IT IS MORE THAN
JUST THE ACTUAL PUBLICATION WE
CARE ABOUT. SO FIRST AND
FOREMOST WE MANDATE A PRE-PRINT
FROM ALL OF OUR RESEARCH NETWORK
MEMBERS SO WE OPERATE WHAT WE
CALL THE COLLABORATIVE RESEARCH
NETWORK, WE HAVE 160
INVESTIGATORS LEADING VARIOUS
TEAMS, 35 TEAMS IN THAT NETWORK.
AND SO OUR OPEN SCIENCE POLICY
IS MEANT TO PROMOTE SHARING
WITHIN THE NETWORK AND THEN
MANAGE THAT SHARING TO OUTSIDE
OF THE NETWORK TO THE PUBLIC. SO
WITH THAT, WE ALSO REQUIRE OUR
GRANTEES TO HAVE FREE ONLINE
ACCESS UPON PUBLICATION WITH A
CCBY LICENSE FOR UNRESTRICTED
USE. FROM THERE WE ALSO REQUIRE
THAT ALL RESEARCH OUTPUTS THAT
ARE ASSOCIATED WITH THE
MANUSCRIPT SO THE DATA, THE
PROTOCOLS, CODE, WHAT HAVE YOU,
ARE DEPOSITED IN PUBLICLY
ACCESSIBLE REPOSITORIES AND IN
THE ePUBLICATION WITH
PERMANENT IDENTIFIER. THE FOURTH
IS APPROPRIATE ATTRIBUTIONS TO
ASAP FUNDED WORK AND THE LAST
BIG ONE IS USING OUR RESEARCH
OUTPUT MANAGEMENT SYSTEM, THIS
TRACKS RESEARCH OUTPUTS THAT ARE
GENERATED BY OUR GRANTEES ON THE
PLATFORM AND ALSO HIMSELF INFORM
WHEN -- HELPS INFORM WHEN
RESOURCES ARE MADE AVAILABLE AND
ALSO HELPS GRANTEES BE ABLE TO
CONNECT WITH EACH OTHER AND FIND
THOSE MATERIALS. BODO MENTIONED
HHMI DOESN'T COVER ARTICLE
PROCESSING FEES THAT IS WHERE WE
DIFFER. WE DO COVER ARTICLE
PROCESSING FEES FOR OUR GRANTEES
ONE DIFFER IN TERMS OF
IMPLEMENTING THE PLAN STRATEGY
IS THAT WE CARE THE ARTICLE IS
ACCESSIBLE UPON PLOYCATION SO WE
ALLOW OUR GRANTEES TO PUBLISH IN
HYBRID YOUR HONOROR JOURNALS AND
GOLD OPEN ACCESS JOURNALS. IN
CONSIDERING THE PRINCIPLES FOR
OUR INITIATIVE TRY TO UNDERSTAND
WHY BOTH OPEN ACCESS AND OPEN
SCIENCE ARE CORE TO OUR
INITIATIVE. ONE SITES IS BASED
ON COLLABORATION. IN ORDER TO
BUILD UPON PEOPLE WORK YOU HAVE
TO FIND IT HAVE TO USE IT. AND
WE BELIEVE PEOPLE SHOULD FIND BE
ABLE TO FIND THAT WITHOUT PAY
WALLS. THE NEXT THING IS THAT WE
BELIEVE SCIENCE TO FUNCTION
EFFECTIVELY, IT IS CRUCIAL THAT
THAT SCIENCE AND DATA UNDERLYING
ARE MADE OPEN. AND THEN WE ALSO
FEEL THE ULTIMATE VALUE OF THE
DATA CAN'T BE PREDICTED. SO
THUS BY HAVING IT OPEN YOU ALLOW
OTHERS TO REANALYZE THE DATA,
GAIN NEW INSIGHT AND BE ABLE TO
INNOVATE ON WHAT YOU HAVE FOUND
WE LAUNCHED THE INITIATIVE BACK
IN 2019, GRANTED OUR FIRST
GRANTS CRN IN 2020. AND SINCE
THEN WE HAVE SEEN THE LANDSCAPE
OR OPEN SCIENCE EVOLVING, WE
LEARN NEXT YEAR NIH IS GOING TO
REQUIRE ALL THE RESEARCHERS TO
INCLUDE DATA MANAGEMENT PLAN AND
THEIR GRANT APPLICATIONS, WE
HAVE LEARNED THAT NASA WILL HAVE
THEIR YEAR OF OPEN SCIENCE NEXT
YEAR. NATIONAL SCIENCE AND
TECHNOLOGY COUNCIL SERVED ABOUT
GUIDANCE AND IMPLEMENTING THE
NATIONAL SECURITY MEMORANDUM.
WHICH NECESSITATES THE USE OF
PERSISTENT IDENTIFIERS AND
PERSON IDs LIKE THE ORCHID. WE
KNOW NATIONAL ACADEMIES CONVENE
A ROUND TABLE FOR OPEN SCIENCE,
THEY RELEASED THEIR TOOL KIT FOR
POST FOSTERING OPEN SCIENCE
PRACTICES WHICH WE WERE HAPPY TO
CONTRIBUTE TO AND GLOBAL FOCUS
ON OPEN SCIENCE CONTINUES TO
GROW, WE HAVE SEEN THE UNESCO
BUILDING AND OPEN EXTENSIVE
NETWORK OF PARTNERS THAT
INCLUDES BROAD STAKEHOLDERS WHO
ARE IMPLEMENTING OPEN SCIENCE
PRACTICES. I MENTIONED OPEN
SCIENCE AT THAT TIME TOP AND IT
WAS MORE INCLUSIVE THAN JUST THE
ACTUAL PUBLICATION ITSELF. WHAT
RESONATES WITH US IS EUROPEAN
COMMISSION DEFINITION WHEREBY
OPEN SCIENCE MEANS YOU ARE
TAKING A NEW APPROACH TO
SCIENTIFIC PROCESS BASED ON
COOPERATIVE WORK AND NEW WAYS
DIFFUSING BY USING DIGITAL
TECHNOLOGIES AND COLLABORATIVE
TOOLS WHICH IS A SIMPLE
DEFINITION FOR US TO RALLY
AROUND. AND SO AS WE THINK ABOUT
OPEN SCIENCE AND EXTENDS THE
PRINCIPLES OF OPENNESS TO THE
WHOLE RESEARCH LIFE CYCLE
OPPOSED TO JUST THE ARTICLE
ITSELF. THESE ARE THINGS WE SEE
IN OUR INITIATIVE AS WELL. SO
THE POINT OF DATA COLLECTION,
URGE CLARIFY USAGE RIGHTS TO
THAT DATA. DATA PROCESSING, WE
DO MANDATE THAT OUR
INVESTIGATORS UTILIZE OPEN
SOURCE SOFTWARE INTERFACE AT THE
VERY LEAST IT IS FINDSABLE. IN
TERMS OF STORING DATA AND
RESULTS WE REQUIRE THAT OUR
GRANTEES USE PERSISTENT
IDENTIFIERS SO THAT THE LINKS TO
THAT DATA ARE ALWAYS AROUND. NO
MATTER WHAT ELSE MAY CHANGE
AROUND THE LINKS TO THAT DATA.
AND ALSO INCLUDE DESCRIPTIVE
METADATA USING THE STANDARDS FOR
YOUR FIELD SO THAT IT CAN BE
CONTEXTUALIZED BY OTHERS WHO
FIND THE DATA. NEXT ON THE
PUBLICATION AND DISTRIBUTION
ASPECT OF THINGS, AGAIN,
PUBLISHING THE ARTICLE OPEN
ACCESS, WE REQUIRE TO BE
IMMEDIATE, AGAIN WE ALLOW BOTH
HYBRID AND GOLD STANDARD OPEN
ACCESS JOURNALS, ENSURING THE
LINKS BETWEEN PUBLICATION DATA
CODE AND METHODS ARE SEAMLESSLY
INCLUDED WITHIN THE PAPER. ONE
THING I WILL NOTE, WE HAVE
PARTNERSHIPS WITH PROTOCOLS AT
IO AND REQUIRE ALL PROTOCOLS USE
IN THE PAPERS ARE ON AN OPEN
PLATFORM AND CAN BE REFERRED TO
AS THROUGH PERSISTENT LINK. WE
ENCOURAGE THE USE OF PUBLICLY
AVAILABLE REPOSITORIES AN THOSE
LINKS BE INCLUDED IN THE PAPER
AT TIME OF PUBLICATION. AND
AGAIN PUBLISHING METADATA WITH
AN OPEN LICENSE. AND THEN AFTER
DOING ALL THIS WE SEE AND
BELIEVE VERY HEARTLY THIS
PROMOTES REUSE OF RESOURCES DATA
THAT PRESENTED IN ARTICLES,
ENSURING THAT YOU HAVE CLEAR
CITATIONS TO BE ABLE TO DO SO
AND ENSURING THE ACCUMULATION OF
CREDIT AT ALL ASPECTS OF THIS AS
WE START WORKING WITH FOLKS WHO
ARE MORE IN THE DATA SPHERE
THERE ARE MORE THINGS
INVESTIGATORS SHOULD BE GETTING
CREDIT FOR OUTSIDE OF JUST THE
ACTUAL PUBLICATION OF CELL, THE
DATA IS REALLY IMPORTANT. SO IN
TERMS OF HOW WE ARE DOING, BACK
IN MARCH WE DID THIS ANALYSIS
AND AT THE TIME WE HAD 37
PREPRINTS, JUST CHECKED OUR
CHANNEL BEFORE IT PRESENTED AND
WE ARE UP TO 46 AT THIS POINT
WHICH LED TO 26 ORIGINAL
RESEARCH PUBLICATIONS. WE DO
HAVE A CHANNEL ON BIOARCHIVE
WHERE WE COLLATE ALL THE
PRE-PRINTS THAT COME IN FOR
INITIATIVE AND WE ARE SEEING
THAT PREPRINTS ARE POSTED ON
AVERAGE FIVE AND A HALF MONTHS
BEFORE FINAL PUBLICATION IS READ
AVAILABLE. -- MADE AVAILABLE.
ONE THING WE DO WITH THE
MANDATORY PRE-PRINT IS WE USE IT
AS A TRAINING WHEELS. THERE IS
A LOT IN THE OPEN SCIENCE SPHERE
TO HAVE TO FIND, SEAT AND
IMPLEMENT. SO WE TRY TO LOWER
THAT BARRIER FOR OUR GRANTEES BY
PROVIDING A NUMBER OF RESOURCES
BUT ALSO CHECKING COMPLIANCE
ALONG THE WAY TO ENSURE ONE,
THAT THEY ARE COMPLIANT WITH
POLICIES SET IN PLACE BUT TWO WE
KNOW MOST VISITORS THOSE WITHIN
OUR INITIATIVE WANT TO COMPLY
WITH ALL OF THE RULES. SO WE
WANT TO MAKE THAT EASY. SO START
WITH PRE-PRINT AND DO A
COMPLIANCE CHECK TO UNDERSTAND
AT ALL THE PLACES YOU SEE HERE
IN THE CIRCLE, WHAT HAS BEEN
DONE AND WHAT STILL NEEDS TO BE
DONE BEFORE THE FINAL PAPER IS
PUBLISHED. SO WHAT WE HAVE SEEN
IS WE REVIEW BEFOREHAND, THIS IS
GROUND ZERO. AND THEN ONCE THE
ACTUAL PUBLICATION IS DONE WE
SEE COMPLIANCE ACROSS THE BOARD
AT DIFFERENT PARTS OF THIS
PROPELLER. SO I THINK WE HAVE
SET UP AND TAKEN ABOUT A YEAR TO
SET UP A SMOOTH COMPLIANCE
PATHWAY, WE HAVE PARTNERED WITH
DATA TO BE ABLE TO DO THAT TO
AUTOMATE M&A THAT PROCESS SO
EVERYTHING FROM CHECKING THE
PROTOCOLS, CHECKING CITATIONS,
DOING WORD SEARCHES TO FIND
WHERE DIFFERENT RESOURCES ARE
MENTIONED AND ENSURING THAT
THERE ARE IDENTIFIERS THAT ARE
ATTACHED TO THOSE THINGS. THE
LAST POINT I MENTION WE HAVE
RESEARCH OUTPUT MANAGEMENT
SYSTEM THIS IS PART OF THE
BROADER OPEN SCIENCE LANDSCAPE
TRYING TO SET UP AND THIS IS A
PLACE WHERE ALL GRANTEES HAVE
ALL INFORMATION WITHIN THIS
PLATFORM EVERYTHING FROM
PROPOSAL THEY SUBMITTED WHICH IS
OPEN AND PUBLISHED FOR EVERYONE
WITHIN NETWORK TO SEE TO EVERY
PROGRESS REPORT TO RESOURCES
THAT ARE GENERATED, SO PEOPLE
WITHIN THE RESEARCH NETWORK HAVE
EARLY ACCESS TO RESOURCES AND
BEKNOW WHEN THOSE RESOURCES ARE
MADE PUBLIC AND PUT INTO PUBLIC
REPOSITORY. IN TERMS OF THINGS
LOGGED SO FAR IN OUR OUTPUT
MANAGEMENT SYSTEM, EVERYTHING
FROM PROTOCOLS TO ANIMAL MODELS
BIOINFORMATICS TOOLS AND
COLLATED IN HERE, WITH THE GOAL
SOME POINT ALL THESE RESOURCES
MADE AVAILABLE TO THE BROADER
NEUROSCIENCE COMMUNITY. AND SO
AS WE THINK ABOUT OPEN SCIENCE
HOW WE ARE IMPLEMENTING IT IF IT
IS WORKING, THERE IS A THREE
MAIN BUCKETS THAT WE ARE
THINKING ABOUT ASSESSING OVER
THE NEXT FIVE TO SEVEN YEARS.
ONE IS ARE RESOURCES FINDABLE
AND ACCESSIBLE BY THE BROADER
PUBLIC NEXT ARE WE ACCELERATING
DISCOVERY, YOU WILL HEAR THE SUB
BULLET POINTS ARE METRICS WE ARE
USING TO GAUGE ANSWERS TO THESE
QUESTIONS. AND LAST PIECE, ARE
WE HELPING TO CHANGE CULTURE OF
OPEN SCIENCE WHICH AGAIN IS OUR
GOAL LIEU THIS INITIATIVE. I
KNOW WE ARE SHORT ON TIME, I'M
GOING TO STOP THERE AND OPEN UP
FOR DISCUSSION.
>> THANK YOU VERY MUCH, THAT WAS
GREAT. I HAVE TO SAY THIS PANEL
IS EXTRAORDINARY AND I'M
GRATEFUL FOR EVERYONE TAKING THE
TIME TO COME PARTICIPATE IN THIS
DISCUSSION. WE DO HAVE TIME FOR
A COUPLE OF QUESTIONS AND I
WOULD REALLY LOVE TO HEAR FROM
FOLKS. SO LET ME KNOW.
>> I HAD QUESTION FOR ANY
EXPERTS. REVIEW OF COMMONS
LAUNCHED A AS WAY SORT OF
INDEPENDENTLY GETTING REVIEWED,
ANYBODY KNOW BUSINESS MODEL FOR
REVIEW OF COMMONS IS, HOW IS
THAT PAID FOR, YOU BROUGHT UP
THE EXCELLENT POINT, REAL COST
IS MANAGING THE PROCESS OF
HOUNDING PEOPLE LIKE ME TO GET
REVIEWS DONE AND INVITING US TO
DO IT. AND I HAVE REVIEWED
COMMENTS BUT I NEVER OCCURRED TO
ME SOMEONE FOOTING THIS BILL BUT
I DON'T KNOW WHO IT IS.
>> I DIDN'T HAVE ANYTHING TO
SAY. I WAS JUST SHAKING MY HEAD
>> I CAN SAY I MEAN THIS IS
EXACTLY WHAT IS MISSING RIGHT
NOW. AT THE MOMENT ALL THESE
REVIEW SERVICES ARE SUPPORTED BY
PHILANTHROPY ORGANIZATIONS. AND
OF COURSE IF WE WANT TO CHANGE
THAT, WE WOULD HAVE FIGURE OUT
HOW WE ARE PAYING FOR -- I AGREE
WITH WHAT MARINA SAID. WE ARE
NOT ADVOCATING THAT IT SHOULD BE
JUST FREE FALL PEOPLE COMMENT ON
BIOARCHIVE. THAT CAN BE PART OF
IT BUT IT NEW EVIDENCE TO BE AN
ORGANIZED PEER REEVED PROCESS
WITHIN THE AGENCY AND THAT NEEDS
TO BE PAID FOR. WE ARE PAYING
FOR PUBLICATION AT THE END AND
QUITE A LOT OF IT. THERE SHOULD
BE SMART WAYS OF SHIFTING MONEY
TO -- SO THAT WE CAN FUND
PRE-PRINT REVIEW. WHERE CURRENT
MONEY IS IN MANAGING PEER
REVIEW, YOU NOT ON THE RECEIVING
END OF THAT MONEY FOR DOING THE
PEER REVIEW. THERE ARE REWARDS
TO YOU OF DOING IT AND THERE
MAYBE OTHER REWARDS TO THOSE WHO
ENGAGE IN PEER REVIEW, I THINK
AS OTHERS HAVE SAID MAKING IT
MORE SITABLE SO WE AT THE
LIBRARY WE DON'T NECESSARILY
DRIVE CHANGES IN THE PROCESS BUT
WE REFLECT THEM AND WE HAVE ALSO
BEEN DOING SOME EXPERIMENTATION
OF ALLOWING FOR OPEN PEER
REVIEWS TO BE SUBMITTED WITH
ASSOCIATED JOURNAL ARTICLES SO
WE CAN LINK THOSE AND THOSE ARE
ACTUALLY GET THEIR OWN
IDENTIFIER. AS OTHER JOURNALS
ARE STARTING TO MOVE IN THAT
DIRECTION PROVIDE A PLATFORM
WHERE WE CAN REFLECT THAT
CHANGE.
>> THANK YOU. GINA.
>> I THINK THIS IS PERHAPS WHERE
THE NIH CAN BE HELPFUL BECAUSE
IT DOES COST A LOT TO WRANGLE
REVIEWERS YET CRITICAL TO THE
QUALITY OF THE PUBLICATIONS. SO
IT MIGHT BE THE NIH -- RIGHT NOW
WHEN YOU WRITE AN RO1 YOU CAN
PUT $3,000 FOR A FIVE YEAR GRANT
FOR PUBLICATION, THAT IS NOT
ENOUGH FOR OPEN ACCESS JOURNALS
AT ALL. NOT EVEN CLOSE. IF YOU
ARE NOT FUNDED BY HHMI OR
WELCOME OR SOMEBODY LIKE THAT
THEN YOU HAVE NO HOPE OF BEING
ABLE TO PAY FOR OPEN ACCESS. SO
I THINK THE NIH REALLY COULD
STEP UP AND DO SOMETHING HERE
AND BE INVENTIVE AND PERHAPS
TODAY WE CAN THROW IDEAS ABOUT
HOW NIH CAN HELP IN THIS
PROCESS. I AGREE WITH MARINA
THAT WE NEED ALL OF THESE
DIFFERENT JOURNALS, SPECIALTY
JOURNALS FROM SPECIALTY AREAS TO
STAY IN BUSINESS OR AT LEAST TO
STAY OPEN BECAUSE THAT IS A
PLACE WHERE PEOPLE GO TO FIND
THESE ARTICLES WHERE TRAINEES
WILL GO TO PUBLIC THEM. I THINK
IT WOULD BE AMAZING TO CHANGEUP
ALL OF ACADEMIA TO A DIFFERENT
PLATFORM SO YOU CAN GET PROMOTED
ON BASED ON THE MERE FACT OF
PUBLICATION NO MATTER WHERE BUT
RIGHT NOW THAT IS GOING TO BE A
MAJOR SYSTEMIC OVERHAUL AND WILL
TAKE BUY IN FROM MILLIONS OF
PEOPLE ESSENTIALLY RIGHT NOW
THAT ARE HAVE BENEFITED, TAKE
BUY IN FROM PEOPLE WHO BENEFIT
FROM THE CURRENT SYSTEM. THAT
ARE AT THE TOP OF THEIR GAME
BECAUSE THEY ARE ABLE TO PLAY
THAT GAME WITH THE CURRENT
SYSTEM. SO THEY ARE THE LEAST
LIKELY TO TRY TO BUY INTO A BIG
MAJOR CHANGE LIKE THIS. THESE
ARE A FEW OF THE PROBLEMS THAT I
HOPE THAT WE CAN ADDRESS TODAY,
THEY ARE BIG ONES THOUGH.
>> ANYONE WANT TO RESPOND TO
THOSE POINTS? I DO JUST WANT TO
NOTE FROM MY PERSPECTIVE I WILL
TURN TO MARINA IN THAT SECOND.
WE TALK A LOT ABOUT THE
IMPORTANCE OF EQUITY AND
INCLUSION IN OUR RESEARCH AND
OUR WORK FORCE. AND IF WE ARE
MAKING A POINT OF INCLUDING
EVERYONE IS INCLUDED IN RESEARCH
EFFORTS WE HAVE TO MAKE SURE
PATH TO PUBLICATION AND NOT CREE
CRATING HAVEs AND HAVE NOTES
AND HOW TO DO THAT TRICKY.
MARINA.
>> NO, I WAS ACTUALLY JUST
ENDORSING WHAT GINA SAID. I
AGREE WITH THE IDEA THAT IN FACT
WE NEED TO MAKE SURE THAT AS WE
THINK ABOUT THE BIGGEST PROBLEMS
WE ARE NOT CREATING NEW PROBLEMS
ACROSS THE SYSTEM.
>> IF I CAN CHIME IN, I THINK
IDEAS ABOUT HOW NIH CAN HELP
MOVE THE PROCESS ALONG ARE
ALWAYS WELCOME. I WOULD LIKE TO
THINK NIH HAD A FAIRLY
SIGNIFICANT ROLE GETTING US
WHERE WE ARE TODAY. THAT 2008
PUBLIC ACCESS POLICY WAS NEW.
AND AND NOT IMPLEMENTED WITHOUT
SIMILAR CONCERNS THAT THIS WOULD
UNDERMINE CURRENT MODEL OF
PUBLISHING AND DISENFRANCHISE.
I THINK WE EVEN HEARD NOBODY
OTHER THAN SCIENTISTS READ THE
LITERATURE OR NEED ACCESS TO IT.
WE HAVE HAD A LOT OF EVIDENCE
OVER THE LAST 14 YEARS. THAT
PUBLISHING HAS SURVIVED SOME
CHANGES AND WE HAVE A LOT OF
PEOPLE WHO USE -- THAT THE
LITERATURE WITHIN THE SCIENTIFIC
COMMUNITY AND BEYOND. THINKING
THROUGH HOW CAN WE GET TO THE
OBJECTIVE WE WANT. GREATER
ACCESSIBILITY TO THINGS IN WAYS
THAT ARE SUSTAINABLE AND
SUPPORTABLE. WELCOME YOUR
THOUGHTS HAVING TO TRY TO MOVE
THAT ALONG.
>> I THINK A NUMBER OF COUNCIL
MEMBERS HAVE TO LEAVE AND WE ARE
IN DANGER OF LOSING OUR QUORUM
SO LAST QUESTION FROM AARON. I'M
FRUSTRATED BECAUSE I WOULD LOVE
TO HAVE ANOTHER HOUR FOR THIS
DISCUSSION. IT IS A RICH
DISCUSSION. ALL TALKS WERE
TERRIFIC. AARON.
>> MY QUESTION IS FOR DR. STERN,
SEEMED LIKE IN THE SECOND POINT
YOU BROUGHT UP THE NEXT STEPS
GOING TO PUBLISHING FIRST THEN
PEER REVIEW SECOND, THAT LOGICAL
NEXT STEP OF THAT IS TO
ELIMINATE JOURNALS AND HAVE
PREPRINTS WITH PEOPLE COMMENTING
WHICH IS INTERESTING. BUT THEN
YOU SAID IN A COMMENT THAT YOU
CAN'T JUST HAVE ANYONE IN THE
WORLD COMMENTING ON THESE
PREPRINTS YOU HAVE TO ORGANIZE
IN SOME WAY. I WONDER IF THAT IS
TRUE, MAYBE IF YOU COULD HAVE
ANYONE COMMENTING BUT PEOPLE
HAVE THEIR CREDIBILITY ASSESS
BASED ON HOW WELL THEY COMMENT.
>> IF THAT WORKS. I WOULD
CERTAINLY ADD THAT I AGREE WE
SHOULD FIND WAYS PEOPLE CAN
CHIME IN ON ARTICLES. THAT IS
WHAT THE INTERNET ALLOWS, IT
CONNECTS EVERYBODY SO PEOPLE
THAT HAVE SOMETHING TO SAY
SHOULD BE ABLE TO SA SAY. ALL IM
SAYING IS DON'T SWITCH FROM
CURRENT SYSTEM RIGHT TO THAT
SYSTEM. IF JOURNALS CAN HAVE AN
IMPORTANT PLACE IMPORTANT ROLE
TO PLAY AS PEER ARE VIEW,
ORGANIZERSSS. CURATION SERVICES,
NOT AS PUBLISHERS BECAUSE IT IS
LIKE BIOARCHIVE OR PUBMED
CENTRAL, WE KNOW -- THE
JOURNALS, I THINK EDITORS WOULD
AGREE THAT THE MOST IMPORTANT
ROLE THEY PLAY IN APPRAISING
REVIEWING CONTENT SO LET'S USE
THE JOURNALS FOR NOW FOR THAT
IMPORTANT ROLE THEY PLAY. SO
THERE DOESN'T RULE OUT
COMMENTING ON THE SIDE BUT IT
DOESN'T MEAN NECESSARILY THAT
JOURNALS HAVE TO DISAPPEAR.
THEY CAN PLAY -- THEY JUST
WOULDN'T BE PUBLISHERSK THEY
WOULD BE PEER REVIEW SERVICE AND
CURATION SERVICES.
>> I AM GOING TO ADJOURN THIS
MEETINGING. I WANT TO THANK ALL
FOUR OF THE TALKS. THEY WERE
ABSOLUTELY GREAT AND I LEARNED
MUCH MORE THAN EXPECTED TO
LEARN. SO THANKS A LOT. WE WILL
CONTINUE THIS DISCUSSION IN
ANOTHER FORUM. WE ARE ADJOURNED